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5Abstract
Modelling antibiotic resistance evolution is inherently a multiscale problem: from the phys-
ical interactions between drug molecules and their targets to the epidemiology of drug re-
sistance in clinical settings. Although predicting the evolution of resistance is a difficult
and ongoing problem, it is known that pathogens are continually adapting to our drug pre-
scription patterns. For this reason, as well as the continual downturn in the discovery of
new drugs, the question of how to best deploy antibiotics has never been more pressing.
The purpose of this thesis is to use tools from control and systems theory to ask the fol-
lowing fundamental question: How can we design rational antibiotic deployment strategies
that do not promote the evolution of antimicrobial resistance?
By re-examining epidemiological models from the literature, in the first part of this thesis
we show that the optimal drug deployment protocol has a universal structure not determined
by biological detail. This class of epidemiological models, however, provide insight into
the underlying mechanisms that influence the spread of disease at the population level but
fail to capture the complex molecular interactions between different antibiotics and bacte-
ria, as well as to provide an experimental system to test the efficacy of different treatment
protocols. Therefore in the second part of the thesis we pose an evolutionary model of an
experimental microbial system that allows us to study drug interactions and the effect that
combination treatments have on the evolution of multidrug resistance. Again, using optimal
control theory we design drug deployment protocols that minimise conditions promoting
the evolution of antimicrobial resistance in a single host.
Finally, in the last part of the thesis we propose an epidemiological model where patients
are considered as individual agents receiving antimicrobial treatment in a clinical setting.
This stochastic and spatially explicit model allows us the possibility to evaluate the effi-
cacy of different drug usage strategies. We conclude with a general principle: the best
performing drug usage policies utilise the highest quality of available information.
On Exactitude in Science
In that Empire, the Art of Cartography attained such Perfection that the map of a single Province
occupied the entirety of a City, and the map of the Empire, the entirety of a Province. In time,
those Unconscionable Maps no longer satisfied, and the Cartographers Guilds struck a Map of the
Empire whose size was that of the Empire, and which coincided point for point with it. The
following Generations, who were not so fond of the Study of Cartography as their Forebears had
been, saw that that vast Map was Useless, and not without some Pitilessness was it, that they
delivered it up to the Inclemencies of Sun and Winters. In the Deserts of the West, still today, there
are Tattered Ruins of that Map, inhabited by Animals and Beggars; in all the Land there is no other
Relic of the Disciplines of Geography.
Suarez Miranda,Viajes de varones prudentes, Libro IV,Cap. XLV, Lerida, 1658.
From Jorge Luis Borges, Collected Fictions.
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Introduction
In 1940, Albert Alexander, a 48 year old London policeman cut himself while shaving. It
was only a minor cut but his case had a major impact in the history of medicine when he
developed septicemia and was treated with an antimicrobial substance Howard Florey and
Ernest Chain had just recently purified. As with many of the great advances in medicine,
the treatment was a success but the patient died. The following attempts to treat blood
poisoning, however, were successful. This promising antimicrobial agent was discovered
accidentally in Saint Mary’s Hospital by Alexander Fleming in 1928, when he observed
in a contaminated dish a mould that prevented the growth of Staphylococcus aureus (a
picture of the famous plate is reproduced in Figure 1a). The mould was later identified
as Penicillium notatum and therefore the antibacterial substance it produced was called
penicillin.
A few years later, in addition to pneumonia and septicemia, at the time the major causes
of death in hospitals, also syphilis, gonorrhoea, meningitis, tonsillitis, rheumatic fever,
scarlet fever, diphtheria and many other diseases were successfully treated with penicillin.
But not everything was good news with this new “wonder drug”. Only a few years after
it was introduced in clinical settings, 25% of the Staphylococcal strains were penicillin-
resistant and by the 1970’s resistance was present in more than 80% of the isolates, a trend
shown in Figure 1b. Nowadays, not only almost none of the staphylococcal infections are
susceptible to penicillin, but they also present high levels of resistance to other antibiotics
like methicillin and vancomycin.
Unfortunately Staphylococcus is not an exception, most of bacterial pathogens present a
remarkable ability to evolve drug resistance to multiple antimicrobial classes. For example,
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(a) (b)
Figure 1: a) Photograph of a culture-plate showing the dissolution of staphylococcal
colonies in the neighbourhood of a Penicillium colony, reproduced from [40]. b) Rates
for penicillin-resistant and meticillin-susceptible strains of Staphylococcus aureus in hos-
pitals (closed symbols) and the community (open symbols), figure extracted from [22].
Mycobacterium tuberculosis has been reported to be resistant to as many as eight different
antibiotics, making some individuals with tuberculosis practically incurable [14]. Actually,
it is known that there is not a single antibiotic class for which bacteria have not evolved
drug-resistance mechanisms [62].
For decades, the antibiotic resistance problem was addressed with a world-wide effort in
finding new antimicrobial agents, but unfortunately the pharmaceutical industry has ba-
sically stopped developing novel antimicrobial substances, focusing their efforts on long-
term treatment of chronic conditions [56, 79]. For instance, the United States Food and
Drug Administration approval of new antibacterial agents decreased 56% from 1983 to
2002 [97].
The paucity of new antimicrobial agents has precipitated what the authors of [44] call “the
search for synergy”, referring to the efforts of the pharmaceutical and medical communities
to find antimicrobial agents that increase their efficacy when used in combination, a drug
interaction known as synergism. For example, the standard treatment protocol for tuber-
culosis in the 1980s was based on a three-drug combination cocktail: isoniazid, rifampin
and pyrazinamide [51]. This regimen was recommended by the American Thoracic Soci-
ety and the CDC when most patients were infected with a susceptible pathogen [1]. A few
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years later, however, this treatment protocol was no longer adequate because of the high
incidence of drug-resistant infections [2]. This observation highlights an important issue
when designing drug combinations: they have to be dynamic in time.
Another possible strategy is to modify drug consumption patterns in health care centres, for
instance by prioritising and restricting different antimicrobial classes according to a prede-
fined hospital-wide policy. A central question, and the one we address in this thesis, is how
should two antibiotics be utilised to treat infected hosts in a hospital or community so as
to minimise the prevalence of antibiotic-resistant pathogens? Clinical trials and theoretical
analyses have been conducted to assess the impact different antibiotic deployment proto-
cols have upon the evolution and spread of drug resistance, moreover previous theoretical
work on this important problem has created a library of epidemiological models we can
explore.
An intervention that has received special attention is antibiotic cycling, a policy in which
two or more antibiotic classes are alternated in time [80]. In a published article [9], we
argue that by relaxing the periodicity constraint of antibiotic cycling, it is theoretically
possible to design drug rotation protocols that are arbitrarily close to the optimum. This
result contradicts previous theoretical research that concluded that “cycling antibiotics may
not be good for your health” [61], claiming instead that antibiotic deployment protocols
based on so-called antibiotic mixing are optimal [13,15]. In mixing protocols, two or more
antimicrobial drugs are used simultaneously for a particular infection and different patients
are treated with different drugs. We will demonstrate later in this thesis that these strategies
based on the random, per-patient allocation of drugs can only be optimal in numerically
rare, non-generic theoretical cases that are not of broad-scale relevance.
Our techniques of analysis make our approach, and subsequent conclusion, distinct from
previous theoretical research. In the first part of this thesis we apply both classical theory
and bespoke optimisation algorithms to determine near-optimal controls for models from
the literature. It is important to mention, however, that in order to exactly determine the
optimal treatment or even the optimal mixing protocol, one would need a model with a
perfect understanding of the future. But is it possible to determine effective treatment
strategies, perhaps suboptimal, based only on current and past patterns of susceptibility
Introduction 19
and resistance? In response to this we propose the development of feedback controls that
take information directly from current observations to inform and adjust future treatment
policies. We believe that this rationale, if applied to public health, could prove invaluable
in the design of effective antibiotic therapies. Of course, we are not promoting the use of
such simple rules for controlling hospitals, as that statement would be far beyond the scope
of this thesis. But we argue that designing such heuristics in theoretical models of drug
deployment provides a tool to probe the surveying effort required to achieve near-optimal
policies.
In response to our paper, the authors of [16] state that even though our mathematical anal-
ysis is correct, non-periodic rotation protocols computed using optimisation techniques are
impracticable policies that rely on the availability of a model that perfectly describes the
patient population dynamics. We agree with Bonhoeffer et al. that without a model cali-
brated against clinical data, it is of limited interest to compute the theoretical optimum and
therefore we only use it as a baseline to evaluate the efficacy of other practicable strategies.
Moreover, we believe that although epidemiological models provide insight into the under-
lying mechanisms that influence the spread of disease at the population level, they fail to
capture the complex molecular interactions between different antibiotics and their targets,
as well as to provide an experimental system to test the efficacy of different treatment pro-
tocols. Hence, in the second part of this thesis we will pose an evolutionary model of an
experimental microbial system that will allow us to control the input of different antibiotics
in time, in order to study the ecological and evolutionary implications of different drug
deployment policies within a single-host.
In particular, we are interested in using this evolutionary model of a microbial microcosm
to design effective multidrug combination therapies. We will show, again using results from
control theory, that although the commensal microbiota may be outcompeted by an invasive
and rapidly evolving pathogen in any fixed multidrug environment, we may still be able to
design drug-deployment protocols based on antibiotic rotation that exclude pathogens from
the system.
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It is noteworthy that this result holds in spite of using two drugs that interact to increase
each other’s efficacy; even in this extreme situation, the optimal protocol is not to use
them in combination but to deploy them sequentially. Furthermore, we will show that even
suboptimal but dynamically changing protocols can succeed where any fixed-ratio combi-
nation treatment fails. This result suggests that in order to remove an evolving pathogen in
the presence of a commensal microbiota, increasing the efficacy of the antibiotics used is
not as important as designing rational deployment strategies.
Interestingly, treating every patient optimally could be interpreted at a population level
as a mixing strategy, which we have already stated to be suboptimal for the community.
The apparent discrepancy between the optimal treatment in a community and the optimal
therapy for an individual is a consequence of different paradigms in health care. Should
we put society first and preserve the efficacy of antibiotics for the community? Or shall we
treat every patient optimally?
To start addressing these questions, in the last part of this thesis we will reconstruct an
epidemiological framework where patients are considered as individual agents interacting
through the transmission of pathogens. This stochastic and spatially explicit model of a
hospital ward will allow us to simulate in silico different hospital-wide strategies of drug
deployment and study the effect that the community has on the disease dynamics of an
evolvable pathogen. This computational framework, in addition to the analysis performed
on the standard epidemiological models and the microbial model system discussed in the
first two parts of the thesis, will allow us to conclude with a general, model-independent
principle: the best performing policies are always dynamic, adaptable and designed using
the highest quality of available information.
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Part I
Epidemiology of drug resistance
22
Chapter 1
Emergence and spread of antibiotic
resistance
Although newsworthy, the problem of antibiotic drug resistance is not new [40]. It is
without exaggeration to say that the continued evolution and spread of antibiotic resistance
in clinically relevant pathogens could prove to be a long-term public health menace. Indeed,
the rate at which bacteria evolve resistance to antibiotics [28, 45, 49] and the continual
downturn in the rate of discovery of new antimicrobials [79] should be sufficient to force
us to continually re-examine our attitudes towards antimicrobial therapy.
Different stewardship programs have been proposed to control antibiotic resistance in health
care centres [67, 94], with the objective of reducing the overall use of antibiotics, slowing
down the transmission rate of resistant strains and minimising conditions that promote the
evolution of drug resistance. For instance by introducing strict hygiene guidelines in health
care workers, by modifying drug prescription patterns in patients or in clinical settings [91]
and in general by continually re-evaluating basic dose adjustment principles [88].
In this thesis we are interested in studying policies based on prioritising and restricting dif-
ferent antimicrobial classes, as well as strategies designed to combine multiple antibiotics
with the purpose of increasing drug efficacy while selecting against resistant phenotypes.
With this in mind, later we will pose different single-host and epidemiological models that
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will allow us to compare the relative merits of different drug usage strategies, but first we
would like to discuss an intervention that has received special attention from the medi-
cal [17, 80] and theoretical [9, 13, 15, 63] communities: antibiotic rotation.
This policy is based on periodically restricting and prioritising antibiotics from different
functional classes, with the intention of decreasing selective pressures to any one antimicro-
bial class. Although the outcome of some clinical trials support their efficacy [3,70,71,84],
other studies argue in the opposite direction [91,106,109,111]. We could cite many studies
both for and against cycling, but suffice to say that there is no clear and definitive evidence
to support the implementation of drug rotation as a universal principle, as it is further dis-
cussed in the following section.
1.1 To rotate, or not to rotate?
Antibiotic rotation was proposed over a decade ago as a way of reducing the incidence of
antibiotic-resistant infections. This view, articulated by Niederman in the editorial Is “Crop
Rotation” of Antibiotics the Solution to a “Resistant” Problem in the ICU? (see [80]) states
“The ‘crop rotation’ theory of antibiotic use has suggested that if we routinely
vary our ‘go to’ antibiotic in the ICU (intensive care unit), we can minimize the
emergence of resistance..."
In the intervening decade, a number of theoretical studies have espoused a different view-
point in proposing that the heterogenous, random deployment of antibiotics in an ICU unit
or hospital can slow the evolution and spread of drug-resistant pathogens. These theoretical
studies have concentrated on a direct comparison between cycling and mixing protocols,
concluding that mixing reduces the prevalence of resistance optimally [13, 15, 61].
Clinical trials designed to evaluate the efficacy of protocols that increase drug heterogene-
ity across both hospitals and surgical wards, a property associated with random mixing,
have had both beneficial [104] and insignificant outcomes [105]. With respect to cycling
protocols, the medical community has tacitly proposed that the nature of antibiotic cycling
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could be relaxed when developing trials and conducting theoretical studies. For example,
in contrast to previous studies that assume the same period of time for each antibiotic to be
deployed, the authors of [17] pointedly ask ‘What is the optimal duration of each cycle?’.
In this thesis we address this question by applying classical results from mathematical sys-
tems theory, and demonstrate that the optimal treatment is neither antibiotic mixing nor
cycling. Instead, a form of drug rotation is optimal. This protocol has some features of
cycling in the sense that only one antibiotic should be deployed throughout the population
at a time, but the optimal therapy does not cycle periodically; the duration of the cycles
must be allowed to vary.
It is important to emphasise there is no discrepancy between the theoretical findings of
[13, 15] and the results presented in this thesis; the apparent difference between the two
sets of results rests in the interpretation of what antibiotic rotation means. The citation of
Niederman hints at a scheduled and cyclical rotation that exchanges one drug for another
periodically, where that period is fixed at the start of a clinical trial, say, just as a crop
rotation might only change the crop with each new season. The results presented in [13,
15] show that this idea may not work for standard epidemiological, SI models of drug
deployment.
We agree with [13, 15] that there is no theoretical basis to support the optimality of sched-
uled antibiotic rotation. However, as we will discuss later in this thesis, it is equally true
that the random allocation of drugs to each patient is not optimal either.
In terms of empirical evidence for and against the cycling of antibiotics, some studies
support rotation [70, 84] but others either advocate against it or at least indicate indiffer-
ence [106, 109, 111]. For example, the rotation of linezolid and vancomycin in an ICU
has been called a ‘promising method to reduce infections with MRSA’ [96] but rotation
has also been implicated as a possible cause of an outbreak of multi-drug resistant Pseu-
domonas aeruginosa [47]. Empirical studies evaluating the efficacy of antibiotic rotation
prior to 2005 have also been criticised for ‘multiple methodological flaws and a lack of
standardization’, a particular criticism being the lack of repetition of cycles within rota-
tional protocols [17].
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In order to place our analysis into an empirical context we will implement the idea that
‘...prescription patterns balancing the use of different antimicrobials should be promoted to
reduce selection pressure’ from [91] to create a feedback control strategy that balances the
use of different antibiotics. To design the rules for this controller we distill the following
observation taken from [3] into a mathematical form:
“A non-premeditated change of antibiotics in empirical therapy, on the basis
of detected resistance patterns, provided promising results in reducing some
antimicrobial resistance rates."
We interpret this quotation as a maxim that can be employed to control the spread of re-
sistance in theoretical models of antibiotic use, this maxim states: if the observed level of
resistance to an antibiotic is too high, exchange it for a different antibiotic.
It is the resultant adaptive rotation of antibiotics based on the observation, or even partial
observation, of those dynamics that may lead to the optimal protocol and minimise selec-
tion for drug-resistant pathogens. We arrive at this theoretical result by observing that the
optimal protocol will exchange one antibiotic for another across the theoretical ICU unit
or hospital, not routinely or randomly, but in a manner commensurate with the epidemio-
logical and evolutionary dynamics observed in each context. For instance, the rotational
protocols as they are modelled in [13,15] switch between the prioritisation of two drugs in
such a way that one of them is designated the ‘go-to’ drug at every moment in time. As we
explain later, this form of antibiotic protocol can be written as a bang-bang function which
allows us to apply standard control-theoretic results (see [41], for example) and deduce the
theoretical optimality, or at least near-optimality, of rotational protocols.
Using optimisation techniques we will compute the optimal rotation protocol for specific
models of drug deployment, and illustrate by example that the implementation of very
simple heuristics can outperform the random allocation of drugs, but first let us be precise
about the differences between antibiotic cycling, antibiotic rotation and antibiotic mixing
protocols.
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Throughout this thesis, unless stated otherwise, we will consider that we can deploy into
the system two antibiotics labelled ‘drug A’ and ‘drug B’.
Definition 1.1.1 If we denote with A(t) and B(t) the fraction of the population receiving
each drug at time t, and we assume that no patient is left untreated, a property expressed
mathematically as B(t) + A(t) = 1, then a rotation protocol satisfies
A(t)B(t) = 0
for almost all t within the time interval [0, T ]. The function A(t) so-defined tells us when
to treat everyone with drug A and hence the number ‘1’ in the must-treat constraint. Con-
sequently if A(t) is zero, everyone in the population is treated with drug B.
Note that the terms alternating protocol and sequential protocol are used synonymously for
the term antibiotic rotation in the remainder of the thesis.
For illustration purposes, we shall use a barcode graphic to denote the deployment of two
different antibiotics as part of a rotational protocol, as shown in Figure 1.1. This graphic
shows that all patients are treated initially with drug A, before a switch is invoked at time
T1 to drug B.
B A AB B
time
1
0
drug choice T
A
(a)
B A AB B
time
1
0
drug choice T
(b)
Figure 1.1: Barcodes are used to represent the timing of switches between antibiotics
A and B: in a rotational protocol each antibiotic is either deployed at its maximum rate,
or is not deployed at all. (a) A congruent cycling protocol whereby T = 3(τ1 + τ2). (b)
A non-congruent cycling protocol: it is possible that the observation time, T , could fall
mid-cycle for the best protocols; this possibility is not analysed here.
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Definition 1.1.2 Cycling protocols can be described by any measurable, almost-everywhere
periodic function A(t) that can take values 0 or 1, denoting that either none of the patients
are being treated with drug A or everyone is being prescribed with this drug. The must-
treat constraint B(t) = 1 − A(t) also holds here, so if A(t) = 0 nobody is receiving
treatment with drug A and drug B is being prescribed across the entirety of the hospital or
community.
Cycling protocols can be characterised using two parameters, τ1 and τ2, and a function
A(τ1, τ2)(t), defined for all t within the time interval [0, T ] such that
A(τ1, τ2)(t) =
{
1 : 0 ≤ t ≤ τ1,
0 : τ1 < t ≤ τ1 + τ2,
and extended so that A(τ1, τ2) has period τ1 + τ2.
Definition 1.1.3 IfA(t) is constant and 0 ≤ A(t) ≤ 1 almost everywhere, then we call this
strategy a mixing protocol. The epidemiological interpretation of A(t) being a constant is
that a fixed fraction of the population is being treated with drug A, while the remaining
individuals are prescribed with antibiotic B.
Any protocol whereby ∫ T
0
A(t)dt =
∫ T
0
B(t)dt
will be described using the prefix ‘50-50’.
Therefore a ‘50-50 mixing’ protocol is interpreted as half of the population is receiving
drug A while the other half is treated with B. Note how the so-called ‘random deployment
of drugs’ throughout a population satisfies in average with this definition.
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1.2 Mathematical models of antibiotic use
From a theoretical perspective, previous studies have investigated the efficacy of different
drug deployment protocols both in the community [15] and in health care centres [13, 63],
the minimisation of treatment duration [30], the evolution of multiple resistance [15, 29],
cost-effectiveness of infection control policies [112] and heterogeneous spatial effects [32].
In the debate on whether periodic cycling, mixing or some other form of antibiotic de-
ployment regimen provides for the most appropriate form of treatment, a number of the-
oretical studies have indicated that periodically cycling antibiotics may not be the best
choice [13, 15, 61]. The modus operandi used within these studies can be described as fol-
lows. A mathematical model describes the dynamics of a population supplied with infected
individuals from a community who are then treated according to a given hospital-wide pol-
icy, where different antibiotic treatment policies are represented by different mathematical
functions that may vary in time. By simulating the model with different treatment policies,
one can compare their respective outcomes and so make a decision as to which treatment
was the most appropriate from all of those simulated. The utility of such a ‘what if?’
modus operandi is clear, simply design different drug usage strategies and compare them
numerically. This approach, however, cannot begin to address questions of generality or
robustness of the most appropriate regimen of those tested.
In the following sections we will briefly describe the most important epidemiological mod-
els of antibiotic use published in the literature [13,15,27]. These deterministic mathemati-
cal models are designed to study the deployment of two antibiotics into a community or a
hospital, and do not explicitly incorporate the spatial dynamics of pathogen transmission.
1.2.1 Bonhoeffer, Lipsitch and Levin (1997)
The first theoretical model that described epidemiology of antimicrobial resistance in a
community was proposed by Bonhoeffer et al. in [15]. A particular case of this model (Case
III) whereby multiply resistant bacteria are not present is illustrated by the compartments
shown in Figure 1.2, and its dynamics can be described with the following set of differential
Chapter 1. Emergence and spread of antibiotic resistance 29
equations:
x˙ = λ− dx− b(yw + ya + yb)x+ rwyw + raya + rbyb + ... (1.1a)
...+ h(1− s)((fa + fb)yw + fayb + fbya),
y˙w = (bx− c− rw − h(fa + fb))yw, (1.1b)
y˙a = (bx− c− ra − hfb)ya + hsfayw, (1.1c)
y˙b = (bx− c− rb − hfa)yb + hsfbyw, (1.1d)
whereby the state variable is given by s := (x, yw, ya, yb); x denotes the density of un-
infected hosts in a hospital or intensive care unit, yw is the density of hosts infected by
wild-type bacterial strain, ya are hosts infected with A-resistant bacteria and yb are hosts
infected with B-resistant strains. There are no multidrug-resistant bacterial strains in this
model, although that case is discussed in [15].
Figure 1.2: Transmission dynamics of the epidemiological model proposed in [15, Case
III]; x denotes the density of uninfected individuals, yw, ya and yb hosts infected with
susceptible, A-resistant and B-resistant bacteria respectively.
The epidemiological interpretation of the parameters used in (1.1) is described in Table
1.1. It is important to mention that there are two different mechanisms by which patients
can be infected with resistant pathogens: through the epidemic spread of resistant pheno-
types or by the acquisition of ‘de novo’ resistance, the latter only occurring in treated hosts.
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Table 1.1: Description of the parameters used in the model of drug deployment in the
community proposed in [15].
parameter meaning
fa, fb the fraction of patients treated with antibiotic A and B
rw, ra, rb recovery rates of wild-type, A-res and B-res infected hosts
b transmission rate of infection
h maximum rate at which patients are treated
s fraction of patients that acquire resistance when treated
d per capita death rate of uninfected hosts
λ arrival rate of uninfected hosts
c infected hosts’ death rate
Recovery from infection coincides with the termination of transmission of pathogens be-
tween patients, and the fitness cost associated with drug resistance is expressed by a higher
recovery rate of infected hosts with resistant bacteria relative to those infected with sus-
ceptible pathogens, a property expressed by the inequality rr > rw. This model does not
include superinfection of wt-infecteds by resistant pathogens.
In (1.1), fa is a variable that may depend on time and denotes the proportion of infected
hosts treated with antibiotic A, fb is the proportion of hosts treated with a second antibiotic
B, we shall invoke a must-treat everyone constraint meaning that fa(t) + fb(t) = 1 for all
times t ≥ 0.
As discussed by Bonhoeffer et al., the optimal antibiotic policy would be the treatment
protocol that preserves and restores antibiotic effectiveness, a goal that could be achieved
by maximising the number of uninfected hosts or by minimising the number of infected
patients. Another possible objective could be to maximise the time before resistant bacte-
ria constitute some fixed fraction of all bacteria of a given species. The analysis of [15]
attempts to balance the short-term benefit due to the use of the antibiotic while trying to
preserve drug efficacy in the long term. Mathematically this optimality criterion can be
represented by minimising the number of infected hosts integrated over time, that is:∫ T
0
(yw(t) + ya(t) + yb(t)) dt.
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The purpose of the study presented in [15] is to evaluate the efficacy of different antibi-
otic usage patterns in preventing the evolution of antibiotic resistance. To achieve this
goal, different single-drug treatments and multi-drug combination strategies were com-
pared through straightforward numerical simulations. In particular, periodic cycling proto-
cols were compared with a 50-50 mixing strategy whereby fixed fractions of the population
receive each drug at any given moment in time. Combination treatments, where drugs are
prescribed simultaneously to each infected host, were also studied.
Definition 1.2.1 The 50-50 mixing protocol for (1.1) is defined by taking a constant value
for the treatment protocol fa, namely
fa(t) = 1/2
for all t ≥ 0. The interpretation of this condition is that exactly half of all infected hosts
are treated with drug A, half with drug B so that fb(t) = 1/2 too. As the model (1.1) does
not track individual treatments, so this strategy corresponds to the random allocation of
the two drugs per infected patient.
The main results of the study presented in [15] can be summarised as follows:
• The performance of different single-drug strategies is independent of the patterns of
antibiotic use, although there is a slight increase in benefit if the drug is used heavily
in the early stages.
• Faster rates of antibiotic treatment accelerate the emergence of resistance.
• When treatment is withdrawn, resistant infections reverse to susceptible more slowly
than resistance is acquired under treatment.
• When more than one antibiotic is employed, multidrug combinations are in most
cases the optimal treatment strategy.
• 50-50 treatments are always superior to antibiotic cycling, regardless of how
frequently the drugs are cycled.
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1.2.2 Bergstrom, Lo and Lipsitch (2004)
A different model was proposed by Bergstrom et al. in [13] to study antimicrobial cycling in
a hospital setting. This model can be represented by compartments like the ones illustrated
in Figure 1.3a, where X denotes uncolonised patients, S denotes the fraction of patients
in an ICU unit colonised with an antibiotic susceptible pathogen, R1 and R2 represent the
fraction of patients colonised by bacteria resistant to antibiotic 1 and 2 respectively. If we
denote the state of the system as s = (S,R1, R2, X), then the model can be written as:
S˙ = µ(m− S)− (τ1 + τ2 + γ)S + βSX + σβ(c1R1 + c2R2)S (1.2a)
R˙1 = µ(m1 −R1)− (τ2 + γ)R1 + β(1− c1)R1X − ... (1.2b)
...− σβ(c1S + (c1 − c2)R2)R1
R˙2 = µ(m2 −R2)− (τ1 + γ)R2 + β(1− c2)R2X (1.2c)
...− σβ(c2S + (c2 − c1)R1)R2
X˙ = µ(1−m−m1 −m2 −X) + (τ1 + τ2 + γ)S + (τ2 + γ)R1... (1.2d)
...+ (τ1 + γ)R2 − βX(S + (1− c1)R1 + (1− c2)R2).
The interpretation of the parameters used in this model are given in Table 1.2.
Note that [13] also imposes the must-treat constraint that τ1(t) + τ2(t) = τmax for all
0 ≤ t ≤ T , where τmax is a fixed parameter that determines the maximum rate of drug use,
and that the 50-50 mixing protocol is defined by taking a constant value for the treatments:
τ1(t) = τmax/2 for all t.
The main difference between this model and the community-based model posed by Bon-
hoeffer et al. is that here individuals enter and leave the ICU unit at a very high rate, and
therefore a hospital is considered to be an open system, while a community is relatively
closed. In addition, patients enter the hospital asymptomatically colonised with the species
responsible for the nosocomial infection. Moreover, antimicrobial drugs are in principle
used at much higher rate in clinical settings than in communities.
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(a) (b)
Figure 1.3: (a) Graphical illustration of the model described by equations (1.2). The
variables and parameters are explained in the main text. (b) Illustration of the model
(1.3) whereby the model (1.2) is extended to include another compartment representing
infections by multidrug resistant bacteria.
The purpose of the mathematical study presented by Bergstrom et al. is to illustrate that
a simple ecological explanation underlies why, in most of their numerical simulations, an-
tibiotic cycling is outperformed by strategies in which each patient under treatment is pre-
scribed with a random antimicrobial drug.
In order to compare the efficacy of different strategies, the objective in the context of this
model can be represented as minimising the frequency of patients colonised by a resistant
strain during an observation interval of length T , a goal that can be achieved by minimising
the following expression: ∫ T
0
(R1(t) +R2(t)) dt.
The main conclusion drawn from this study is that the prevalence of drug resistance is
greater for cycling of any period than 50-50 mixing, and in fact increases monotonically
with the cycle period.
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Table 1.2: Meaning of parameters used in the model of an ICU unit posed in [13].
parameter meaning
τ1, τ2 rate of use of drugs 1 and 2 per unit time (days)
m,m1,m2 patients enter hospital in states S,R1 and R2 at rates µm, µm1 and µm2 resp.
c1, c2 fitness cost of resistance to bacteria
σ relative rate of secondary colonization to primary colonization
β rate constant for colonization of uncolonized individuals
γ untreated patients colonized by susceptible bacteria remain
colonized 1/γ days on average
µ rate of patient turnover in the hospital
α represents physician compliance with cycling program
1.2.3 Chow, Wang and Castillo-Chavez (2007)
In order to consider multidrug resistance in the model of an ICU unit described by equations
(1.2), an unpublished study by Chow et al. [27] extends this model to include the possibility
of individuals being colonised by a bacteria that is resistant to both antibiotic 1 and 2.
The underlying transmission dynamics of this model can be represented by the compart-
ments illustrated in Figure 1.3b, and written mathematically as:
S˙ = µ(m− S)− (τ1 + τ2 + γ)S + βSX + σβ(c1R1 + c2R2 + c12R12)S (1.3a)
R˙1 = µ(m1 −R1)− (τ2 + γ)R1 + β(1− c1)R1X − ... (1.3b)
...− σβ(c1S + (c1 − c2)R2 − c12R12)R1
R˙2 = µ(m2 −R2)− (τ1 + γ)R2 + β(1− c2)R2X + ... (1.3c)
...− σβ(c2S + (c2 − c1)R1 − c12R12)R2
R˙12 = µ(m12 −R12)− γR12 + β(1− c12)R12X + ... (1.3d)
...− σβc12(S + (1− c1)R1 + (1− c2)R2)R12
X˙ = µ(1−m−m1 −m2 −m12 −X) + (τ1 + τ2 + γ)S + (τ2 + γ)R1 + ... (1.3e)
...+ γR12 + (τ1 + γ)R2 − βX(S + (1− c1)R1 + (1− c2)R2 + (1− c12)R12).
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Table 1.3: The parameters used in the extension of the model of an ICU unit to include
colonisation by multidrug resistant pathogens.
parameter meaning
R12 patients colonised by bacteria that are both antibiotic 1 and 2-resistant
m12 patients enter hospital in states R12 at rates µ12
c12 fitness cost of multidrug resistance to bacteria
The interpretation of the parameters used in addition to the ones described in Table 1.2
are given in Table 1.3. Note that we also have to modify the treatment payoff in order to
minimise both single-drug and multidrug-resistant infections in an observation interval of
duration T : ∫ T
0
(R1(t) +R2(t) +R12(t)) dt.
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Chapter 2
A control-theoretic approach
Here we take tools from the theory of optimal control and re-examine the epidemiological
models presented in the previous chapter, with the purpose of answering the following
fundamental questions. What is the optimal drug deployment protocol? Is the optimal
policy robust to modelling and parametric uncertainties? How easy is it to design and to
implement? How effective is it?
In this chapter we will show that the optimal treatment protocol has a universal form that
is model-independent and a classical engineering solution: a bang-bang control whose
structure is independent of the underlying biology. Moreover, this solution has a clear
epidemiological interpretation: to achieve optimality one should deploy a single antibiotic
throughout the entire population, eventually replacing it with a different one. We will also
show that through the design of feedback controllers it is possible to decide based on local
patterns of resistance when it is best to switch antibiotics. Finally, we will demonstrate
that antibiotic mixing protocols are only optimal in rare circumstances that are not robust
to parametric uncertainties.
It is important to mention that we are not the first to propose that optimal control theory
could be employed to probe either problems in drug delivery or the problem of antibiotic
deployment. For example, [19] finds bang-bang solutions to the question of how to use
principles of optimality to aid immunotherapy, while [59] applies control theory to the
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chemotherapy of HIV. A discussion can be found in [86] of how to use an optimal control
approach to decide how to best deploy antibiotics, but a claim is made that the failure of
certain convexity requirements prevents the construction of analytic solutions of problems
like the ones we study, a conclusion based on a discussion in [55, 90]. Of course, we agree
with these studies that optimal control theory could be an aid of unprecedented power in
the design and analysis of antibiotic deployment policies.
2.1 Parameter values for simulations: the importance of asymmetry
A crucial biological assumption is used in [13, 15] to simplify the modelling problem,
namely antibiotic symmetry. This assumption is not benign. It is a mathematical degener-
acy and we will use it to prove that antibiotic rotation is optimal whenever such a symmetry
property is not present in a mathematical, epidemiological model of antibiotic use.
Throughout the thesis the term parameter-initial condition set (PICS) will be used for the
set of epidemiological parameters and initial conditions defined within the models (1.1)
and (1.2), note that each element of a PICS forms a pair that we shall write throughout as
(p, s0). The following important definition makes explicit the term symmetric as it is used
in [13] and [15].
Definition 2.1.1 If (p, s0) denotes a PICS for (1.1), we say it is symmetric if
ra = rb and ya(0) = yb(0).
If (p, s0) denote a PICS for (1.2), we say it is symmetric if
c1 = c2,m1 = m2 and R1(0) = R2(0).
The two PICSs (p(1), s(1)0 ) and (p
(2), s
(2)
0 ) so-defined are asymmetric in the sense of Defini-
tion 2.1.1, contrasting with the values chosen for numerical simulations in [13, 15] where
symmetric values are used.
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Mathematical models that have symmetric parameter values and initial conditions can be
thought of as descriptions of antibiotic deployment problems in which the fundamental
epidemiological properties of the drugs are identical. This means that there are equal fitness
costs of antibiotic resistance to the pathogenic bacteria, equal transmission rates of those
pathogens or equal prevalence of resistant phenotypes at the beginning of an observation
period. However, while it is natural to support antibiotic symmetry on the grounds of
numerical parsimony, we claim it is unlikely that two antibiotics will exert precisely the
same selection pressures on bacterial pathogens. As a result we have chosen to use slightly
different parameter sets for our illustrative simulations given later in the Section 2.6 from
those found in [13, 15] in order to mimic the deployment of two antibiotics from distinct
functional groups as defined, for example, in the sense of [116].
Furthermore, we make the claim that both models (1.1) and (1.2) must reflect this fun-
damental property on biological grounds too. For instance consider two antibiotics, ri-
fampicin and sorangicin A, that have the same mode of action and bind to the same residue
on their common target protein, inhibiting the synthesis of mRNA by binding to the β sub-
unit of RNA polymerase. Rifampicin causes the bacterial cell to abort transcription at the
elongation phase, as does sorangicin, albeit with slightly different abortive transcripts and
the gene rpoB controls resistance mutations to both antibiotics. However, it is known [20]
that mutations in rpoB conferring resistance to rifampicin need not confer resistance to so-
rangicin because of the greater flexibility of the sorangicin A molecule (also see [115]);
thus functionally identical antibiotics may be different from an evolutionary perspective.
As a result we argue that we should seek to understand the structure of the optimal solutions
for all parameter sets, whether symmetric or asymmetric, and in the remainder of this
chapter we will discuss the mathematical reasons why the symmetric case is so special.
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2.2 Statement of the control problem
A control problem is to determine an admissible control such that the response of the system
is driven towards a given target in such a way that a certain optimality criterion is achieved,
expressed by minimising some measure of cost or by maximising a given payoff functional.
If there exists at least one successful control that satisfies the corresponding constrained
optimisation problem, then we say that the system is controllable.
For example, the optimal control problem for (1.1) is to determine the protocol fa(t) that
minimises the observed prevalence of resistance over a given time period of length T :
Problem 1
{
min
∫ T
0
(yw(t) + ya(t) + yb(t)) dt subject to constraints
0 ≤ fa(t) ≤ 1, fb(t) = 1− fa(t) and equation (1.1),
while the optimal treatment problem for (1.2) is to minimise the observed prevalence of
antibiotic-resistant infections subject to treating at the maximum rate possible. We state
this mathematically as follows:
Problem 2
{
min
∫ T
0
(R1(t) +R2(t)) dt subject to constraints
0 ≤ τ1(t) ≤ τmax, τ2(t) = τmax − τ1(t) and equation (1.2).
Remark 1 In Problem 1 the units of the treatment payoff functional∫ T
0
(yw(t) + ya(t) + yb(t)) dt
is the total number of patients infected over the period observed. In Problem 2 the treat-
ment payoff ∫ T
0
(R1(t) +R2(t)) dt
must be multiplied by the total population size in the hospital (some fixed and unknown
constant) in order to represent the total number of patients infected with antibiotic-resistant
pathogens over the period observed. So,
∫ T
0
(R1(t) +R2(t)) dt/T is the per unit time,
mean fraction of patients infected with drug-resistant pathogens; it is unimportant whether
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or not we divide by T when minimising the treatment payoff as T is a fixed parameter.
In order to solve Problems 1 and 2, first note that the differential equations can both be
written in the abstract form
s˙ = f(s, p) + A(t) g(p) · s+B(t) G(p) · s, s(0) = s0 ∈ Rk. (2.1)
Equation (1.1) can be written in the form (2.1) as follows: first set s = (x, yw, ya, yb) and
then
f(s, p) = (λ− dx− b(yw + ya + yb)x+ rwyw + raya + rbyb, ...
(bx− c− rw)yw, (bx− c− ra)ya, (bx− c− rb)yb)
so that
g(p) =

0 h(1− s) 0 h(1− s)
0 −h 0 0
0 hs 0 0
0 0 0 −h
 and G(p) =

0 h(1− s) h(1− s) 0
0 −h 0 0
0 0 −h 0
0 hs 0 0
 .
For equation (1.2) we have s = (S,R1, R2, X) and
f(s, p) = (µ(m− S)− γS + βSX + σβ(c1R1 + c2R2)S,
µ(m1 −R1)− γR1 + β(1− c1)R1X − σβ(c1S + (c1 − c2)R2)R1,
µ(m2 −R2)− γR2 + β(1− c2)R2X − σβ(c2S + (c2 − c1)R1)R2,
µ(1−m−m1 −m2 −X) + γS + γR1 + ...
...+ γR2 − βX(S + (1− c1)R1 + (1− c2)R2)
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with
g(p) =

−1 0 0 0
0 0 0 0
0 0 −1 0
1 0 1 0
 and G(p) =

−1 0 0 0
0 −1 0 0
0 0 0 0
1 1 0 0
 .
The fact that (1.1) and (1.2) can both be written in the form of (2.1) allows us to deduce
properties of these two specific models by deducing properties from the more general and
structural form of (2.1).
Now, equation (2.1) is a differential equation on a four-dimensional state-space Σ of non-
negative vectors, so s(t) ∈ Σ for all t, where the parameter vector p lies in a space J of
positive parameter values and so a PICS, (p, s0) say, is an element of J × Σ. In Problem
1 we have s = (x, yw, ya, yb) whereas in Problem 2 we write s = (S,R1, R2, X). The
parameter-dependent linear maps g(p) and G(p) describe how the different rates of input
of each antibiotic into the system drive the epidemiological dynamics of that system.
The optimality criteria in Problems 1 and 2 can now be written in an abstract form by
defining a weight vector, call itw, setting A(t) +B(t) ≡ C, the latter a fixed constant, and
then seeking a protocol A(t) ∈ L∞(0, T ) that achieves
Problem A
{
min
∫ T
0
〈w, s(t)〉dt subject to constraints
0 ≤ A(t) ≤ C, A(t) +B(t) ≡ C and equation (2.1);
the optimal protocol that solves Problem A will be denoted throughout byA∗(t). Note that
both Problems 1 and 2 have the same form as Problem A and so any statement made of
Problem A regarding the structure ofA∗(t) has immediate consequences for both Problem
1 and Problem 2.
For each measurable control or deployment function A satisfying 0 ≤ A(t) ≤ C, the
corresponding solution sA obtained by solving the differential equation (3.2) yields a value
of the functional
J (A) :=
∫ T
0
〈w, sA(t)〉dt
that will be denotedJ (A) throughout the remainder and called the treatment objective. The
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function of t, 〈w, sA(t)〉, will be called the running objective associated withA. Moreover,
for Problems 1 and 2 the weight vectors are
w = (0, 1, 1, 1) and w = (0, 1, 1, 0),
respectively.
Implementing the must-treat constraint A(t) +B(t) = C in equation (2.1) yields
s˙ = f(s, p) + A(t) g(p) · s+ (C− A(t)) G(p) · s,
= f(s, p) + C ·G(p) · s+ A(t)(g(p)−G(p)) · s, (2.2)
and so we define, here and throughout,
G(p) := g(p)−G(p) and F(s, p) := f(s, p) + C ·G(p) · s.
Thus, if there is any parameter value p′ for which g(p′) = G(p′) then the set
{(p′, s0) : s0 ∈ Σ}
must lie in the mixing PICS because the independence of equation (3.2) of A in this case
renders the treatment objective identical for all deployment protocols. This is a trivial form
of degeneracy that causes the mixing PICS M to be non-empty; we discuss less trivial
examples below.
The Lagrangian of Problem A is
L(s,λ, A) =
∫ T
0
〈w, s〉+ 〈λ,−s˙+ F(s, p) + A · G(p)s〉 dt,
and the Hamiltonian H is
H(s,λ, A) = 〈w, s〉+ 〈λ,F(s, p)〉+ 〈λ,G(p)s〉 · A,
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finally, the adjoint variable λ satisfies the final-value problem
− λ˙ = w + (Fs(s, p)T + A · G(p)T )λ, λ(T ) = 0. (2.3)
As is well-known, the Hamiltonian associated with (3.2-2.3) is maximised at all times along
an optimal solution (s∗,λ∗, A∗) of Problem A with respect to the control variable A:
H(s∗(t),λ∗(t), A∗(t)) = max
0≤a≤C
H(s(t),λ(t), a).
Now max{H(s∗(t),λ∗(t), a)|0 ≤ a ≤ C} occurs when a = C if 〈λ∗(t),G(p)s∗(t)〉 > 0
and when a = 0 if 〈λ∗(t),G(p)s∗(t)〉 < 0, if 〈λ∗(t),G(p)s(t)〉 = 0 then A(t) is said to be
singular. The solution of the optimal control problem Problem A is therefore a bang-bang
function A∗(t) taking only the values 0 and C unless t takes values in an interval where the
switching function (λ∗(t),G(p)s∗(t)) is zero:
A∗(t) =

C if 〈λ∗(t),G(p)s∗(t)〉 > 0
0 if 〈λ∗(t),G(p)s∗(t)〉 < 0
something else if 〈λ∗(t),G(p)s∗(t)〉 = 0.
(2.4)
Bang-bang controls correspond precisely to the antibiotic rotational protocols of Problem
A and from the form of the optimal control A∗ given in (2.4) we deduce that Problem A
may only have a solution that is a mixing protocol when
σ(t) := 〈λ∗(t),G(p)s∗(t)〉 = 0 (2.5)
for almost all t between 0 and T .
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2.3 When is mixing optimal?
Now, we will use condition (2.5) to rule out mathematical models within Problem A for
which mixing outperforms antibiotic rotation, by deducing the technical conditions on F
and G under which there can be no solution of Problem A representing an antibiotic mixing
protocol.
Theorem 2.3.1 Suppose that ω∗ ∈ (0,C) is a fixed constant and that
〈w,G(p)s0〉 6= 0, (2.6)
then there is a T > 0 such that for no T ∈ (0, T ) is A∗(t) ≡ ω∗ a mixing solution of
Problem A. However, if 〈w,G(p)s0〉 = 0 and either
〈w,G(p)(F(s0, p) + ω∗G(p)s0)〉 6= 0, or (2.7a)
〈w, (Fs(s0, p) + ω∗G(p))G(p)s0〉 6= 0, (2.7b)
then there is a T > 0 such that for no T ∈ (0, T ) is the constant function A∗(t) ≡ ω∗ a
solution of Problem A.
Proof Begin by defining a new time-scale τ := t/T and re-writing the Euler-Lagrange
equations of Problem A, namely (3.2-2.3), in the form
s˙ = T (F(s, p) + A(t)(g(p)−G(p))), s(0) = s0, (2.8)
−λ˙ = T (w + (Fs(s, p)T + A · G(p)T )λ), λ(1) = 0. (2.9)
Now setm := λ/T so that
− m˙ = w + T (Fs(s, p)T + A · G(p)T )m), m(1) = 0. (2.10)
To complete the proof we shall need the following auxiliary lemma.
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Lemma 2.3.2 Suppose that s(t) = (s1(t), ..., sk(t)) is any continuous function defined on
[0, 1] such that s(0) = s0,m ≤ si(t) ≤ M for all 1 ≤ i ≤ k and that A : Rk → L(Rk) is
a continuous map. If w ∈ Rk is any vector then the solution λ ∈ C1([0, 1],Rk) of
λ˙(t) = T (A(s(t))λ+w)
with λ(1) = 0 satisfies
‖λ(t)‖∞ ≤ ‖w‖2(eTρ − 1)ρ−1,
where ρ = max{‖A(s)‖2 : m ≤ s ≤ M}. Hence m(t) := λ(t)/T satisfies ‖m(t)‖∞ ≤
‖w‖2(eTρ − 1)/(Tρ).
Proof Let Φ(t) be the smooth, one-parameter family of matrices that satisfies
Φ˙(t) = T · A(s(t))Φ(t), Φ(0) = I.
If u ∈ Rn is any vector then |(A(s)u,u)| ≤ ‖A(s)‖2‖u‖22 and so
d
dt
‖Φ(t)u‖22 = 2T (A(s(t))Φ(t)u,Φ(t)u) ≤ ‖A(s(t))‖2 · 2T‖Φ(t)u‖22
≤ max
m≤s≤M
‖A(s)‖2 · 2T‖Φ(t)u‖22
and so ‖Φ(t)u‖2 ≤ eρT t‖Φ(0)u‖2 = eρT t‖u‖2 from where ‖Φ(t)‖2 ≤ eρT t. Now λ(t) =
T
∫ t
1
Φ(t− t′)wdt′ and so
‖λ(t)‖∞ ≤ ‖λ(t)‖2 ≤ T
∫ 1
0
‖Φ(t− t′)‖2‖w‖2dt′ ≤ T‖w‖2
∫ 1
0
eTρ(t−t
′)dt′
and the result follows. 
The proof of Theorem 2.3.1 follows immediately below and to reduce notational clutter we
assume without loss of generality that the constant C defined in Problem A equals one.
Suppose that a parameter value T , that we label T ∗, exists for whichProblem A has optimal
control A∗ ≡ ω∗ ∈ (0, 1) with treatment objective J (ω∗) and so we may suppose (s∗,m∗)
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is a solution of the re-scaled Euler-Lagrange equations (2.8-2.9). If we now define
S∗(t) := s∗(t)− s0,
we may re-write the Euler-Lagrange equations associated with Problem A as a nonlinear
operator equation that we denote E(S,m, T, ω) = 0, where
E(S,m, T, ω) :=
(
−S˙ + T (F(s0 + S, p) + ω · G(p)(s0 + S))
m˙+ T (FTs (s0 + S, p) + ω · G(p)T )m+w
)
.
Hence E(S∗,m∗, T ∗, ω∗) = 0 for (S∗,m∗) ∈ U × V where
U := {S ∈ C1([0, 1],Rk) : S(0) = 0} and V := {m ∈ C1([0, 1],Rk) : m(1) = 0}
are Banach spaces when endowed with standard C1 norms and
E : U × V × R→ C0([0, 1],Rk)× C0([0, 1],Rk)
is an everywhere continuously Fréchet differentiable nonlinear mapping.
Define the following isomorphism of Banach spaces D : U × V → C0([0, 1],Rk) ×
C0([0, 1],Rk) given by the differential operator
D(S,m) =
d
dt
(−S,m).
Being an isomorphism, D is a linear operator of Fredholm index 0 but then
∂S,mE : U × V → C0([0, 1],Rk)× C0([0, 1],Rk)
is also a linear, Fredholm mapping of index-0 because it is a compact perturbation of D.
Thus, ∂S,mE(S∗,m∗, T ∗, ω∗) is an isomorphism if and only if it is injective and so, seek-
ing a null-space of the linear operator ∂S,mE(S∗,m∗, T ∗, ω∗) we must solve the linear
differential equation
∂S,mE(S∗,m∗, T ∗, ω∗)[X, Y ] = [0,0]
Chapter 2. A control-theoretic approach 47
for X and Y .
Computing the form of the derivative matrix ∂S,mE(S∗,m∗, T ∗, ω∗)[X, Y ] gives
∂S,mE(S∗,m∗, T ∗, ω∗)[X, Y ] =

−X˙ + T ∗(Fs + ω∗G)X
Y˙ + T ∗((FTs + ω∗GT )Y + ...
...+ Fss(s0 + S∗)T [m∗, X]
 ,
where the entries in this matrix are evaluated at (S∗,m∗, T ∗, ω∗) and we deduce
−X˙ + T ∗(Fs + ω∗G)X = 0
for some function X ∈ U . Standard uniqueness theorems for non-autonomous ordinary
differential equations now yield X(t) ≡ 0 as X(0) = 0, but then Y = 0 immediately fol-
lows and so ∂S,mE(S∗,m∗, T ∗, ω∗), having been shown to be injective, is an isomorphism
for all (S∗,m∗, T ∗, ω∗) ∈ U×V ×R2 with E(S∗,m∗, T ∗, ω∗) = 0, ω∗ ∈ [0, 1] and T ∗ > 0.
As a consequence, we can apply the implicit function theorem to solve E(S,m, T, ω) = 0
near to any given solution (S∗,m∗, T ∗, ω∗) to provide a locally unique, two-dimensional
solution surface on which one can write S = S(T, ω) ∈ U,m = m(T, ω) ∈ V such that
E(S(T, ω),m(T, ω), T, ω) ≡ 0,
where S(T ∗, ω∗) = S∗ and m(T ∗, ω∗) = m∗. Denote the common domain of definition
of S(T, ω) andm(T, ω) as provided above by the implicit function theorem by Ω′ and then
define Ω to be Ω′ ∩ (0, T ∗]× (0, 1).
We shall call the two-parameter function (S(T, ω),m(T, ω)) the mixing surface of Prob-
lem A for it contains every possible small-T mixing solution of this optimal control prob-
lem. We can extend the domain of this surface, currently Ω, to the entire rectangular do-
main [0, T ∗] × [0, 1] using Lemma 2.3.2 and the implicit function theorem, but we shall
only sketch the argument as follows.
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First fix ω = ω∗. If
inf{T : (S(T, ω∗),m(T, ω∗), T, ω∗) : (T , T ∗]→ U × V × [0,∞) such that
E(S(T, ω∗),m(T, ω∗), T, ω∗) = 0} > 0
then we can find a sequence (S∗n,m
∗
n, T
∗
n , ω
∗) ∈ U × V × [0, T ∗] to form this infimum. By
Lemma 2.3.2 this sequence is C0-bounded, but from the form of E(S∗n,m∗n, T ∗n , ω∗) = 0
we can bootstrap to readily obtain C2 bounds on this same sequence and so extract C1-
convergent subsequences that we do not relabel that converge to a solution of E(S,m, T, ω∗) =
0. We can then apply the implicit function theorem using the fact that ∂S,mE(S,m, T, ω∗)
is an isomorphism at this point to further extend the definition of (S(T ),m(T ), T, ω∗) to a
lower value of T . This is a contradiction which ensures that
inf{T : (S(T, ω∗),m(T, ω∗), T, ω∗) : (T , T ∗]→ U × V × [0,∞) such that
E(S(T, ω∗),m(T, ω∗), T, ω∗) = 0} = 0.
With a further application of the implicit function theorem at each point (T, ω∗) ∈ [0, T ∗]×
{ω∗}, we can extend the domain of definition of the mixing surface in an entirely analogous
manner to a rectangular strip [0, T ∗]× (ω∗ − η, ω∗ + η), for some η > 0, that contains the
line [0, T ∗]×{ω∗}. Lemma 2.3.2 can then be used to bootstrap and so continuously extend
the domain of definition of the mixing surface to the strip [0, T ∗]× [ω∗−η, ω∗+η]. Further
applications of this bootstrapping process and the implicit function theorem then allow one
to extend this domain from a thin strip to the entire rectangle [0, T ∗]× [0, 1].
Although the mixing surface is now defined on [0, T ∗] × [0, 1], because mixing solutions
must be totally singular in the construction of the optimal control (2.4) this surface only
contains mixing solutions of Problem A when the switching function σ defined in (2.5)
equals zero as a function in C0[0, 1] when evaluated on that surface. In other words,
σ(T, ω)(t) := 〈G(p)(s0 + S(T, ω)(t)),m(T, ω)(t)〉 = 0
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must be satisfied for all t between 0 and 1 in order for the mixing protocol ω to be a solution
of Problem A.
Our goal now is to use the infinite-dimensional version of Taylor’s theorem to determine
conditions that must be satisfied by F and G under the assumption that mixing is optimal.
From this working assumption, the optimal control of Problem A isA∗(t) ≡ ω∗ identically
in t which is a constant and so smooth function. Accordingly we can apply the infinite-
dimensional version of Taylor’s theorem and write, for 0 ≤ t ≤ 1 and fixed ω > 0,
σ(T, ω)(t) = σ(0, ω)(t) + T∂Tσ(0, ω)(t) +O(T
2),
where the O(T 2) term here is measured in the C0-norm. Solving E(S,m, T, ω) = (0, 0)
when T = 0 and ω is arbitrary yields the unique solution
S(t) = 0, m(t) = (1− t)w.
Continuing with the application of the Taylor’s theorem and expanding the solution locus
of E(S,m, T, ω) = (0, 0) locally as a Taylor series, we therefore obtain
S(T, ω)(t) = 0+T∂TS(0, ω)(t) +O(T
2), m(t) = (1− t)w+T∂Tm(0, ω)(t) +O(T 2).
Let us now compute the T -derivative ∂TS(T, ω)(t) that we denote by ST ∈ U , for the
derivative ∂Tm(T, ω)(t) we shall writemT ∈ V . On differentiating the equation E(S,m, T, ω) =
0 with respect to T we find
d
dt
ST = F(s0, p) + ω · G(p)s0 (2.11a)
− d
dt
mT = (Fs(s0, p)T + ω · G(p)T )m (2.11b)
where m(t) = (1 − t)w. Solving (2.11 a-b) and incorporating boundary conditions we
obtain, for 0 ≤ t ≤ 1 and at T = 0,
ST (t) = t(F(s0, p) + ω · G(p)s0), mT (t) = 1
2
(1− t)2(Fs(s0, p)T + ω · G(p)T )w.
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But the following expression for the switching function σ is identically zero in ω, T and t:
0 = σ(T, ω)(t) = 〈G(p)(S(T, ω)(t) + s0),m(T, ω)(t)〉
= 〈G(p)s0 + G(p)S(T, ω)(t), (1− t)w + TmT (0, ω)(t) +O(T 2)〉
= 〈G(p)s0 + G(p)(S(0, ω)(t) + TST (0, ω)(t) +O(T 2)〉,
(1− t)w + TmT (0, ω)(t) +O(T 2)〉
= 〈G(p)s0 + TG(p)(ST (0, ω)(t) +O(T )),
(1− t)w + TmT (0, ω)(t) +O(T 2)〉
= (1− t)
compare with (2.6)︷ ︸︸ ︷
〈G(p)s0,w〉 +T (1− t)〈G(p)ST (0, ω)(t),w〉+ ...
...+ T 〈G(p)s0,mT (0, ω)(t)〉+O(T 2)
(2.12)
In order for the mixing constant ω∗ to be the optimal solution of Problem A from the O(1)
terms in (2.12) we require 〈G(p)s0,w〉 = 0, but the O(T ) terms must also be identically
zero in t. Hence, the quadratic expression in t
t(1− t)〈G(p)[(F(s0, p)+ω ·G(p)s0)],w〉+ 1
2
(1− t)2〈G(p)s0, (Fs(s0, p)T +ω ·G(p)T )w〉
must be zero for all t ∈ [0, 1] and all (T, ω) in the domain of σ, concluding the proof. 
Theorem 2.3.1 is a negative result in the sense that it does not help us find solutions of
Problem A, but it can be used to tell us when antibiotic mixing is not a solution of Problem
1 and Problem 2 in concrete cases. In particular, we have the following two corollaries
which state that Problem 1 and Problem 2 have optimal controls that are mixing protocols
only when their respective sets of parameters and initial conditions (PICSs) are symmetric.
Corollary 1 Suppose that system parameters (given by the vector p) and initial conditions
(given by the vector s0 = (x(0), yw(0), ya(0), yb(0))) are non-negative in (1.1) with h > 0
and suppose also that Problem 1 has an optimal mixing treatment f ∗a (t) that we denote
by the constant ω∗ ∈ (0, 1). If yw(0) > 0 and h > 0, then the PICS (p, s0) is necessarily
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symmetric:
ω∗ =
1
2
, ra = rb and ya(0) = yb(0), (2.13)
and so ya(t) = yb(t) for all t ≥ 0.
Proof On setting w = (0, 1, 1, 1), s0 = (x(0), yw(0), ya(0), yb(0)) and using the func-
tions F and G to represent the system (1.1), we find
G(p) =

0 0 −h(1− s) h(1− s)
0 0 0 0
0 hs h 0
0 −hs 0 −h
 .
Applying condition (2.6) and using
G(p)s0 = ((ya(0)− yb(0))h(1− s), 0, hsyw(0) + hya(0),−hsyw(0)− hyb(0))
we obtain
(w,G(p)s0) = (0, 1, 1, 1) · ((ya(0)− yb(0))h(1− s), 0, hsyw(0) + hya(0), ...
...,−hsyw(0)− hyb(0)) (2.14)
= h(ya(0)− yb(0)) = 0 (2.15)
But then
h(ya(0) + hsyw(0))(rb − ra + h(2α− 1)) = 0 (2.16)
and
h(ya(0)(rb − ra) + h(2α− 1)(ya(0) + hsyw(0))) = 0 (2.17)
follow from conditions (2.7 a-b) of Theorem 2.3.1. Assuming h > 0 and yw(0) > 0,
the first part of the corollary (2.13) follows on solving the three algebraic relations (2.15),
(2.16) and (2.17).
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The last part of the statement of this corollary follows by noting that if δ(t) := ya(t)−yb(t),
along solutions of (1.1) the function δ satisfies δ(0) = 0 and δ˙(t) ≡ 0 if the restriction
(2.13) is imposed from where we deduce that δ is identically zero as required. 
The following shows that a similar statement can be made for Problem 2.
Corollary 2 Suppose that system parameters (given by the vector p) and all initial condi-
tions (given by the vector (S(0), R1(0), R2(0), X(0)) are non-negative in (1.2) and suppose
Problem 2 has a mixing optimal control τ ∗1 that we denote by the constant ω∗ ∈ (0, τmax),
then
R1(0) = R2(0), c2 = c1 +
τmax − 2ω∗
β(X(0) + σS(0))
, m1 = m2 +
2(2ω∗ − τmax)σR1(0)2
λ(X(0) + σS(0))
.
(2.18)
As a result, if the 50-50 mixing protocol ω∗ = τmax
2
is optimal then c1 = c2 and m1 = m2,
therefore R1(t) = R2(t) for all t ≥ 0.
Proof On setting w = (0, 1, 1, 0), s0 = (S(0), R1(0), R2(0), X(0)) and using the func-
tions F and G to represent the system (1.2), we find that
G(p) =

0 0 0 0
0 1 0 0
0 0 −1 0
0 −1 1 0
 .
Using the fact that G(p)s0 = (0, R1(0),−R2(0), R2(0)−R1(0)) we obtain
〈G(p)s0,w〉 = R1(0)−R2(0) (2.19)
and the first part of (2.18) follows from condition (2.6). The remaining two conditions
of Theorem 2.3.1, (2.7 a) and (2.7 b), yield the following algebraic relations for elements
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within the mixing PICS:
µm1 −R1 τ − β R1Xc1 − σ β Sc1R1 − 2σ β R12c1 + 2σ β R12c2 + ... (2.20)
...+ 2αR1 − µm2 + β R1Xc2 + σ β Sc2R1 = 0
and
−R1 τ − β R1Xc1 − σ β Sc1 R1 + 2αR1 + β R1Xc2 + σ β Sc2R1 = 0, (2.21)
where the initial condition of each variable, S,R1, R2 and X , has been omitted for clarity,
so that S denotes S(0) and similarly for the other variables. On solving the relations (2.20)
and (2.21) for (m1, c2) in terms of all the other variables, equation (2.18) results.
Finally, if ω∗ = τmax
2
is optimal and we define the function δ(t) := R1(t) − R2(t), δ can
be shown to satisfy δ(0) = 0 and δ˙(t) ≡ 0 along solutions of (1.2) when one imposes the
restriction that c1 = c2 and m1 = m2 from (2.18). The result now follows. 
Corollaries 1 and 2 represent analogous statements in terms of Problems 1 and 2 that may
be summarised as follows: we do not yet know whether antibiotic mixing protocols are
optimal for Problems 1 and 2, but if mixing is optimal for one of these models at some
parameter value, the parameters and initial conditions within that model must be symmetric
in the sense of Definition 2.1.1. These two results form the essence of our argument,
ensuring as they do that many biologically interesting parameter values exist for which
antibiotic mixing is not the optimal protocol. Indeed, these corollaries show that mixing
may only be optimal in mathematically rare cases.
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2.4 Optimal protocols: bang-bang controls
The results of the previous section are entirely negative and give no clue as to what the op-
timal deployment protocols might actually be for a given mathematical model. So, we now
apply standard control-theoretic results to establish the epidemiological result that alternat-
ing protocols are optimal for Problem A, or at least ‘-suboptimal’ in a sense described
below.
The set of admissible controls U for Problem A is the set of measurable functions taking
values almost everywhere between 0 and C:
U = {φ ∈ L∞[0, T ] : 0 ≤ φ(t) ≤ C for almost all t ∈ [0, T ]},
we are interested in conditions under which a solution of Problem A exists and lies in U .
The set of bang-bang functions B is contained within U and is defined by
B = {φ ∈ U : ∃ partition 0 = t1 < ... < tn = T : φ(t) ∈ {0,C} ∀ t ∈ (tk, tk+1)} .
It is important to note that bang-bang functions B exactly describe the rotational protocols
of equation (3.2) because the range of a function φ ∈ B can only contain the two values 0
and C. In terms of Problem A, if A(t) = φ(t) and B(t) = C−φ(t) then A and B represent
a rotational protocol that is completely described by φ.
The following basic existence theorem tells us that an optimal control exists for Problem
A provided (3.2) has a natural control-independent, point-dissipative bound. More im-
portantly, it shows that the optimal deployment protocol can be approximated arbitrarily
closely in a suitable sense by functions that rotate between the two antibiotics.
Theorem 2.4.1 Suppose that there is a finite constant C depending on C, p, T and s0 such
that for any function A ∈ U , the solution s of (3.2) with s(0) = s0 satisfies, for any norm
‖ · ‖,
sup
0≤t≤T
‖s(t)‖ ≤ C(C, p, T, s0). (2.22)
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Then Problem A has at least one solution A∗ ∈ U with corresponding state response s∗
which satisfies (3.2) with A = A∗. For each  > 0 there is a function A ∈ B such that if
s(t) is obtained by setting A = A in (3.2), then A is -suboptimal in the sense that∫ T
0
〈w, s(t)〉dt <
∫ T
0
〈w, s∗(t)〉dt+ .
Proof Suppose that the sequence (sn, An) provides the infimum
J ∗ := inf {J (A) : A ∈ U} ,
then we may assume that there is an Ainf ∈ U such that An ∗⇀ Ainf in L∞(0, T ) as n→∞
because U is compact with respect to the weak∗ topology on L∞. Without the loss of
any generality, let us shift the initial datum to zero in equation (3.2) by assuming that sn
satisfies
s˙n = F(s0 + sn, p) + An · G(p)(s0 + sn), sn(0) = 0,
instead of (3.2). We obtain the bound
∥∥ d
dt
sn
∥∥
∞ ≤ ‖F(s0 +sn)‖∞+C‖G(p)‖1‖s0 +sn‖∞,
but ‖sn‖ ≤ C(C, p, T, s0) and as all finite-dimensional norms are equivalent it follows that
the sequence (sn) ⊂ W 1,∞0 ((0, T ),Rk) is bounded (the space W 1,∞0 ((0, T ),Rk) appropri-
ately incorporates the zero boundary condition at t = 0). As a result (sn) has a weak∗
convergent subsequence that we do not relabel, converging to sinf ∈ W 1,∞0 ((0, T ),Rk). As
the nonlinear mapping N : W 1,∞0 (0, T )× L∞(0, T )→ L∞(0, T ) given by
N (s, A) = − d
dt
s+ F(s0 + s, p) + A · G(p)s
is continuous with respect to weak∗ convergence inW 1,∞0 (0, T )×L∞(0, T ), we see that the
limiting pair (s0 + sinf , Ainf) satisfies (3.2), that is N (sinf , Ainf) = 0 and the result follows
on setting A∗ = Ainf . 
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2.5 The optimal mixing protocol
As pointed out in Appendix B3 of [15], the idea of an optimal mixing protocol is mean-
ingful in the context of asymmetric antibiotic deployment problems whereby asymmetric
PICS values are used. In such a case, the optimal mixing protocol has to be adjusted from
the 50-50 value of ω = 1/2 to account for their different evolutionary and epidemiolgical
properties.
So, let sω(t) be the solution of the differential equation
s˙ = f(s, p) + C ·G(p)s+ ω(g(p)−G(p)) · s, s(0) = s0
which sees the constant deployment of two antibiotics at some rate ω ∈ [0, C]. The opti-
mal mixing protocol for equation (3.2) is found by solving a one-dimensional optimisation
problem which asks for the single value ω between 0 and C, denoted ω∗, for which the
treatment objective
J (ω) :=
∫ T
0
〈w, sω(t)〉dt
is minimal. It is clear that the optimal mixing protocol is suboptimal in the context of (3.2)
because
J (ω∗) = min
0≤ω≤C
ω constant
J (ω) ≥ min
0≤A(t)≤C
A measurable
J (A) = J (A∗), (2.23)
by definition. Note that we have already proven in Corollaries 1 and 2 of the previous
section that equality is possible in (2.23) for Problem 1 and Problem 2 only when the
parameters and initial conditions used within those problems are symmetric.
Theorem 2.4.1 can be applied to Problems 1 and 2 to provide the main mathematical result
presented here as a corollary.
Corollary 3 Problems 1 and 2 have optimal controls f ∗a (t) ∈ L∞(0, T ) and A∗(t) ∈
L∞(0, T ) respectively. If their respective PICSs are asymmetric then there are infinitely
many antibiotic rotation protocols that outperform antibiotic mixing in terms of the perfor-
mance measure J (A).
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Proof From Theorem 2.4.1 we only have to establish the existence of a dissipative bound
of the form (2.22) for equations (1.1) and (1.2), the result then follows from the second part
of Theorem 2.4.1.
1. From equation (1.1) define the strictly positive vector v = (d, c, c + hsfb, c + hsfa)
and vmin = min{v} which is either c or d if hs > 0 and fa + fb = 1.
Define the state vector s = (X, yw, ya, yb), the vector of initial conditions s0 =
(X(0), yw(0), ya(0), yb(0)) and the vector 1 = (1, 1, 1, 1). Also define the parameter
vector p = (λ, d, c, h, rw, s, ra, rb, b) for completeness.
Equation (1.1) is point dissipative in the sense that if fa ∈ L∞(0, T ) is any measur-
able function with 0 ≤ fa(t) ≤ 1, fb(t) = 1− fa(t) and hs > 0 then
〈1, s(t)〉 ≤ λ
vmin
+ e−vmint
(
〈1, s0〉 − λ
vmin
)
for all t ≥ 0. To see this define n(t) := 〈1, s(t)〉 − λ
vmin
, then
d
dt
n = 〈1, s˙(t)〉 = λ− vTs(t) =
(
λ− 〈v, s(t)〉
vmin
)
vmin,
but −〈v,s(t)〉
vmin
< −〈1, s(t)〉 and so the following differential inequality results
d
dt
n <
(
λ
vmin
− 〈1, s(t)〉
)
vmin = −nvmin.
Integration of the latter inequality when n(0) > 0 implies n(t) < e−vmintn(0), the
result now follows because if n(0) < 0, then n(t) can never be positive and so
sup
0≤t≤T
‖s(t)‖1 ≤ λ
vmin
+ e−vminT
(
〈1, s0〉 − λ
vmin
)
=: C(p, T, s0). (2.24)
2. Now consider (1.2) and define the state vector s = (S,R1, R2, X), the vector of
initial conditions s0 = (S(0), R1(0), R2(0), X(0)), the vector 1 = (1, 1, 1, 1) and
the vector of parameters p = (µ, σ,m,m1,m2, γ, β, α, τmax, c1, c2).
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Equation (1.2) is point dissipative in the sense that if τ1 ∈ L∞(0, T ) is any measur-
able function with 0 ≤ τ1(t) ≤ τmax, τ2(t) = τmax − τ1(t) then
〈1, s(t)〉 = 1− µe−µt〈1, s0〉,
for all t ≥ 0. To see this define n = (1−(S+R1 +R2 +X))/µ = (1−〈s,1〉)/µ and
a short calculation shows that n˙ = −µn. As a result n(t) = e−µtn(0) and therefore
〈1, s(t)〉 = X(t) +R1(t) +R2(t) + S(t) = 1− µe−µtn(0), t ≥ 0
and so
sup
0≤t≤T
‖s(t)‖1 ≤ 1− e−µT + e−µT 〈1, s0〉 =: C(p, T, s0). (2.25)
The bounds (2.24) and (2.25) ensure that Theorem 2.4.1 can be applied to Problems 1 and
2 and the result follows. 
The following theorem illustrates that when condition (2.6) of Theorem 2.3.1 applies, the
optimal antibiotic deployment protocol cannot be antibiotic mixing. Indeed, within the
optimal protocol there is a time interval over which one of the drugs should not be deployed
and the analysis immediately below tells us that this is because condition (2.6) can be
thought of as telling us when the prevalence of resistance to one of the antibiotics is too
high. We formalise this idea in the following theorem.
Theorem 2.5.1 Suppose that there is a finite constant C depending on C, s0, T and p (but
not A) such that for any function A ∈ U , the solution s of (3.2) with s(0) = s0 satisfies
‖s‖ ≤ C(C, p, T, s0). Also assume that condition (2.6) holds:
〈w,G(p)s0〉 6= 0
and write s∗(t) for the solution of (3.2) corresponding to an optimal controlA∗(t) of Prob-
lem A. As a result, to each T we can associate at least one optimal control A∗T by Theorem
2.4.1.
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Under these restrictions there exists uncountably many T > 0 for which A∗T (·) takes either
the value 0 or C on a non-trivial sub-interval of [0, T ] of the form [0, τ) and so cannot be a
mixing protocol.
Proof
Let (Tn) be any positive sequence of times converging to zero and letA∗Tn be an optimal so-
lution of Problem A associated with these times; such a sequence is well-defined from the
conditions of the theorem. Now define the switching function σn(t) := 〈mn(t),G(p)sn(t)〉
where sn and mn provides a solution of the re-scaled Euler-Lagrange equations given by
the pair (2.8) and (2.10) when the function A(t) in those equations is given by the optimal
control A∗Tn . (The rescaling alluded to changes the time interval of the problem from [0, T ]
to [0, 1] and so this will be assumed in the remainder of the proof.)
As Tn → 0 in the Euler-Lagrange equations (2.8) and (2.10), the associated solutions
(sn,mn) with control An := A∗Tn satisfies
sn → s0 and mn → (1− t)w,
as n→∞, where the convergence is strong inW 1,∞(0, 1), as can be seen by bootstrapping
on the assumption of the existence of the a-priori bound ‖sn‖ ≤ C(p, T, s0). Thus, the
corresponding sequence of switching functions (as given in (2.5) but now with m(t)/T
replacing λ(t))
σn(t) :=
1
T
〈G(p)sn(t),mn(t)〉 satisfies σn(t)→ (1− t)
T
〈w,G(p)s0〉,
strongly in W 1,∞(0, 1) as n→∞.
However, the affine function of t, (1− t)〈w,G(p)s0〉 defined for 0 ≤ t ≤ 1 is non-zero on
[0, 1) by assumption and has a transverse zero at t = 1. As a result, by the properties of
uniform convergence, there is a sequence τn converging to 1 from below such that for all
large enough n the function σn(t) is non-zero in [0, τn).
Now let A0n(t) denote any measurable function bounded below by 0 and above by C. From
2.5 The optimal mixing protocol 60
(2.4) the optimal control An has the form
An(t) =

C : σn(t) > 0,
0 : σn(t) < 0,
A0n(t) : σn(t) = 0,
for each n, it follows for sufficiently large n that An has the form
An(t) =
{
C : 0 ≤ t ≤ τn,
A0n(t) : τn < t ≤ 1,
if we assume that 〈w,G(p)s0〉 > 0. If, on the other hand 〈w,G(p)s0〉 < 0, then
An(t) =
{
0 : 0 ≤ t ≤ τn,
A0n(t) : τn < t ≤ 1,
completing the proof. 
Applying Theorem 2.5.1 to Problems 1 and Problems 2 gives the following natural con-
dition on the form of the optimal controls. From equation (2.15) in the case of Problem 1,
condition (2.6) can be written
h(ya(0)− yb(0)) 6= 0
whereas from equation (2.19) in the case of Problem 1 this abstract condition becomes
R1(0)−R2(0) 6= 0.
We can see from an epidemiological perspective that the abstract condition (2.6) has a very
simple and practical interpretation: if resistance to one of the antibiotic is greater than to
the other, do not use that antibiotic.
We now ask what happens when we take the idea hinted at in the previous paragraph of
deploying only one antibiotic when the situation demands, for example use only drug 2
if if R1(t) > R2(t), and extrapolate it as a deployment rule into the future. While this
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protocol will not usually produce an optimal policy, in the next section we show that it can
produce effective rotational protocols that are superior to antibiotic mixing.
2.6 Numerical examples
Throughout this chapter we shall use the parameter set for Problem 1 defined by
p(1) :=
{
λ = 100, d = 1, c =
3
2
, h = 1, rw = 0, s =
1
10
, ...
..., ra =
9
10
, rb =
1
10
, b =
4
100
}
with the following initial conditions
s
(1)
0 :=
{
x(0) = (c+ rw)/b, yw(0) =
λ
c
− d
b
− drw
bc
, ya(0) = 0, yb(0) = 0
}
.
This set of parameters differs from the values given in [15] as they used s = 1/1000, ra =
1/10 and the parameter b does not appear to have a defined value in this reference. The
only parameter that we allow to change in this section, unless otherwise explicitly stated,
is the length of time used in the numerical experiment which we denote, both here and
throughout, by the parameter T .
Let us clarify the reason why we consider a different parameter set than [15] is because
we believe that there is no biological reasons on why to consider drug symmetry, and the
mathematical importance of breaking this symmetry has already been discussed in (2.1).
For these reasons we will make explicit the notion that the two antibiotics A and B are
chosen to come from different functional groups in the sense, for example, of [116]. This
leads us to enforce the restriction on the parameters that
ra 6= rb.
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When working with Problem 2 we shall use the numerical parameter set
p(2) :=
{
µ =
1
10
, σ =
1
4
,m =
7
10
,m1 =
1
20
,m2 =
1
20
, γ =
3
100
, β = 1, ...
..., α =
4
5
, τmax =
1
2
, c1 =
35
100
, c2 =
1
20
}
with initial conditions
s
(2)
0 :=
{
S(0) =
1
5
, R1(0) =
3
10
, R2(0) =
1
10
, X(0) =
2
5
}
.
2.6.1 Drug rotation outperforms mixing
The first numerical example, illustrated in Figure 2.1, provides a comparison of equation
(1.1) for symmetric and asymmetric parameter sets, where optimal mixing is compared
with a sequence of cycling protocols. In the symmetric case of Figure 2.1a where 50-50
mixing provides the optimal mixing protocol, the protocols that cycle between the two
antibiotics are inferior to optimal mixing; note that the optimal protocol itself is not known
for these parameters so this figure is a comparison of several sub-optimal protocols. In
Figure 2.1c where asymmetric parameters are used (the values in (p(2), s(2)0 )) and 50-50
mixing performs poorly as a result, a range of cycling protocols biased to one of the drugs
outperform optimal mixing provided each cycle occurs sufficiently quickly.
The purpose of this computation is to show that cycling and mixing protocols cannot be
compared in any definitive sense: cycling can beat mixing and vice versa, the precise na-
ture of the comparison depends on the structure of the cycling itself and on the numerical
parameters used in the mathematical model.
Figure 2.2 shows the result of a numerical computation that deploys an optimisation al-
gorithm to determine the best rotational protocols where the asymmetric parameter set
(p(1), s
(1)
0 ) has been used to parameterise the model (1.1). While both antibiotic rotation
protocols outperform optimal mixing, if only by relatively small amount with less than 1%
difference, the dynamics of antibiotic rotation shown as black lines exhibit spikes whereby
drug resistance can increase sharply after the introduction of a new antibiotic regime. Nev-
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Figure 2.1: Two different parameter sets, one symmetric and one asymmetric, are used
in Problem 2 to compute the response to the cycling protocols shown in the right-hand
column and mixing protocols: in (A-B) the symmetric parameter values are taken from
[13] but in (C-D) we used the asymmetric set (p(2), s(2)0 ) defined in Appendix A, taking
T = 50 in both cases. The (red) mixing and (black/solid) cycling lines in the two figures
illustrate that cycling protocols may be outperformed by the optimal mixing protocol and
vice versa (the symmetric case (A) and the asymmetric case (C), respectively). (The
dashed lines in (C) are a reproduction of the data from (A); the cycling protocols used
in (D) are biased towards more frequent use of one of the drugs whereas the cycling
protocols in (B) may be described as 50-50.
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Figure 2.2: For a treatment duration of T = 50, the PICS used to simulate (1.1) is
(p(1), s
(1)
0 ): the best 5 and 6-switch controls achieve treatment objectives of 1259 and
1257 patients, respectively, optimal mixing is worse at 1260 and 50-50 mixing is worse
still at 1506 patients.
ertheless, it is with rotational protocols, and not through mixing protocols, that we can
minimise the performance measure defined in [15].
2.6.2 Adaptive rotation protocols
With such a large body of theoretical and numerical evidence that optimal mixing can be
outperformed not only by the difficult-to-determine optimal treatment but by very many
different rotating protocols, how might we find just one of the latter without employing
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Figure 2.3: Average of patients carrying resistant bacteria for different mixing propor-
tions in model (1.2) when T = 50. Note that 50-50 mixing is very ineffective and that the
best mixing proportion is as good as the best periodic cycling. The opposite is also true,
as the worst mixing protocol is as ineffective as the worst periodic cycling, in this case to
the deployment of a single-drug.
searching algorithms of any kind? From a practical perspective it is important to know
if we can simply inspect the current state of the system to find patterns of resistance and
susceptibility of both current and historically observed pathogens and subsequently use that
information to decide when to invoke a switch of antibiotics?
In short, is possible to design suboptimal, but effective closed-loop feedback controls based
on practicable heuristics? To probe this issue, consider the following feedback control laws:
Rule 1: in Problem 1 use antibiotic A until ya(t) > yb(t) and then switch to antibiotic B.
Similarly, if yb(t) > ya(t) switch to A.
Rule 2: in Problem 2 use antibiotic 2 if R1(t) > R2(t), otherwise use 1.
One further concept needed to complete the definition of the feedback controls is the idea
of a sample time. The variable t in Rule 1 and Rule 2 may refer to all instances of time or t
could be a sample time whereby the control decision is taken periodically or at some other
prescribed instants in time. In the numerical examples of the next section we take the latter
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approach due to its practical relevance to managing antibiotic use in hospitals and ask how
often must the system be sampled so that the feedback rules outperform antibiotic mixing?
This can be interpreted in the sense of how much information do we need so that a protocol
based on exploiting that information outperforms protocols founded on no information at
all, like cycling and mixing.
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Figure 2.4: Rule 2 applied to (1.2) when T = 50 and 25 maximum possible switches.
(A) The state response obtained Rule 2. (B) The running treatment objective (the func-
tion R1(t)+R2(t)) obtained using 50-50 mixing (shown in red, with treatment objective
equal to 15), optimal mixing (blue, treatment objective close to 11.7) and the rule-based
feedback (black, treatment objective close to 11.61).
Figure 2.5 shows one outcome of applying Rule 1 to Problem 1 using the same asymmet-
ric parameter values as Figure 2.2 where it is evident that the rule-based control measure is
superior to optimal mixing even though the rule only implements seven switches of antibi-
otic. Figure 2.4 is an analogous computation that implements Rule 2 on Problem 2 using
parameters (p(2), s(2)0 ). Similarly, the rule-based controller produces rotational protocols
that outperform optimal mixing.
Finally, in Figure 2.6 both Rules 1 and 2 have been applied to equations (1.1) and (1.2)
in the search for suboptimal rotational protocols that outperform antibiotic mixing. With a
time parameter T of fifty units, no more than N switches of antibiotic were allowed on any
given simulation and the dynamical systems (1.1) and (1.2) were sampled T/N time units
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Figure 2.5: Rule 1 applied to (1.1) with T = 50 and 23 maximum possible switches.
(A) The state obtained using Rule 1 has a performance of 1252 patients, less than op-
timal mixing strategy (1261) and 50-50 mixing (1506). (B) Comparison of the running
treatment objectives (the function ya(t) + yb(t) + yw(t)) of optimal mixing (blue line)
and 50-50 mixing (red line) with the rule-based feedback treatment (black line). As the
black line is lowest on average, the feedback outperforms all mixing protocols.
apart to make the deployment decision as to which antibiotic would be used until the next
sample. The sampling parameter N is shown along the horizontal axis in Figure 2.6 where
it is labelled as sampling points and both diagrams in the figure show that the performance
of these rule-based controls (as plotted on the vertical axis) improves dramatically with
increasing N , although not monotonically. In both cases a value of N is reached above
which the feedback rules Rule 1 and Rule 2 outperform optimal mixing. We deduce from
this computation that there are infinitely many alternating protocols superior to optimal
mixing.
2.6.3 Releasing the must-treat constraint
We have shown that even simple heuristic-based controls are effective in controlling the
prevalence of single-drug resistance, but what happens if we consider the possibility that
bacteria can evolve resistance to multiple antibiotics? In order to take into account this pos-
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Figure 2.6: Comparing the performance of optimal mixing (blue), 50-50 mixing (red)
with Rule 1 and Rule 2 (boxes). The filled boxes illustrate the number of sampling
points for which the rules-based controllers outperform optimal mixing. The asymmetric
parameter sets used for these simulations are defined in the text and T = 50 for both
models (1.1) and (1.2), any number from 1 to 50 sampling points were used with at most
one sample per unit time. Diagram (A) shows results obtained for (1.1) and (B) are results
for (1.2).
sibility, we numerically simulated an extension of the model (1.2) described by equations
(1.3).
It is clear from Figure 2.7 that by constantly deploying antibiotics into the system, we are
always selecting in favour of antibiotic-resistant phenotypes, either single-drug resistant
or multi-drug resistant. If such selective pressures occur independently of the patterns of
drug usage, it is not clear that it may be possible to design policies that are effective in
controlling the evolution of drug resistance.
A possible strategy would be to reduce the overall antimicrobial use in clinical settings,
and thus decrease the selective pressures in favour of resistance, and indeed such an in-
tervention has been trialled and reported to be partially effective [39]. From a control-
theoretic perspective, it is clear that the must-treat constraint, expressed in Problem 2 as
τ2(t) + τ1(t) ≡ τmax, is a suboptimal constraint that if relaxed would yield policies that
perform least as good as the previously estimated optimal.
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Figure 2.7: (a) Fraction of patients carrying resistant bacteria under different treatment
policies in a model that includes multidrug resistance. The yellow line represents the
optimal mixing protocol, the red line the 50-50 mixing and in black the feedback heuristic
defined in Rule 2. (b) Frequencies of each strain under the feedback protocol. Note how
as time increases there is a steady increase in the frequency of hosts colonised with a
bacteria resistant to antibiotics 1 and 2.
In clinical settings releasing this constraint would introduce a moral dilemma: some pa-
tients would remain untreated. This predicament was discussed in [42], where it is argued
that the ultimate solution to the antibiotic resistance problem would require us to put society
before the individual and allow some patients to go untreated.
Of course, it would be difficult to trial such a strategy in practice, but in a theoretical
model of antibiotic deployment like the ones discussed in this thesis it is an easy task to
implement. For example, we could solve the following optimisation problem:
Problem 3
{
min
∫ T
0
(R1(t) +R2(t) +R12(t)) dt subject to constraints
0 ≤ τ1(t) ≤ τmax, τ2(t) + τ1(t) ≤ τmax and equation (1.3).
in order to find the optimal control that minimises multidrug resistance. But instead of
synthesising the theoretical optimum, for illustration purposes only, we implement the fol-
lowing simple rule-based heuristic:
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Rule 3: in Problem 3 use antibiotic 1 if R1(t) > R2(t) and (R1 + R2) < R12, deploy
antibiotic 2 if R1(t) > R1(t) and (R1 +R2) < R12. If (R1 +R2) ≥ R12 do not deploy any
drugs, that is τ1 = 0 and τ2 = 0.
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Figure 2.8: Releasing the must-treat constraint is effective in controlling drug resis-
tance. However, the intervals of time where no drug is deployed are responsible of a
sharp decrease of uncolonised patients and a dramatic increase in patients infected by a
sensitive strain. (a) Fraction of patients carrying resistant bacteria in time. The barcode
illustrates the drug used at each moment in time under the feedback control: blue corre-
sponds to drug 1, green to drug 2 and a white box represents time intervals when no drug
is deployed. (b) Strain frequencies over time for the feedback control.
Figure 2.8 shows the implementation of Rule 3 in an exemplar situation of model (1.3). A
feature to notice is that only short intervals of no drug deployment have a huge impact in
the prevalence of multidrug resistance. However, it is important to notice that these sudden
decreases in levels of resistance are accompanied by a very sharp increase on the fraction of
the population that is colonised by the sensitive strain, a feature illustrated in Figure 2.8b.
This observation highlights the risk of considering hospital-wide strategies that include
periods of time where no antibiotics are used within a population. It may be possible,
however, to decide on a per-patient basis which individuals can be left without treatment
without a significant risk to their health state, but the SI models discussed so far do not
allow us the possibility of tracking the health state of each individual in time. With this in
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mind, in the last part of this thesis we will pose an agent-based model of a hospital ward
that will allow us to design individualised strategies of drug deployment.
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Chapter 3
In general, which is optimal: mixing or
cycling?
In this chapter we ask the question Which antibiotic deployment protocols select best
against drug-resistant microbes: mixing or periodic cycling? and demonstrate that the
statistical distribution of the performances of both sets of protocols, mixing and periodic
cycling, must have overlapping supports. In other words, it is a general, mathematical result
that there must be mixing policies that outperform cycling policies and vice versa.
It is important to mention that in order to illustrate that 50-50 mixing is not always superior
to antibiotic cycling as claimed in [13, 15], in the previous chapter we constructed coun-
terexamples whereby a specific period of rotation between drugs from different functional
classes and with different costs of resistance outperformed even the best mixing protocol.
We did not claim that any periodic cycling protocol could outperform all antibiotic mixing
protocols.
What we can assert, and prove in this chapter, is a general property of theoretical models of
drug deployment as proposed in [13, 15] that, mathematically speaking, the best periodic
cycling protocols are as good as the best mixing strategies. More precisely, we prove that
the statistical support of the distributions of performances of both classes of protocol must
overlap and believe that this property might be invoked as a tentative explanation of the
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inconclusiveness of recent clinical trials designed to evaluate the efficacy of cycling [17].
3.1 Optimal cycling and mixing: two impractical protocols
The criticism in [16] that protocols determined using optimal control theory cannot be im-
plemented in practise is valid. While the randomised allocation of drugs in a population (or
50-50 mixing) described in [13,15] are practicable (also see [104]), we argue that the opti-
mal mixing protocol defined in [16] as optimally dividing the drugs between appropriately
sized patient groups is also an impractical, theoretical concept.
Moreover, even if it may be possible in theory to determine the best period of cycling, the
best mixing proportion or even the optimal protocol, doing so certainly does not answer the
much harder question
What is the likelihood that a given rotation will outperform a given mixing
protocol?
The difficulties in providing a meaningful answer to this are not to be underestimated. One
would need a mathematical model of the epidemiological dynamics at play in the hospital
capable of making hindcasts and predictions calibrated against known data. This would be
akin to predicting the weather, only potentially harder because of the absence of physical
laws. Attempts have been made at using simple mathematical models to produce forecasts
of antibiotic resistance evolution over the coming decades [69], but criticism of the lack of
biological depth followed [50]. The best one can ever hope for is to provide an ensemble
of possible futures, as in [29]. As a result, it would be churlish to assert, on the basis of
any one epidemiological model, that a specific protocol achieves optimality in real, clinical
contexts or even just for a large class of mathematical models.
The purpose of the previous chapter was to provide general results, really little more than a
reformulation of known mathematical ideas, which are subsequently applied to two specific
mathematical models taken from [13, 15]. These applications illustrate that a wide variety
of conditions are met whereby the best non-periodic rotations can outperform the best mix-
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ing protocol and such conditions are not rare but arise when so-called drug symmetries are
broken. The negative answer to Brown and Nathwani’s question posed in the clinical re-
view [17], Does resistance to different antibiotics develop at the same rate? provides one
example of such an asymmetry.
The difficulty of determining optimal treatment protocols in practice is real and so we pro-
posed adaptive rotation protocols as a practicable strategy that relies only on observations
of local patterns of susceptibility and resistance to decide which drug, A or B, to give. Note,
we do not claim that our adaptive feedback rule is anywhere near to being optimal nor a
good approximation for such. It is a merely a tool for determining rotational protocols that
outperform optimal mixing and we find, by example, that even this simple heuristic can
achieve this goal for particular exemplar models. We do claim that the adaptive protocols
discussed in Section 2.6.2 that seek to exploit more information by sampling the patient
cohort for drug-resistant pathogens more frequently, in turn, perform better. We give ex-
amples to show that such protocols can, given enough information, outperform optimal
mixing; [16] does not provide any evidence that this statement is false. Furthermore, it
is absolutely true that the difference in performance between optimal rotation and opti-
mal mixing found in models may be marginal, but this difference will be specific to the
parameters implemented within any particular model and specific to the model itself.
We would like to emphasize that the analysis provided in the previous chapter and in [9]
hold for a large class of epidemiological models∗ and independent of any particular pa-
rameter values or initial conditions. In particular, our only assumption over the interval of
observation, T , is that it has to be finite, for our arguments to work it cannot be infinite.
For this reason, we disagree with [16] that the arguments presented in [9] are only valid
in general for short intervals of observation and are solely due to ‘transients’. One must
also bear in mind that as T is finite it is also a parameter in the problem and that optimal
mixing, optimal cycling and the theoretically optimal protocol may well all depend on T
itself. Hence there is no general rationale to support the idea that an optimal protocol found
at T = 50, say, will also be optimal when extended to T = 51, let alone to T =∞.
∗There are many antibiotic deployment problems that one could pose outside of the mathematical class
that we analyse in this article, but this class does encompass some of the models presented in [13, 15].
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Instead of seeking for a particular set of parameters where periodic cycling outperforms
mixing in specific models, in the following section we will provide statistical arguments
that may help understand the difficulties that arise when trying to quantify the differences
between cycling and mixing, and we will demonstrate that it is always possible to find
cycling protocols that outperform mixing, and vice versa.
3.2 Cycling versus mixing: a theorem concerning their statistics
Rather than delve into the details of any particular epidemiological scenario or mathemat-
ical model, we shall keep this analysis general and work for the moment in an abstract
framework. First of all, we shall need the vector of all the different patient classes. Follow-
ing previous approaches we could write
y(t) = (S(t), RA(t), RB(t), X(t)),
say, where each entry represents a time-series of the proportion of patients in different
classes: drug-susceptible bacterial infections, drug-A resistant infections, drug-B resistant
infections and uncolonised patients, respectively.
In principle we would need a mathematical model to describe how the vector y(t) changes
in time. Let us assume that the hospital will operate at its maximal capacity at all times
so that the sum of elements in y(t) must be a constant value. We may assume without the
loss of any generality that this value is unity in the remainder, hence the entries of y(t) will
contain the relative proportions of each of the different patient classes.
Let us now suppose the existence of a dynamical model, specifying none of its detail, of
the form
d
dt
y = F (y) + A(t)Ga(y) +B(t)Gb(y); (3.1)
the models in [13, 15] are of this form. In (3.1) the functions Ga and Gb describe how
the dynamics of the ICU unit or hospital ward are affected when we use one of the drugs,
drug A or drug B. For example the use of drug A might well be positively correlated with
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selection for drug A-resistant pathogens, thus increasing the value of d
dt
RA(t). For equation
(3.1) to make any sense we also need an initial condition. We could say y(0) = (1, 0, 0, 0)
so that all patients are infected with the drug-susceptible pathogen to begin with, but with
no drug-resistant pathogens. Clearly there are many other choices that could also be used
and we will not restrict attention to any one in particular. Let us also suppose that policy
ensures that everyone in the hospital is treated, according to our assumptions this means
that A(t) +B(t) = 1 for all times.
Under mild conditions, the resulting equation
d
dt
y = F (y) + A(t)Ga(y) + (1− A(t))Gb(y). (3.2)
can be shown to define a mathematical dependancy or mapping in the sense that to each
function A(t) representing a drug-deployment policy, we can associate a solution y(t) that
depends on A; we will write y(A) or y(A)(t) for this dependancy. Provided that there
exists a constant K independent of A such that for any solution of (3.2) there results
lim sup
t→∞
‖y(t)‖ ≤ K, (3.3)
the vector-valued function y(A)(t) can be extended to the entire interval [0, T ]. As we
tacitly assumed earlier in this discussion that the entries of y(A)(t) sum to unity for all t
and for any bounded function A between 0 and 1, we may assume (3.3) holds throughout
our discussion.
We want to decide upon a drug deployment policy, A(t), that minimises some performance
criterion. So, we now define a weight vector w that gives the relative importance of each
component of y(A)(t). A mathematical optimisation procedure can determine the optimal
policies by locating a function or family of functions A(t) between 0 and 1 such that the
measure of the performance of the protocol A defined by
J (A) := 1
T
∫ T
0
〈w,y(A)(t)〉dt (3.4)
is minimal.
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So, for example, if w = (0,−1,−1, 0), then the performance of our policy is measured
by the number of observed drug-resistant infections per unit time: 〈w,y(t)〉 = −RA(t)−
RB(t); throughout the remainder, the latter will be our performance criterion. Likewise, if
w = (0, 0, 0, 1) then 〈w,y(t)〉 = X(t) and maximising J (A) corresponds with increasing
the number of uncolonised patients seen over the observation period.
Notice that the performance measure can be thought of as a functional: to each protocol
A(t), a function defined on the interval [0, T ] taking values in the interval [0, 1], we can
associate the value J (A). Our performance measure J (·) makes sense as a mapping when
we supply it with a domain, so let us define the following spaces of functions:
Let Per denote the set of all periodic functions bounded between 0 and 1, defined on the
observation interval [0, T ] and with period T/n for some integer n ≥ 1; these functions are
so constrained because we cannot possibly treat more than all the patients in the hospital or
ward. Let BB be the set of functions bounded between 0 and 1 such that for all t between
0 and T one of either α(t) = 0 or α(t) = 1 must be true, where α represents any function
in BB; thus BB represents the set of protocols that only deploy one drug at a time. Now
define Cyc := BB ∩ Per which is the set of all congruent, periodic cycling protocols. The
set of mixing protocols, Mix, is much smaller and defined by the constant functions, so that
a mixing protocol α satisfies α(t) = c for 0 ≤ t ≤ T and some constant c between 0 and
1; the value c = 1/2 corresponds to the so-called ‘50-50’ or random mixing protocol. The
following mathematical results are key to our argument.
We say that a sequence of functions (un) ⊂ L∞([0, T ],Rn) converges weak∗ to u if
lim
n→∞
∫ T
0
ϕ(t) · un(t)dt =
∫ T
0
ϕ(t) · u(t)dt
for all ϕ ∈ L1([0, T ],Rn) and we write un ∗⇀ u as n→∞.
Assume that F (·), Ga(·) and Gb(·) are smooth functions and that there is a K independent
of A such that for any solution of (3.2), there results (in any finite dimensional norm)
lim supt→∞ ‖y(t)‖ ≤ K.
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Theorem 3.2.1 The mapping J : L∞([0, T ],Rn) → R defined in (3.4) is a continuous
functional with respect to weak∗ convergence and for each m ∈ Mix there is a sequence
(cn) ⊂ Cyc such that cn ∗⇀ m as n→∞. There is an optimal mixing protocol and a worst
mixing protocol, namely values m,m ∈ [0, 1] such that
J (m) = min
0≤m≤1
J (m) and J (m) = max
0≤m≤1
J (m).
Proof The first part follows almost immediately from, for example, [66, Theorem 1],
the weak∗ continuity of J (·) with respect to A ∈ L∞([0, T ],Rn) stemming from the form
of (3.2) as a smooth differential equation defined affinely with respect to A. The last part
follows because the map m 7→ J (m) is a continuous function defined on the interval [0, 1]
and so achieves its extreme values. 
Corollary 4 The best possible performance of the set of congruent antibiotic cycling pro-
tocols is at least as good as the best performance of the mixings in the sense that
sup
A∈Cyc
J (A) ≥ sup
A∈Mix
J (A).
Proof Suppose, seeking a contradiction, that supA∈Cyc J (A) < supA∈Mix J (A) = J (m)
where m ∈ [0, 1] is a constant. However, by Theorem 3.2.1 of the appendix there is a
sequence cn
∗
⇀ m as n→∞ and therefore
J (m) = lim
n→∞
J (cn) ≤ sup
A∈Cyc
J (A) < sup
A∈Mix
J (A) = J (m)
because J is continuous with respect to weak∗ convergence. This is a contradiction and
the result follows. 
Let us examine more closely what this mathematical result means theoretically for our am-
biguously phrased question of whether ‘cycling or mixing is best’. Firstly, because of the
form of J (it is continuous with respect to weak∗ convergence) a type of robustness with
respect to the cycles follows: if there is at least one cycling protocol that outperforms opti-
mal mixing, there are infinitely many nearby cycling and acyclical drug rotation protocols
that also outperform optimal mixing.
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Secondly, if the optimal mixing protocol, m say, performs better than all the congruent
cycling protocols and yet  > 0 is any number giving a measure of sub-optimality, then
there is a congruent cycling policy Acyc and a corresponding state response y(A
cyc
 ) such
that
J (m)−  < J (y(Acyc )).
This tells us that if the optimal antibiotic mixing performs better than all the cycling pro-
tocols in our model, if we want a cycling policy that performs within 99% or 99.9% of the
performance of the best mixing, there are cycling policies in Cyc that will achieve this.
From the perspective of seeking theoretical support for antibiotic cycling this appears to
represent a positive outcome but, particularly in light of the accompanying critique [16], we
will discuss the following result. We believe it may have important practical implications.
Corollary 5 The worst possible performance of the set of congruent antibiotic cycling
protocols is at least as bad as the worst performance of the mixings in the sense that
inf
A∈Cyc
J (A) ≤ inf
A∈Mix
J (A).
Proof The proof is almost identical to Corollary 4. 
Let us now define the performances of the worst and best mixing protocols:
p := min
0≤m≤1
J (m) and p := max
0≤m≤1
J (m).
If we draw the graph of the performance surface J (A(τ1, τ2)) as a function of (τ1, τ2) then
Corollaries 4 and 5 predict that this two-dimensional graph will either just touch, or lie
above p in one region of the (τ1, τ2) plane. The same theory predicts it will also either
just touch, or lie below p in another region of the plane. Figure 3.1 illustrates a particular
instance of this idea, it was obtained using a model from [13] whereby the performance
surface of the cycling protocols does in fact pass below the performance of the optimal
mixing protocol (by around 1% or less); Figure 3.1(b) illustrates where this property is
satisfied in the (τ1, τ2)-plane.
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(a) (b)
Figure 3.1: (a) The performance measure J defines a performance surface formed from
a sample of congruent cycling protocols (shown as a blue-green surface); red shows the
performance of optimal mixing (p), yellow of 50-50 mixing and green the worst possible
mixing (p). (b) The red region shows the neighbourhood from (A) where the best cycling
protocols outperform the best mixing, the yellow region shows where cycling outperforms
50-50 mixing. In both (A) and (B) we used T = 50.
Let us phrase this slightly differently: for each performance measure p ∈ (p, p) lying
anywhere between the extreme performances of the best and worst mixing protocols, there
is a congruent cycling protocol defined by (τ1, τ2) such that p = J (A(τ1, τ2)). From this
we deduce what might be called an interlacing property: for any model of the form (3.2)
there exist congruent cycling protocols, labelled (τ11, τ12) and (τ21, τ22), and two mixing
protocols, m1 and m2, such that
J (m1) < J (A(τ11, τ12)) < J (m2) < J (A(τ21, τ22)). (3.5)
In light of this, when we ask Which is optimal: mixing or cycling? it is impossible to
answer unless further clarification is given as to what meaning is really intended by that
question. In more statistical language, (3.5) means that the support of the two distributions
of all possible performances of the mixing protocols and the congruent cycling protocols
must overlap, with the distribution of performances of the cyclings having the potentially
larger support because of Corollaries 4 and 5.
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This universal result within the model class (3.2) points to one possible reason for the incon-
clusive nature of clinical trials performed over the last decade when evaluating the efficacy
of cycling. If such a trial were to be mimicked computationally by simulating a model such
as (3.2), if model parameters are sampled sufficiently widely one must find an inequality
like (3.5) within the simulated data. Indeed, this property is observed in Figure 3.2 com-
puted using a model from [13] where one can clearly see that the empirical distributions of
performances of cycling and mixing protocols have almost identical supports.
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Figure 3.2: Two histograms comparing the distribution of performances of mixing pro-
tocols and a sample of the congruent cycling protocols determined using the mathematical
model given in [13]; the same parameters are used in both plots except that (A) T = 50
and (B) T= 200 time units. Note, consistent with the theoretical results given in the text,
the support of the mixing distribution lies either on or within the cycling distribution in
both cases.
In order to generate Figure 3.2 we constructed an approximation of the probability density
function of the performances of mixing protocols numerically directly from the perfor-
mance locus {J (m) : 0 ≤ m ≤ 1}. For the cycling protocols we first defined a set
of periods ρ := T/N where N = 1, ..., 30 are integers, we then defined τ1 := tρ and
τ2 := (1 − t)ρ where t = 0/M, 1/M, 2/M, ...,M/M = 1, so that τ1 + τ2 = ρ, we fi-
nally set M = 100. The performances of the 3,030 different congruent cycling protocols:
D := {J (A(τ1, τ2)) : τ1 = tρ, τ2 = (1− t)ρ, ρ = T/N,N = 1, ..., 30, t = 0, 1/100, ..., 1}
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were then binned (using 25 bins) with the histc command in Matlab. If the choice of
time units as days and other parameter values given in [13, 16] could be justified from em-
pirical data, some of the cycling protocols used to form D could be eliminated as clinically
impractical.
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Part II
Optimal antibiotic deployment into a
single-host
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Chapter 4
Controlling the evolution of resistance
Since the discovery of antibiotics conventional wisdom has recommended that bacterial
infections should be treated aggressively [37]. This principle was even stated as a moral
by Alexander Fleming himself: “if you use penicillin, use enough” [40]. The hit-early
and hit-hard prescription paradigm has impinged upon our understanding of antimicrobial
treatment to the point that nowadays it is widely believed that shortening treatment duration
may be responsible for promoting the evolution of drug resistance. Indeed, high doses of
antimicrobials increase drug efficacy and thus reduce the length of treatment, allowing less
time for resistance to emerge. But high drug doses also impose stronger selective pressures
in favour of drug-resistant bacteria.
The potential for promoting drug resistance, however, is not the only issue when designing
treatment protocols. It is known that broad-spectrum antibiotics can be associated with
harmful side effects [31] and more importantly, can be responsible for disrupting an innate
protective mechanism known as colonisation resistance, by shifting the balance between
commensal microbiota and enteropathogenic bacteria in favour of the pathogens, increasing
the risk of infections [34, 98, 100].
Here we address the following fundamental questions: how do we deploy a single, bac-
teriostatic antibiotic into a single-host in order to remove optimally the pathogen and its
antibiotic resistant mutants? Can we design drug deployment protocols that support the
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commensal microbiota and therefore promote colonisation resistance? To begin to address
these questions, the purpose of this chapter is to use optimal control theory to show that
the optimal drug deployment protocol is model-independent and a classical engineering
solution, interpreted in this context as intermittent periods of maximum drug deployment.
4.1 A possible control-theoretic formulation
The task of constructing a biologically-realistic mathematical model describing the disease
dynamics of a host organism is difficult and ongoing. Later in this thesis we will propose
a model of a microbial microcosm that will allow us to design and evaluate the efficacy of
different antibiotic usage strategies, but in the search of general results, first we shall work
within a core modelling framework that comprises a large class of evolutionary models of
bacteria growing under resource limitation and under the effect of an antimicrobial agent.
This abstract model contains n different commensal bacterial phenotypes competing for
limited resources with m different types of rapidly-evolving pathogens. Let us represent
with vectors C and P the densities of each phenotype of commensal and pathogenic bac-
teria respectively. If we denote with S the concentration of available resource and with A
the concentration of antibiotic present in the environment, then we can represent the state
of the system with the variable x = (S,C, P,A).
Therefore the dynamic equations that describe the growth and subsequent evolution of the
state of the system will be given by x˙ = F(x) suitably augmented with initial conditions.
As our goal is to control the input of antibiotic in order to to drive the state of the system
towards a pathogen-free state, let us write the system of equations in a more convenient
form
x˙ = F(x, δ) = G(x) + δ(t)A0e, x(0) ∈ R1+n+m+1 (4.1)
where δ(t) represents our control variable, A0 denotes an external supply of antibiotics and
e = (0, 0, ..., 0, 1) ∈ R1+n+m+1.
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In order to ensure our abstract model possesses the gravity of the situation facing users
of antibiotics, we quite purposefully impose an ominous set of restrictions on the physio-
logical and evolutionary responses of the commensal and pathogen populations to the an-
tibiotic. In particular, we impose the restriction that there are no environmental conditions
under which the commensal has the highest growth rate. At low antibiotic concentrations
the wild-type pathogen colonises the host, and at high antibiotic concentrations the resis-
tant pathogens outcompetes every other bacterial phenotype. In this case we say that the
pathogen population has complete competitive advantage, a property that can be described
mathematically in the nonlinear function G(x).
4.1.1 Optimality of antibiotic pulsing
The question we would like to address is how can we design drug usage strategies to ensure
the prevalence of the commensal population in such a severe situation? In answer to this,
the nature of the control problem we wish to solve can be stated as follows.
Find a control strategy δ(t) on some time interval [0, T ] for T ≤ ∞ such that pathogen
density is reduced while growth of commensal bacteria is still supported. We could achieve
this with a feedback stabilisation approach by writing δ = Kx and seeking a matrix K to
render the pathogen-free steady-state of equation (4.1) stable, although real-time control
decisions are not generally available to biological systems such as this. Instead we are going
to use tools from optimal control theory [102] to determine the control δ that maximises a
given payoff functional that illustrates our objective.
Of course, the precise details of the optimal control will depend on the objective functional
we choose to consider. For instance, in the numerical examples presented later in this thesis
we will use a saddle point functional that maximises the overall commensal population
while minimising the density of pathogens, but we could define simpler objectives like for
example minimising pathogen density in an experiment of duration T , or maximising the
commensal population. In any case, the payoff functional would be linear with respect to
both the control and state variables, so we can write it down in terms of a sign-indefinite
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weight vector w ∈ R1+n+m+1, ie.
J (δ) =
∫ T
0
〈w,x(t)〉 dt, (4.2)
where angle brackets denote the standard inner product. Now, if we denote with the fixed
constant δmax ≥ 0 the maximum rate at which we can introduce antibiotics into the system,
then the set of admissible controls is the set of measurable functions taking values almost
everywhere between 0 and δmax,
Ω = {δ ∈ L∞[0, T ] : 0 ≤ δ(t) ≤ δmax for almost all t ∈ [0, T ]}.
Note that because we want to control an experiment of fixed duration T , then this control
problem is referred to as a fixed time, free end-point problem, and therefore it is immediate
that Ω 6= ∅ for T > 0. Then our constrained optimisation problem is to determine an
admissible control δ∗(t) such that
J (δ∗) = max
δ∈Ω
J (δ)
subject to the system of ordinary differential equations defined in (4.1).
In order to show that there exists an admissible control δ∗ ∈ Ω such that J (δ∗) ≥ J (δ) for
all δ ∈ Ω, let us suppose that
sup
δ∈Ω
J (δ) = lim
k→∞
J (δk)
for (δk)∞k=1 a supremising sequence of admissible controls with associated responses (xk)
∞
k=1 ∈
W 1,∞([0, T ]).
Note that the objective functional J : L∞ → R is continuous with respect to the weak*
topology. Moreover Ω is a closed and convex subset of L∞ and therefore Ω is compact
with respect to the weak* topology on L∞. Then because 0 ≤ δk ≤ d almost everywhere,
we can assume without loss of generality that δk
∗−⇀ δ∗ as k →∞.
Also, because the system is dissipative, x(t) is uniformly bounded and there ∃M > 0 such
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that |x(t)| < M for all 0 ≤ t ≤ T . Then we can obtain a W 1,∞([0, T ]) bound on the
sequence (xk) with a weak convergence xk
∗−⇀ x∗ as k →∞. Furthermore,
lim
k→∞
J (δk) = lim
k→∞
∫ T
0
〈w, xk〉 d =
∫ T
0
〈w, lim
k→∞
xk〉dt =
∫ T
0
〈w, x∗〉 dt = J (δ∗).
Hence, J (δ∗) = sup{J (δ) : δ ∈ Ω} and therefore δ∗ is optimal.
Now by using standard results from control theory we can synthesise the optimal control
by forming control theory Hamiltonian
H(x,λ, δ) : = 〈λ,F(x, δ)〉 − 〈w,x〉
= 〈λ,G(x)〉+ 〈λ, δA0e〉 − 〈w,x〉 ,
where λ is called the adjoint variable and satisfies the final-value problem
− λ˙ = w + (∇xG(x))Tλ, λ(T ) = 0. (4.3)
Well-known results from control theory state that the Hamiltonian associated with the con-
strained optimisation problem determined by equations (4.1-4.3) is maximised at all times
along the optimal solution (x∗,λ∗, δ∗),
H(x∗,λ∗, δ∗) = max
δ∈Ω
{H(x,λ, δ)} .
Furthermore, as the Hamiltonian is linear with respect to the control variable δ(t), then the
condition max{H(x∗,λ∗, δ) | 0 ≤ δ ≤ δmax} holds when δ(t) = δmax and 〈λ∗, A0 e〉 > 0,
or δ(t) = 0 and 〈λ∗, A0 e〉 < 0, a control known as bang-bang.
In the context considered here, where a single antibiotic is deployed into a host, bang-bang
controls can be interpreted as time intervals of maximum drug deployment with intervals
where no drug is deployed. This antibiotic deployment strategy is what is described in the
medical literature as an intermittent or pulsing dosage schedule [36, 53, 54]. However, if
〈λ∗, A0 e〉 = 0 then we say that the control is singular and in this case we cannot make any
claims about the optimality of pulsating controls.
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But we argue that pulsating protocols are, in general, superior to ones that define a fixed
drug dose throughout an experiment of duration T . To show this property, let us define a
partition of the interval [0, T ] as IN = (ti)Ni=1 such that
0 = t0 < t1 < · · · < tN−1 < tN = T,
and let PC(IN) represent the space of piecewise constant functions on IN taking values
0 or δmax on each subinterval (ti, ti−1). Then the set of admissible pulsating protocols is
defined as
Ωp = {δ ∈ L∞[0, T ] : ∃N, IN and d ∈ PC(IN) such that δ(t) = d(t)}.
Because Ωp is a weak* dense subset in Ω (see [103]), therefore
max
δ∈Ω
J (δ) = sup
δ∈Ωp
J (δ).
4.2 Other therapeutically relevant controls
The solution of any such control problem will only be of limited interest if we cannot
implement its solution in practise. Indeed, it must be stated that there is little expectation
that an optimal control computed using optimisation algorithms will turn out to be optimal
in real experimental systems. Moreover, we wish to make clear that we are not proposing
to compute optimal pulsating schedules for therapeutic purposes, as that statement would
be far beyond the scope of this thesis. Our only purpose when determining the optimal
pulsating strategy is to provide us with a baseline that can be used to compare theoretically
optimal treatments with other strategies easier to implement in clinical and experimental
systems, like the ones described below.
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4.2.1 Optimal duration of antibiotic therapy
The first question we could ask when designing drug usage strategies, is how much antibi-
otic should we use? Or if we fix the drug dosage, we then could ask what is the optimal
treatment duration? Surprisingly, there is no consensus on the medical and pharmaceutical
communities on how to answer these simple questions.
High-doses of antibiotic are believed to be more effective clearing infections, but they are
also responsible for promoting the evolution of drug resistance, and thus decreasing drug
efficacy for future treatments. For instance, long-term treatments, usually preferred in clini-
cal settings, have been associated with unnecessary side effects [74] and with a considerable
increase in treatment costs [81]. Furthermore, it has also been shown that patients that re-
ceive unnecessarily long treatments were significantly at more risk of acquiring nosocomial
infections [82].
Interestingly, there is clinical evidence that shorter duration of antibiotic therapy has the
same clinical effect than the current guidelines that prefer long-term high-dose treatments.
For example, a 3-day antibiotic therapy does not lead to inferior clinical results when treat-
ing community acquired pneumonia than a standard 8-day treatment [38, 89]. Similarly, it
has been shown that an 8-day course of antibiotic therapy for ventilator-associated pneu-
monia was equally effective as a 15-day course [23].
While in practise the optimal treatment duration may always remain elusive, computing
the optimal stopping time in a theoretical model of drug deployment is a simple task. To
achieve this, let us assume that we will deploy antibiotics at maximum rate δmax during θ
units of time, where 0 ≤ θ ≤ T . Then our control can be written as
δ(t; θ) =
 δmax if t < θ0 if t ≥ θ.
The optimal stopping time that we will denote θ∗ can be computed by numerically max-
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imising the objective functional defined in (4.2) for each value of θ ∈ [0, T ], that is
J (δ(t; θ∗)) = max
θ∈[0,T ]
J (δ(t; θ)).
4.2.2 Tapering dosage strategies
There is clinical evidence that support high-dose, short-course therapies to treat bacterial
infections like pneumonia [92], but it is also known that early cessation of antibiotic therapy
can be associated with increased mortality in critically ill patients [85]. So instead of
stopping treatment completely, it has been proposed that treatment should start with a high
dose of antibiotics and gradually reduce drug dosage to decrease side-effects due to long-
term drug treatment.
This strategy is called drug tapering and it has been reported to be an effective method to
reduce recurrent episodes of Clostridium difficile disease attributed to the disruption of the
intestinal microflora as well as to the persistence of non-vegetative spores [73, 101].
In general, tapered drug deployment protocols consist of a stepwise or a continuous de-
crease of drug dosage over a period of time. As the statement of our control problem
allows us to continuously control the input of antibiotic into the system, then for the pur-
pose of this paper we will consider the latter, and thus define this treatment protocol as
follows:
• Start treatment with maximum dosage, a property expressed as δ(0) = δmax.
• Gradually decrease drug input with a rate of descent given by a parameter α ∈
[0, pi/2], so the control is defined as δ(t;α) = tan(pi − α)t + δmax. Then α = 0
corresponds to deploying antibiotic at maximum dose at all times, while α = pi/2
denotes a situation where no antibiotic is used at all.
• Let t = tα be the first moment in time when δ(t) = 0. Do not deploy antibiotics
afterwards, that is tα ≤ t ≤ T .
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Of course, every rate of descent αwill produce different controls δ(t;α) with corresponding
payoffsJ (δ(t;α)). We will call the optimal tapering parameter, α∗, the parameter such that
J (δ(t;α∗)) = maxJ (δ(t;α)) for all α ∈ [0, pi/2].
4.2.3 Adaptive pulsing
It is important to notice that in order to precisely determine the optimal pulsing treatment or
even the optimal tapering strategy, one would need a calibrated model with perfect under-
standing of the future. But is it possible to determine effective treatment strategies, perhaps
suboptimal, based only on current and past patterns of susceptibility and resistance? In
response to this we propose the development of feedback controls that take information
directly from current observations to inform and adjust future treatment policies.
The difficulty with this approach is the appropriate design of feedback rules. While it is
theoretically possible to use linear feedback laws to stabilise the pathogen-free equilibrium
of equation (6.2), we prefer to consider feedbacks that might be implemented in a practical,
empirical setting.
In the following chapter we will illustrate using numerical examples that we can construct
antibiotic deployment strategies based on feedback controls that are effective in supporting
the commensal population. These controls have been proposed as adaptive management
strategies in ecological settings, and are predicated on the very simple maxim, if antibiotic
resistance is high, cease its use immediately. As we are considering the scenario where we
only have one available antibiotic this must mean that controls will oscillate between peri-
ods of deployment and non-deployment, and thus we call them adaptive pulsing protocols.
Note that feedback controls may be costly in the sense that in order to be implemented, it
may be necessary to have complete information about the state of the system at all instants
in time, represented in this case as having detailed genotypic information of every bacteria
present in the system. While it may be possible to have rapid genotypic identification of
resistance genes [11], these tests are not yet widely available in clinical settings. As a result
we seek feedbacks based on much coarser information, for instance by making observations
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at discrete times every ϑ units apart. Then the control δ(t) during the time interval [ϑi, ϑi+1]
would be determined in response to observations on the state of the system at time t = ϑi by
setting δ(t) = δ(x(ϑi)) for some suitably-chosen feedback law defined within the function
or rule δ.
4.3 Colonisation resistance
A dense microbial community inhabits the intestine, so for invasive pathogens to colonise
the gut they first have to outcompete the commensal bacteria. This protective mechanism
is called colonisation resistance [110], and although the molecular basis of the interac-
tions between host, pathogens and microbiota remains largely unknown, it is believed
that pathogenic bacteria have developed different strategies to overcome colonisation resis-
tance. For example by triggering the host’s immune response and in consequence chang-
ing the population structure of the gut ecosystem, allowing the pathogens to colonise the
host [98].
It is known as well that broad-spectrum antibiotic treatment can decrease the overall mi-
crobial population in the gut considerably. Therefore a side effect of chemotherapy can
be to disrupt colonisation resistance by shifting the balance between microbiota and en-
teropathogenic bacteria in favour of the pathogens, increasing the risk for gut infections
[99, 100].
Furthermore, it has been reported that although there is day-to-day variability in the diver-
sity patterns of the human microbiota, the average community composition remains stable
over several months in the absence of perturbations. However, the effect of antibiotics on
the gut microbiota is profound and very rapid, with a loss of diversity and a shift in the
community composition occurring a few days after drug treatment is initiated. Although
the microbiota eventually returns to a stable state after the end of the treatment course, it
often shifts to a different stable average state [34]. The health consequences of this new
ecological equilibrium are fundamentally unknown [33], but there is evidence that sug-
gests that disrupting these co-evolved microbial communities can be associated with health
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problems like inflammatory bowel disease.
This counterproductive outcome of antibiotic therapy highlights the necessity of studying
the complex interactions between microbial evolution and human disease, and in partic-
ular the ecological and evolutionary implications of antimicrobial treatment within-host
dynamics. For this reason, the main objective of the mathematical models discussed in
the remaining of this thesis is to design antibiotic deployment protocols that support the
commensal microbiota while driving the pathogenic population to extinction.
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Chapter 5
Modelling bacteriostatic antibiotics
In order to compare the efficacy of the theoretical optimal control with the practicable
treatment strategies discussed in the previous chapter, here we will pose a mathematical
model of a proxy for a host organism that takes into consideration the competition for
resources between different bacterial subpopulations and under the effect of a bacteriostatic
antimicrobial agent. This model is based on the mass action law and the inhibitory effect
by the antimicrobial agent is constructed from kinetic interactions between drug molecules
and their targets.
5.1 The Growth Inhibition Coefficient γ(A)
Antibiotics are termed bactericidal if they kill bacteria, for example by inhibiting cell wall
biosynthesis and therefore enhancing the likelihood of cell lysis, or bacteriostatic if they
suppress bacterial growth rate by inhibiting DNA replication, RNA transcription or by in-
terfering with protein synthesis and other aspects of cellular metabolism. For example, the
bacteriostatic antibiotic Rifampicin inhibits the function of RNA polymerase during tran-
scription by binding to its β subunit [107], while Streptomycin targets the 30S ribosomal
subunit and inhibits translation [83]. Resistance to antibiotics can therefore arise through
mutations that alter the structure of the protein targeted by the drug, although such muta-
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tions may come at a cost of reduced fitness in antibiotic-free environments [6, 43, 60].
With rifampicin in mind and following [4] we continue by developing a mathematical
model of the inhibition of transcription by an RNA polymerase-binding antibiotic with
the following kinetic model. In this model σ denotes the concentration of free sigma fac-
tors in the cell that promote transcription and P represents the concentration of free RNA
polymerase that must bind to a gene’s promoter region to initiate transcription of DNA
into mRNA, so that Pσ is the concentration of promoters bound to polymerase. The vari-
able R will denote the concentration of unbound gene promoter regions so that PRσ is a
complex that can initiate transcription of mRNA, the latter at a concentration denoted M .
The variable A represents the concentration of an antibiotic molecule that binds to P to
form a non-functional polymerase-antibiotic complex with concentration denoted PA. We
describe this process as follows
σ + P
k1−−⇀↽−
k−1
Pσ,
P + A
k2−−⇀↽−
k−2
PA,
σ + PA
k3−−⇀↽−
k−3
PAσ ,
Pσ +R
k4−−⇀↽−
k−4
PRσ
k5−→ R + Pσ +M.
A consequence of producing the inhibited polymerase complex PA is a reduction in the
availability of free polymerase which then reduces the rate of RNA production, where the
latter is given by k5PRσ as P
R
σ denotes the fraction of gene promoters bound to a sigma
factor-polymerase complex.
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d
dτ
σ = −k1σ · P + k−1Pσ − k3σ · PA + k−3PAσ , (5.1a)
d
dτ
A = k−2PA − k2P · A, (5.1b)
d
dτ
P = −k1σ · P + k−1Pσ − k2A · P + k−2PA, (5.1c)
d
dτ
PA = k2P · A− k−2PA − k3PA · σ + k−3PAσ , (5.1d)
d
dτ
Pσ = k1σ · P − k−1Pσ + (k5 + k−4)PRσ − k4Pσ ·R, (5.1e)
d
dτ
PAσ = k3PA · σ − k−3PAσ , (5.1f)
d
dτ
PRσ = k4Pσ ·R− (k5 + k−4)PRσ , (5.1g)
d
dτ
R = −k4Pσ ·R + (k5 + k−4)PRσ , (5.1h)
d
dτ
M = k5P
R
σ . (5.1i)
For the remainder of this thesis the timescale pertinent to cell growth will be denoted with
t, so the variable τ denotes a fast timescale at which the production of a single transcript
happens. Note that the total concentration of bound and unbound polymerase does not
change over time and so we may define the following constant
Ptot := P + PA + Pσ + P
A
σ + P
R
σ . (5.2)
Now let us assume that the production of RNA is a much slower process that the binding
and unbinding of other complexes. Therefore we can make the following quasi-steady-state
assumption:
d
dτ
R =
d
dτ
PRσ =
d
dτ
PAσ =
d
dτ
PA =
d
dτ
Pσ = 0. (5.3)
Then from equation (5.1b) we deduce
PA =
k2P · A
k−2
(5.4)
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Similarly from (5.1f) and (5.1g),
PAσ =
k3Pσ · A
k−3
(5.5)
PRσ =
k4Pσ ·R
(k5 + k−4)
(5.6)
Also from (5.1e)
Pσ(k−1 + k4R) = k1σ · P + (k−4 + k5)PRσ
and using (5.6)
Pσ(k−1 + k4R) = k1σ · P + k4Pσ ·R.
Subtracting k4Pσ ·R from both sides:
Pσ =
k1σP
k−1
(5.7)
Finally, defining κ1 = k1/k−1, κ2 = k2/k−2 and κ3 = k3/k−3 and using (5.2) we derive
Ptot = P + PA + Pσ + P
A
σ + P
R
σ
= P + κ2P · A+ κ1P · σ + κ1κ3P · σ · A+ κ1k4
k−4 + k5
P · σ ·R
and the rate or velocity of mRNA transcription, d
dτ
M , is given by v := k5PRσ and so we
define
v = v(A) := k5P
R
σ =
κ1k4k5
k5 + k−4
· R · σ · Ptot
1 + κ1σ + κ145R · σ + A(κ2 + κ1κ3σ) , (5.8)
where κ145 := κ1k4/(k5 + k−4).
Note that the rate of RNA production, v(A), in (5.8) tends to zero as A → ∞ leading the
cell ever-closer to complete inhibition. Then the rate of production of RNA in the absence
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of antibiotic is given by
v(0) = k5P
R
σ =
κ1k4k5
k5 + k−4
· R · σ · Ptot
1 + κ1σ + κ145R · σ
and therefore the relative decrease in transcription rate due to the presence of antibiotic
takes the form
v(A)
v(0)
=
1
1 + A
(
κ2+κ1κ3σ
1+κ1σ+κ145R·σ
) =: 1
1 + κA
, (5.9)
for some parameter κ = κ(σ,R) ≥ 0 that can be thought of as the phenotype of each
cell. Note that κ is a single-cell measure of antibiotic efficacy in the sense that if A50 is the
antibiotic concentration required to halve the transcription rate, then A50 = 1/κ.
We used the one-parameter freedom in (5.9) to fit the binding affinity data of rifampicin
and the related antibiotic molecule rifabutin to RNA polymerase using data taken from
[115]. The result is shown in Figure 5.1 where the R2 values of the least-squares fitting
procedure are given in the legend of the figure. While this gives good agreement, it does
not demonstrate that transcription rate decreases with antibiotic concentration in the same
manner as (5.9), but is consistent with this hypothesis.
While this is a vast over-simplification of the true molecular biology that does not include
features like RNA degradation, for example, this model will at least provide us with some
broad insights into how an antibiotic like rifampicin slows transcription and so inhibits
cell growth. We could go further in the model and include the fact that rifampicin-bound
polymerase can bind to gene promoters to produce short RNA oligomers (trimers) [115].
This more complex model, however, leads to a form for γ(A) that closely resembles the
one presented above in (5.9) but whose derivation is somewhat more lengthy, so we have
omitted it for the sake of brevity.
In order to determine the growth rate of each cell phenotype we shall assume that the
concentration of antibiotic in the environment and inside the cell are the same and that
cell growth rate = constant× resource uptake rate× transcription rate. (5.10)
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Figure 5.1: Effects of rifampicin (Rif) and rifabutin (Rfb) on the binding of 3H rifampin
to wild-type RNAP. This data was obtained using the standard method of competing each
antibiotic against a radioactively marked Rif molecule 3H-rif with a fixed concentration
of 250nM and a reduction in the bound radioactive molecule is assumed to be due the
binding of the non-radioactive drug. (Data taken from [115, Figure 3] where no error bars
are given, R2 values are provided in the figure legend.) This illustrates that the fraction
of Rif and Rfb-free RNAP as a function of the concentration of each drug follows a curve
of the form 1/(1 + p ·A) where A is the drug concentration and p is a parameter used in
the datafit.
Hence the growth rate of each bacterial type is not only determined by the resource avail-
ability that we shall denote by S, or S(t) at time t, but also by the concentration of the
antibiotic present in the environment that we denote by A and A(t) respectively. If we do
not consider stress responses like down regulation of transcription at low-resource envi-
ronments, then bacterial growth rate can be written as a standard monotonic and saturating
Monod function in S multiplied by an antibiotic-dependent conversion constant c(A) that
converts units of the limiting resource to biomass and describes the efficiency of cell pro-
duction per unit resource. Thus the per-cell, per-unit time growth rate can be written in the
form
G(S,A) =
Vmax S
K + S
· c(A)
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where Vmax represents a maximal resource uptake rate and K is a half-saturation constant
also known as the cell’s affinity for the limiting resource.
Working under the assumption that (5.10) holds for each cell then, if the antibiotic molecule
has no effect on the uptake of the limiting resource so that Vmax and K are independent of
A, it follows that the antibiotic must reduce the efficiency of the cell in this simple scenario.
Indeed, in order to compensate for a reduction in growth rate in the presence of antibiotic,
a cell could produce more polymerase but this has the net effect of increasing the resources
needed to create a single cell and so leads to a decrease in cell efficiency. Therefore using
(5.9) and (5.10) we can write c(A) as a product of the cell conversion rate in an antibiotic-
free environment c := c(0) and a dimensionless inhibition coefficient, γ(A), such that
γ(A) :=
G(S,A)
G(S, 0)
=
c(A)
c
=
v(A)
v(0)
=
1
1 + κA
. (5.11)
We then can model a population of bacteria growing under resource limitation and under
the effect of a bacteriostatic antibiotic with the following set of differential equations
S˙ = u(S)B, (5.12a)
B˙ = G(S,A)B, (5.12b)
A˙ = −aAB, (5.12c)
with initial conditions x(0) = (S (0),B(0),A(0)) where S(t) is the concentration of re-
source in the environment at time t, A(t) the concentration of antibiotic and B(t) the den-
sity bacteria. u(S) represents a resource uptake function defined as
u(S) =
VmaxS
K + S
(5.13)
and therefore G(S,A) = c u(S)γ(A). Also, c and a are constants that denote conversion
rates for resource and antibiotic respectively.
In summary, although different antibiotic classes may have different mechanisms of action,
in some cases it may be possible to describe their inhibitory effect on bacterial growth by a
5.1 The Growth Inhibition Coefficient γ(A) 102
0 2 4 6 8 10
0
1
2
3
4
x 107
[ERY] (µg/ml)
Ba
ct
er
ia
l d
en
sit
y
 
 
Model
Data
0 0.05 0.1 0.15 0.2 0.25 0.3
0
1
2
3
4
x 107
[DOX] (µg/ml)
Ba
ct
er
ia
l d
en
sit
y
 
 
Model
Data
Figure 5.2: Dose-response curves of Escherichia coli exposed to different antibiotic
concentrations. Dotted lines represent experimental data with standard error bars and
solid lines predictions of the model described by equations (5.12a-c) with growth param-
eters: Vmax = 0.000251µg / cell / h, K = 0.62 µg/ml, c = 1.8 · 104 cells/µg. (left)
Erythromycin is a macrolide that binds to the 50s ribosomal subunit inhibiting protein
synthesis, with inhibition parameters given by κ1 = 3.46 ml/µg and κ2 = 0.079 ml/µg.
The fit has anR2 = 0.973. (right) Doxycycline a tetracycline that binds to the 30S subunit
and inhibits binding of aminoacyl-t-RNA to the acceptor site on the 70S ribosome. Fitted
inhibition parameters are κ1 = 0.068 ml/µg and κ2 = 0.198 ml/µg with an R2 = 0.966.
Numerical fit performed using a constrained optimisation algorithm and experimental
methods described in Appendix D.
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growth inhibition function that satisfies the following properties:
I1. γ(0) = 1,
I2. γ(A) ≥ 0 for all A ≥ 0 and
I3. γ′(A) ≤ 0 for all A ≥ 0
For the numerical examples presented in this thesis we shall extend the definition of the
function in (7.5) by writing γ(A) = (1 + κA)−1 = 1− κA(1 + κA)−1 and we shall permit
a two-parameter dependence of the form
γ(A) = 1− κ1A
1 + κ2A
.
In this case limA→∞ γ(A) = 1−κ1/κ2 and so, provided κ1 < κ2, γ(A) represents a growth
inhibition function that cannot lead to complete inhibition for finite A.
We used this two-parameter inhibition function to model the effect of two bacteriostatic
antibiotics that inhibit protein synthesis: erythromycin that binds to the 50s subunit of
the bacterial 70s rRNA complex and doxycycline that binds to the 30S ribosomal subunit.
Notably, in both cases we were able to predict the dose-response curve of an isogenic pop-
ulation of E. coli growing under resource limitation and exposed to various concentrations
of each antibiotic, as shown in Figure 5.2.
5.2 Evolutionary dynamics
In a clinical context the effect that the evolution of antimicrobial resistance has on the
efficacy of treatment protocols is fundamental. For example, consider the case of a lethal
infection by enteropathogenic bacteria, by this we mean that the invasive pathogen has
a higher growth rate than the commensals in an antibiotic-free environment so they will
ultimately colonise the host. But at high antibiotic concentrations, pathogenic bacteria are
outcompeted by commensals because the latter are less susceptible to the antibiotic. It is
clear from this example that in order to drive the pathogens to extinction, the best treatment
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protocol is to deploy as much antibiotic as soon as possible. But what happens if we
consider an evolutionary system where the invasive pathogen can evolve resistance to the
antibiotic used? Can we design drug usage strategies that minimise conditions that promote
the evolution of resistant pathogens? In order to address these questions and to understand
the evolutionary implications of antimicrobial therapy, for the remainder of this thesis we
shall consider that pathogenic bacteria can evolve resistance mechanisms.
There are several genetic and biochemical mechanisms that may confer antimicrobial re-
sistance upon bacteria [5]: i) by changing the structure of target molecules to prevent an-
tibiotics from binding, ii) by inactivating antibiotics through enzymatic degradation, iii) by
excluding the entry of antibiotics through the cell wall or iv) by actively effluxing them
from the cell. These resistance mechanisms are illustrated in Figure 5.3.
Figure 5.3: Resistance mechanisms can be acquired by structurally altering target
molecules to prevent antibiotic binding, excluding antibiotics from cell entry, inactiva-
tion of antibiotics through enzymatic degradation, or pumped out of the cell. Figure
reproduced from [5].
Interestingly, the cellular targets of antimicrobial agents are of a very limited nature [120].
While some drugs, like beta-lactamases, attack bacteria by inhibiting cell wall biosynthe-
sis and causing lysis, other substances inhibit DNA replication, RNA synthesis or protein
synthesis by binding to the ribosome or the RNA polymerase. This limitation on the modes
of action of most antimicrobial substances allow bacteria to evolve resistance mechanisms
through a single-point mutation or the accumulation of multiple mutations. In some cases
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mutations can confer resistance to several antibiotics simultaneously, what is known as
cross-resistance.
Although it is known that horizontal gene transfer, within and between species, play an
important role in the prevalence and spread of resistance mechanisms, for the purpose of
this thesis we will consider that resistance mechanisms are acquired vertically, through a
phenotypic mutation occurring with probability  > 0 during cell division.
If we denote with the vector P = (P1, P2, . . . , Pn) the densities of n different bacterial
types, then the rate of mutation from bacterium type j into type i can be represented by
the ij-th entry of a mutation matrix M . Hence the evolutionary dynamics of the system is
described by the stochastic mutation matrix
M = (1− )I + M,
where I is the identity matrix representing clonal reproduction, 0 <   1 the probability
of point mutation and M the n-by-n matrix where the mij entry represents the mutation
rate of bacterial type i into phenotype j.
Note that if 1 denotes a vector of ones of the appropriate dimension, 1 = (1, 1, ..., 1), then
1TM = 1 and 1TM = 1
will all be assumed throughout andM will be assumed to be irreducible in the sense that
there is a number p such that no entry ofMp is zero.
5.3 Competitive advantage and fitness cost of resistance
The derivation of the previous section allows us to model mutations that may occur when
a cell divides and that confer antibiotic resistance. However, in the case of rifampicin
this mutation entails a configurational change to the β-subunit of the RNA polymerase
complex, so a mutation that proves beneficial in the presence of antibiotic may well have
an associated cost at low concentrations of that antibiotic. In order to describe this situation
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mathematically we suppose that a bacterium, the wild-type say, has the growth rate (in an
environment (S,A) of limiting resource concentration S and antibiotic concentration A)
Gwt(S,A) = cwt · V
wt
max S
Kwt + S
· γwt(A),
and that a mutant bacterium has the growth rate
Gmut(S,A) = cmut · V
mut
max S
Kmut + S
· γmut(A).
Antibiotic resistance of the mutant phenotype is then expressed through the property that
lim
A→∞
Gwt(S,A) < lim
A→∞
Gmut(S,A),
but the cost of that resistance mutation is incurred through the property that
Gwt(S, 0) > Gmut(S, 0),
meaning that a reduction in bacterial fitness occurs in an antibiotic-free environment. We
will call such a wild-type bacterium antibiotic susceptible and the mutant will be called
antibiotic resistant, even though strictly speaking both types are susceptible. Then the
patterns of susceptibility and resistance of each subpopulation of bacteria are contained
within the growth inhibition curves, like the ones described in Figure 5.4.
Now suppose that both previously discussed bacterial types, drug resistant and drug sus-
ceptible, are pathogens and that there is third bacterium of an entirely different species
that we deem the commensal, suppose also that its growth response is given by the func-
tion Gcom(S,A). For the purpose of this paper we are considering that pathogens are fitter
than commensals, an assumption based on the idea that commensal microbiota would be
doomed to extinction if no antibiotic treatment were given to the host or if the antibiotic
were over-deployed. In our model we say that the pathogen population has complete com-
petitive advantage if the following condition holds for all A, S ≥ 0:
Gcom(S,A) < max
{
Gwt(S,A), Gmut(S,A)
}
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Figure 5.4: (a) Percentage of growth rate inhibition as a function of antibiotic concen-
tration. (b) Growth rate as a function of antibiotic concentration in the environment. Here
we can see that the resistant strain has a higher growth rate when the antibiotic concen-
tration is high, while the fitness cost associated with resistance is expressed by having a
lower growth rate when the antibiotic concentration is low. Note that for any concentra-
tion of antibiotic, commensal bacteria are outcompeted by at least one type of pathogenic
bacteria.
In other words, in all abiotic environments and at all antibiotic concentrations the pathogen
has a phenotype that is fitter than the commensal bacterium and in such a scenario we might
reasonably expect the pathogen to out-compete the commensal for resources irrespective
of how an antibiotic is deployed, a situation illustrated in Figure 5.4. In the following
chapter we will use optimal control theory and optimisation algorithms to show that we can
support the commensal microbiota in such dire circumstances by appropriately fluctuating
the concentration of drug in the environment.
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Chapter 6
Designing effective single-drug
deployment protocols
Using optimal control theory as the basic theoretical tool, the purpose of this chapter is to
investigate the efficacy of different antibiotic treatment protocols in the direst of circum-
stances described as follows. The commensal bacteria resident in an experimental proxy
of a host organism compete for resources with a rapidly evolving and fitter pathogen, the
latter so-named because the commensals would be doomed to extinction if no antibiotic
treatment were given to the host or if the antibiotic were over-deployed.
As it is difficult to study pharmacodynamics and pharmacokinetics in a mammalian host
in the presence of a pathogen and in real time, although perhaps not impossible with ad-
vances in imaging techniques [118], the experimental microbial system in which we are
going to study antibiotic deployment strategies are continuous culture devices. In partic-
ular, chemostats provide ideal experimental systems to test different patterns of drug use
because they can be mechanically adapted to control the supply of different antibiotics
dynamically throughout the course of an experiment of duration T hours.
In this chapter we will show that it is possible to design optimal drug deployment protocols
that support the commensal microbiota and drive the pathogens to extinction by appropri-
ately fluctuating the concentration of drug in the environment. Furthermore, we will discuss
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the efficacy of different antibiotic usage strategies and show that dynamically changing an-
timicrobial therapies may be effective in clearing a bacterial infection even when every
‘static’ monotherapy fails.
6.1 Chemostat model
Bioreactors have been used for decades to model the complex ecological interactions be-
tween hosts and pathogens in a controlled environment. In particular, continuous culture
devices like chemostats offer the possibility to grow bacteria with a constant input of re-
source, maintaining bacterial growth rate at steady state. We could also adapt a second
supply vessel to the chemostat to dynamically control the input of antibiotics into the sys-
tem while maintaining resource input constant, as illustrated in Figure 6.1.
In a three week chemostat experiment, roughly 200 generations of bacteria can be grown,
so it is possible to study the evolution of microbes at a large time scale. Also, the con-
centration of bacterium per unit of volume is so high and uniformly distributed, that it is
possible to describe the ecological interactions between different bacterial populations with
deterministic models based on the mass action law as the one described below.
Let us denote with S(t) the concentration of limiting resource in the chemostat at time t,
A(t) the concentration of antibiotic, C(t) a variable representing the density of commensal
bacteria and P (t) a vector of n pathogenic types. Note that we are imposing the condition
that commensal bacteria are isogenic and immutable. The reason behind this strong biolog-
ical assumption is that we are considering that commensal bacteria are composed of many
different species, and while resistance might be able to evolve, in some of these species
it would not. By making the assumption that commensal bacteria are immutable we are
saying that the commensal community as a whole will behave as if it is mostly composed
of susceptible bacteria.
Then the state of the system can be represented by x(t) := (S(t), C(t),P (t), A(t)) ∈
R1+1+n+1. Our goal is to find antibiotic deployment strategies that minimise pathogen
densities while still supporting the commensal population, so we shall utilise the following
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saddle-point objective functional
J (δ) :=
∫ T
0
(
C(t)−
n∑
i=1
Pi(t)
)
dt. (6.1)
Note that this payoff functional can be written in the form J (δ) = ∫ T
0
〈w,x(t)〉dt, where
w is a vector of the sign-indefinite form
w = (0, 1,−1,−1, ...,−1, 0) ∈ R1+1+n+1.
Then our control problem would be to find a δ∗ that maximises (6.1) subject to the following
equations that describe the evolutionary and ecological dynamics of the system:
S˙ = d(S0 − S)− uc(S) · C − 〈up(S), P 〉 , (6.2a)
C˙ = Gc(S,A) · C − dC, (6.2b)
P˙ = M (Gp(S,A) · P )− dP, (6.2c)
A˙ = δA0 − dA− A(acC + 〈1, apP 〉), (6.2d)
with initial conditions x(0) = (S (0),C (0),P(0),A(0)) where A(0) = 0 and S (0) = 0 are
the initial concentration of antibiotic and limiting, abiotic resource in the chemostat. The
parameter S0 is the supply concentration of abiotic resource and d the washout rate of the
chemostat. The maximum input of antibiotic is bounded by the chemostat’s dilution rate,
and therefore for the remainder of this paper we will consider δmax = d.
Functions uc(S) and up(S) denote uptake rates of the limiting resource by commensal and
pathogenic bacteria, respectively, growth rates G∗p(S,A) are vectors whose entries have the
form c∗ ·γ∗(A) ·u∗p(S) where a superscript asterisk (∗) here represents a placeholder for any
of the pathogenic bacterial phenotypes. The symbol 1 denotes a vector of ones, (1, 1, ..., 1)
of the appropriate dimension and brackets standard inner products. Parameters ac and ap
are the binding rates of commensal and pathogen to the antibiotic molecule and A0 is the
concentration of antibiotic held in a second supply vessel, as shown in Figure 6.1.
The irreducible matrix M represent phenotypic mutation processes, namely changes in
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Figure 6.1: Diagram of a chemostat with dilution rate d and nutrient input S0 adapted
to supply antibiotic A0 at a rate δ and to maintain the volume and resource input rate
constant.
phenotype that arise due to errors that occur during cell division and these matrices can be
further decomposed into the form
M = I + (M − I)
where the rate of mutations is the same for all phenotypes and equals . The matrix M =
(mji), where i and j represent labels of two different pathogenic phenotypes, contains the
probabilities that the phenotype of an offspring cell is i, given that the phenotype of the
parent cell is j at division and a mutation occurs that changes the phenotype.
The dynamics of (6.2a-d) could be complex. Note that when  = 0, A(0) = 0 andA0 = 0, a
situation that represents an absence of mutations and with no antibiotic agent present in the
environment, equation (6.2) obeys a competitive exclusion principle in the sense that only
one type of either commensal or pathogenic bacteria will persist. Moreover, if the pathogen
has complete competitive advantage over the commensal, one of the pathogenic phenotypes
will go to fixation in the chemostat as time increases. However, if one forces  to take on
some positive but small value, we can deduce from the implicit function that a steady-state
O()-close to the competitive exclusion state will then be locally stable and support the
long-term dynamics of this system; one might say that this new steady-state is in mutation-
selection balance. Global stability of this balanced state is not easy to prove, however, and
indeed it is known that competitive exclusion, or indeed a small perturbation of it, is not
necessarily expected in the presence of a growth inhibitor due to the possible existence
of cycles in population densities [95]. The article [114] demonstrates that a model with a
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form of inhibition closely related to the one used in (6.2) obeys the competitive exclusion
principle.
Interestingly, the model defined by equations (6.2) is able to capture some of the population-
level effects of the constant deployment of antibiotic at different concentrations. For exam-
ple, it is observed experimentally that there exists a critical antibiotic concentration such
that the population of bacteria decreases suddenly, a feature illustrated in Figure 6.2c. This
threshold is known as the Minimum Inhibitory Concentration (MIC) and it is used as a
quantitative pharmacodynamic parameter that characterises every antibiotic [64,108]. This
model shows that the apparent MICs can be explained as a population-level effect conse-
quence of the experimental setup (length of the experiment or initial densities of each strain,
for example), and that it is not necessary to assume thresholds in protein activity or in the
growth inhibition curve to produce the plateaus and sharp drops observed experimentally
when measuring optical densities.
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Figure 6.2: a) Densities of bacteria at time T as a function of the antibiotic concentration
in the supply vessel with a constant input rate. b) Frequencies at time T as a function of
A0. c) Optical density (susceptible and resistant bacteria) at time T as a function of the
input of antibiotic. Note the plateau and subsequent sharp drop in final densities, this
feature is observed experimentally and is used to characterise antibiotic efficacy and drug
resistance.
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Note the model given by equations (6.2) can be written in the abstract form x˙ = G(x) +
δ(t)A0e, where x = (S,C,P , A) and x(0) ∈ R1+1+n+1. Also, we can write equation (6.1)
in the form J (δ) = ∫ T
0
〈w,x(t)〉 dt, where w is has the following form
w = (0, 1,−1,−1, ...,−1, 0) ∈ R1+1+n+1,
and from the discussion in the previous section we can prove that there exists a pulsating
drug deployment protocol that is optimal. With this in mind, the purpose of the following
section is to present numerical examples in order to compute the theoretical optimal control
and compare it with other treatment protocols of therapeutic interest.
6.2 Evaluating the efficacy of different strategies
For the purpose of this section let us now explicitly consider that pathogens can evolve drug
resistance to the antibiotic used, and so we set n = 2 and write P = (PS, PR), where PS is
the susceptible wild-type pathogen and PR the antibiotic-resistant first-order mutant. The
mutation matrix for this two-phenotype system is
M =
(
1−  
 1− 
)
= (1− )I + 
M︷ ︸︸ ︷(
0 1
1 0
)
.
To evaluate the efficacy of different drug deployment protocols, first we compute the the-
oretical optimal control by solving a regularised version of the optimisation problem (see
Appendix B). The switching function, illustrated in Figure 6.3, determines precisely the
moments in time where it is necessary to switch on or off the antibiotic input in order to
maximise the payoff functional defined in (6.1). For example, the near-optimal control for
an experiment of duration T ≈ 42 and parameters defined in Table A.1 consists on one
long interval of drug deployment followed by a short pulse, as shown in Figure 6.4a.
We now compare this theoretical optimal control with a simple feedback rule designed to
stop the treatment when resistant pathogens start to colonise the host, a heuristic that can
6.2 Evaluating the efficacy of different strategies 114
35.6 35.7 35.8 35.9 36
0
0.2
0.4
0.6
0.8
1
Feedback and Optimal control b/bmax
time(t)
Re
lat
ive
 ra
te
 o
f in
flu
x o
f a
nt
ibi
ot
ic
 
 
optimal control
switching function
42.81 42.815 42.82 42.825 42.83 42.835 42.84 42.845 42.85
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
Feedback and Optimal control b/bmax
time(t)
Re
lat
ive
 ra
te
 o
f in
flu
x o
f a
nt
ibi
ot
ic
 
 
optimal control
switching function
Figure 6.3: Two zooms of the switching function and the optimal control computed for
the set of parameters defined in Table A.1: note the non-uniformity of the computational
mesh needed to resolve spiking in the optimal control. Note also that the boundary spike
near T = 42.85 arises as an artefact of the regularisation discussed in Appendix B.
be interpreted as
FB : δ(x) =
{
δmax if PR < C + PS
0 otherwise
Figure 6.4b) shows an implementation of the rule FB to the same set of parameters and
sampling the system every ϑ = 2 units of time. Note that the resulting pulsating control
is similar to the optimal control, consisting on a large interval of drug deployment and
followed by short pulses.
Now we proceed by computing the optimal tapering control, illustrated in Figure 6.4c. In
this example, the optimal tapering control decreases antibiotic input at a rate α∗ = 0.72 and
stops completely drug input when T ≈ 28. Similarly, we can compute the optimal stopping
time and obtain that the best single-pulse control stops the treatment when θ = 24.2.
The responses to these controls are illustrated in Figure 6.5, and show that although the
single-pulse, feedback and tapering controls perform poorly relative to the optimal control,
they still manage to support the prevalence of commensal bacteria, a property that none
of the fixed-dose protocols achieves in the complete competitive advantage scenario we
are considering. Indeed, Figure 6.6 shows that the payoff of the tapering and feedback
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Figure 6.4: The figures in the top illustrate three different control strategies: (left)
Optimal control (centre) Feedback control (right) Tapering control. The bottom figures
show the corresponding concentration of resource of antibiotic inside the chemostat as a
function of time.
controls outperform both the maximum deployment of antibiotic and the null treatment,
but certainly not the optimal control.
A feature to notice in Figure 6.7a is that some tapering parameters produce controls with a
very poor performance and that support either the susceptible or the drug-resistant pathogenic
population, as shown in Figure 6.8. Only a small set of tapering parameters are able to
outperform the feedback heuristic or even the maximum deployment of antibiotic. For ex-
ample the tapering control illustrated in Figure 6.4c) corresponds to the optimal tapering
parameter α∗ = 0.72, a value determined numerically by maximising the payoff functional
for different values of α ∈ [0, pi
2
]. The same argument applies to single-pulse protocols; al-
though the neighbourhood of the optimal stopping time θ = 24.2 produce controls that out-
perform the feedback control, the majority of stopping times fail to control the pathogens,
a property shown in Figure 6.7b.
It is important to notice that the optimal tapering parameter as well as the optimal stopping
time depend both in the length of the experiment T and the initial conditions of the system,
and therefore are very difficult to estimate in practice and are not robust to modelling and
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Figure 6.5: Bacterial densities of pathogens and commensals for different antibiotic
deployment protocols. a) No drug is deployed, δ(t) = 0, b) maximum antibiotic deploy-
ment, δ(t) = δmax, c) near-optimal control, δ∗, d) single-pulse with optimal stopping
time θ = 24.2, e) feedback control with measurements every ϑ = 2 units of time, and f)
optimal tapering control with rate of descent α = 0.72. Notice that pathogens outcom-
pete commensals if no drug is used or if it is over-deployed, but commensals have the
highest densities at the end of the experiment with the dynamic strategies implemented.
parametric uncertainties. Moreover, the optimal pulsing control is not only difficult to
determine in a practical scenario, but it is also difficult to synthesise in a theoretical model
like the one we are considering. One of the complications arises from the difficulty to
compute numerically the switching function as time increases and consequently the number
of pulses. The feedback control, however, does not increase in computational complexity
as we increase the length of the experiment, because only observations on the current state
of the system are used to determine the deployment or not of antibiotics. For example,
Figure 6.9a shows a long-term experiment of duration T = 400 where the adaptive pulsing
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Figure 6.7: (a) Payoff J of the system for tapered controls with different parameters
α ∈ [0, pi/2]. (b) Payoff corresponding to single-pulse controls with different stopping
times θ ∈ [0, T ]. Note how in both cases the range of parameters that outperforms the
feedback-based control is very small.
strategy results in a series of eventually periodic pulses of antibiotic into the chemostat:
a pulse suppresses the growth of the antibiotic-susceptible pathogenic phenotype and the
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Figure 6.8: Frequency of resistance as a function of the tapering parameter. If the taper-
ing parameter is low and therefore the antibiotic is over-deployed the resistant pathogens
colonise the host. Conversely, when the tapering parameter is high and therefore not
enough antibiotic is used the susceptible phenotype has the higher frequency. The taper-
ing parameter that minimises pathogen density in an experiment of duration T = 42.85
is α∗ = 0.72 and is illustrated by the dotted line.
non-deployment of antibiotic suppresses the resistant pathogen. We claim that with the
correct timings of these pulses it appears possible to support the commensal population.
Finally, the feedback heuristic FB also seems to be robust to changes on the maximum
antibiotic dose, as shown in Figure 6.9b. This is an important feature, because in fixed-
dose regimes increasing the concentration of antibiotic corresponds to an increase in the
frequency of resistant pathogens at the end of the experiment. While the adaptive pulsing
strategy yields the same coexistence pattern between pathogens and commensals indepen-
dent of the drug concentration A0.
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Figure 6.9: (a) Bacterial densities under the adaptive pulsing protocol for T = 400
hours; note that feedback control FB with samples taken every ϑ = 20 units of time
leads to an eventually-periodic input of antibiotics sufficient to ensure that the commen-
sal persists in an oscillatory fashion with the pathogen. (b) Frequency of pathogens at
the end of the experiment as a function of the antibiotic concentration in the supply ves-
sel, A0. The shaded areas represent the cumulated frequencies of susceptible and drug
resistant pathogens under a fixed-dose protocol. High doses of antibiotic select for re-
sistant pathogens, and low doses select for susceptible pathogens. Circles represent the
frequency of pathogens, both susceptible and resistant, under the adaptive pulsing strat-
egy.
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Chapter 7
Antibiotic interactions
The emergence of antimicrobial resistance is a consequence of the selective pressure im-
posed by the prescription of that antibiotic. This reasonable hypothesis suggests that mul-
tidrug combination treatments could help reducing the prevalence of resistant phenotypes.
However, a single point mutation or the accumulation of multiple mutations may confer on
bacteria resistance to several antibiotics, what is known as cross-resistance.
For this reason, in order to reduce the prevalence of multidrug resistance, we argue that
it is important to understand the molecular interactions between antibiotics and to study
the effect that different combination protocols have on the evolution of antimicrobial resis-
tance. The purpose of the chapter is to characterise the profiles of interaction between two
bacteriostatic antibiotics from the kinetic interactions between drug molecules and their tar-
gets, with the purpose of studying the ecological and evolutionary implications of different
multidrug combinations.
7.1 Classifying drug interactions
Drug combinations can be classified as synergistic if they interact to increase each other’s
effect, antagonistic if their combined effect is less than the most effective drug used indi-
vidually or additive when they do not interact. Although this intuitive classification of drug
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interactions seems straightforward, the difficulty of rigorously defining the null interaction
has been a matter of controversy for decades and the subject of a series of misconcep-
tions [10, 44].
The most widely accepted test to quantify drug interactions are isobolograms as proposed
by Loewe [65] to measure synergy. This experiment measures in vitro the susceptibility
of a population of bacteria growing in a bidimensional array of different combinations
of antibiotics. Optical densities are measured at the end of the experiment and from the
dose-response surface so obtained (see Figure D.1 for an example), the interaction can be
classified by lines of equal drug effect that are known as isoboles.
For the purpose of this thesis, instead of modelling population-level dose-response sur-
faces directly, we are going to derive them as an emergent property of a model constructed
from the competitive inhibition of an essential metabolite at a single-cell level, a method
discussed in [24–26].
First, let us consider that at any given moment in time, two antibiotics are present in the
environment at concentrations A and B and measured in micrograms per millilitre. If
the basal concentrations for each drug are denoted by A0 and B0 respectively, and the
fixed effective dose is ∆, then any drug combination can be represented by the proportion
between both drugs, a property described by the parameter σ ∈ [0, 1] in the expression
∆ = σA0 + (1− σ)B0. (7.1)
Using (7.1) we can define the optimal drug ratio σ∗, where 0 ≤ σ∗ ≤ 1, as the proportion
σ that minimises the growth inhibition coefficient γ(σA0, (1− σ)B0) for σ in [0, 1],
γ(σ∗A0, (1− σ∗)B0) = min
0≤σ≤1
γ(σA0, (1− σ)B0).
Any treatment that deploys a fixed combination of drugs at a constant ratio, σ say, will be
called a combination treatment in the remainder.
As mentioned before, two drugs act synergistically when their combined effect is larger
than the effect of each drug used separately, a property represented by σ∗ being inside the
7.2 Synergistic interaction between two antibiotics with the same target 122
interval (0, 1). Conversely, if the optimal drug combination is to use only one of the drugs,
that is σ∗ = 0 or σ∗ = 1, then we say their interaction is antagonistic. If γ(σA0, (1−σ)B0)
is constant as a function of σ and so σ∗ could be any value between 0 and 1, we then say that
either the drugs do not interact with each other, or their interaction is additive; we consider
the latter two statements to be synonymous.
7.2 Synergistic interaction between two antibiotics with the same tar-
get
Motivated by the interaction between rifampicin and closely related drugs like rifabutin
and sorangicin A, consider the following kinetic model:
A+ P
k1−−⇀↽−
k−1
PA, B + P
k2−−⇀↽−
k−2
PB, σ + P
k3−−⇀↽−
k−3
Pσ, (7.2a)
σ + PA
k4−−⇀↽−
k−4
PAσ , σ + PB
k5−−⇀↽−
k−5
PBσ , σ + PAB
k10−−⇀↽ −
k−10
PABσ , (7.2b)
B + PA
k8−−⇀↽−
k−8
PAB
k−9−−⇀↽−
k9
PB + A, (7.2c)
Pσ +R
k6−−⇀↽−
k−6
PRσ
k7→M + P + σ +R. (7.2d)
Equation (7.2) describes the concentration of RNA polymerase P , an antibiotic pair A and
B that bind to P and the final product mRNA that we denote by M . Messenger RNA is
transcribed when P binds to a sigma-factor, here denoted σ and the Pσ complex then binds
to the promoter regionR of some gene on the bacterial chromosome. With the consumption
of ATP, not modelled here, the eventual transcription of M results whereupon the promoter
region of the gene, the sigma factor and RNA polymerase unbind from the transcription
unit of the gene. In the model (7.2) we have encoded the assumption that both antibiotics
A and B block the binding of the mature transcription unit, which here is just an RNA
polymerase-sigma factor complex, to the promoter region of the gene.
However, this does not really describe how the drugs rifampin (rif) and sorangicin A work.
To more closely respect the details of the mode of action of these molecules we would need
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(a) Antagonism
(b) Synergism
Figure 7.1: Growth rate inhibition surfaces as a function of the concentration of two bac-
teriostatic antibiotics. The black line illustrates the constraint that the total concentration
of antibiotics in the environment is fixed. (a) We say they have an antagonistic interaction
if growth rate is inhibited maximally by using just a single-antibiotic. (b) Conversely, if
their interaction is synergistic, then the optimal mixing protocol is a combination of both
antibiotics
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to include a cascade of additional terms of the form
PAσ +R→ PARσ →M3 + P + σ +R and PBσ +R→ PBRσ →M5 + P + σ +R.
Here M3 and M5 represent oligomers just a handful of nucleotides long which are the
abortive mRNA-like transcripts produced when rifampicin-like drugs are bound to RNA
polymerase [115]. However, we do not believe that this more complicated model provides
any additional theoretical insight into the interactions of drugs targeting the same enzyme,
equation (7.2) is already sufficient to have non-trivial, synergistic drug interactions as we
now aim to show.
Assuming mass-action kinetics of (7.2) we obtain the following model for the time-course
of concentrations of each of the agents involved in the production of mRNA:
d
dτ
PABσ = k10σ · PAB − k−10PABσ , (7.3a)
d
dτ
PAB = k8PA ·B − k−8PAB + k9A · PB − k−9PAB − k10σ · PAB + k−10PABσ , (7.3b)
d
dτ
PAσ = k4PA · σ − k−4PAσ , (7.3c)
d
dτ
PBσ = k5PB · σ − k−5PBσ , (7.3d)
d
dτ
PA = − k8PA ·B + k−8PAB − k4σ · PA + k−4PAσ + k1P · A− k−1PA, (7.3e)
d
dτ
PB = − k9PB · A+ k−9PAB − k5σ · P5 + k−5PBσ + k2P ·B − k−2PB, (7.3f)
d
dτ
PRσ = k6Pσ ·R− (k7 + k−6)PRσ , (7.3g)
d
dτ
Pσ = − k6Pσ ·R + k−6PRσ + k3P · σ − k−3Pσ, (7.3h)
d
dτ
R = − k6Pσ ·R + (k7 + k−6)PRσ , (7.3i)
d
dτ
σ = − k3P · σ + k−3Pσ − k4PA · σ + k−4PAσ − k5PB · σ + k−5PBσ + ... (7.3j)
...− k10σ · PAB + k−10PABσ + k7PRσ ,
d
dτ
M = k7P
R
σ , (7.3k)
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where A and B are assumed to be held at constant values during transcription.
Equation (7.3) has the following constants, namely the total available RNA polymerase
Ptot := P + Pσ + PA + PB + PAB + P
A
σ + P
B
σ + P
AB
σ + P
R
σ
and the totality of gene promoters Rtot := R + PRσ . Let us now assume that all process
have equilibrated so that M is produced at a constant rate or velocity in (7.3k), then
PABσ = k10/k−10 · σ · PAB and PAB =
k8B · PA + k9A · PB
k−8 + k−9
.
Now, PAσ =
k4
k−4
PA · σ and PBσ = k5k−5PB · σ so that with (7.3e) and (7.3f) in equilibrium,
we obtain
0 = − k8PA ·B + k−8PAB − k4σ · PA + k−4PAσ + k1P · A− k−1PA,
0 = − k9PB · A+ k−9PAB − k5σ · P5 + k−5PBσ + k2P ·B − k−2PB,
that can be rewritten using the preceding algebraic relationships for PA and PB as a function
of P,A and B: k−1 +B k8k−9k−8+k−9 − k9k−8k−8+k−9A
− k8k−9
k−8+k−9
B k−2 + A
k9k−8
k−8+k−9
( PA
PB
)
= P
(
k1A
k2B
)
. (7.4)
The linear equation defined by (7.4) can be solved to give
PA = P · A · κA(A,B) and PB = P ·B · κB(A,B)
where κA and κB are rational functions of the form
κ(A,B) =
p1 + p2A+ p3B
1 + p4A+ p5B
,
where each of the five parameters p1, ..., p5, and with one set for each of the two antibiotics,
are various combinations of the rate parameters in (7.2).
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Continuing with the equilibrium assumptions, PRσ = Pσ · R · k6/(k7 + k−6) follows from
(7.3g) but then adding the latter to (7.3h) yields Pσ = k3σ · P/(k−3 + R k6k7k7+k−6 ) =: σ · P ·
n(R), whence
PRσ = σ · P ·
k3R
k−3 +R k6k7k7+k−6
k6
k7 + k−6
=: σ · P ·m(R).
By defining κAB(A,B) := (k8κA(A,B) + k9κB(A,B))(k−8 + k−9)−1 we can write
Ptot = P ·
(
1 + n(R)σ + AκA +BκB + ABκAB +
k4σ
k−4
AκA +
k5σ
k−5
BκB +m(R)σ
)
,
= P · (1 + (n(R) +m(R))σ + AκA(1 + `4σ) +BκB(1 + `5σ) + ABκAB)
and so
d
dτ
M = k7σ·P ·m(R) = k7σ ·m(R) · Ptot
1 + (n(R) +m(R))σ + AκA(1 + `4σ) +BκB(1 + `5σ) + ABκAB
,
a function that we denote by v(A,B). If we finally define γ(A,B) to be the dimensionless
reduction in the production rate of mRNA due to A and B then γ(A,B) = v(A,B)/v(0, 0)
which equals
γ(A,B) =
1 + (n(R) +m(R))σ
1 + (n(R) +m(R))σ + AκA(1 + `4σ) +BκB(1 + `5σ) + ABκAB
,
=
1
1 + A · qA(R, σ)κA +B · qB(R, σ)κB + AB · qAB(R, σ)κAB . (7.5)
We have written qA(R, σ) in place of (1 + `4σ)/(1 + (n(R) + m(R))σ) for brevity, the
functions qB and qAB are similarly defined as (1 + `5σ)/(1 + (n(R) +m(R))σ) and 1/(1 +
(n(R) +m(R))σ) respectively.
The simpler expression than (7.5)
γ(A,B) =
1
1 + AκA +BκB + ABκAB
(7.6)
is used for convenience in the numerical simulations presented in this thesis, where κA, κB
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and κAB are assumed to be constant and all three strictly positive. To see that the function
γ(A,B) so-defined yields a synergistic interaction let σ lie strictly between 0 and 1 and
consider the expression
1
γ(A,B)
− 1
γ(σA, (1− σ)B) = (1− σ) · AκA + σ ·BκB + (1− σ + σ
2) · ABκAB
> 0.
As a result, γ(σA, (1 − σ)B) < γ(A,B) whenever 0 < σ < 1 and so the drugs A and
B synergise because they are most effective at reducing the rate of mRNA synthesis when
used in combination.
We note that interactions between drugs targeting different enzymes in a pathway do not
necessarily lead to such simple functional forms for the drug inhibition surface as the one
described in (7.6), see [58, 119] for example, explaining our restriction to drugs targeting
the same enzyme. However, we argue that in some cases this simple model may be able
to capture the interaction between two antibiotics that bind to non-overlapping sites of the
same target and whose interaction is known to be synergistic, for example the drug pair
studied in [48] and illustrated in Figure 7.2.
7.3 Predicting the dose-response surface
The derivation of the previous section allows us to quantify the inhibitory effect of a drug
combination of two bacteriostatic antibiotics with a synergistic interaction. The obtained
growth inhibition surface (7.6) describes the inhibition of the production of an essential
metabolite at a single-cell level, but does not necessarily explain the observed population-
level inhibition. Here we ask if we can predict an experimentally obtained population-level
dose-response surface from the single-cell inhibition surface.
Let us assume that at any given moment in time two antibiotics are present in the environ-
ment at concentrations A and B. As discussed in Chapter 5, if we consider that bacterial
growth rate can be described by a function G(S,A,B) that depends on the concentrations
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Figure 7.2: The shape of the isoboles of equal effect illustrates that doxycycline and
erythromycin have a synergistic interaction, as lower-dose drug combinations have the
same effect as high-dose monotherapies.
of both drugs and upon the concentration of a limiting resource S in the environment, then
this growth function can be modelled as a standard Michaelis-Menten term multiplied by a
growth inhibition coefficient γ(A,B) that depends on the concentration of both drugs,
G(S,A,B) = c · u(S) · γ(A,B). (7.7)
Again, c denotes a resource conversion rate and u(S) is the resource uptake function de-
fined in equation (5.13) and γ(A,B) a function such that γ(A, 0) = γA(A) and γ(0, B) =
γB(B), where γA(A) and γB(B) are growth inhibition functions that characterise the sin-
gle, separate use of each antibiotic.
Therefore if we represent with P (t) the density of an isogenic population of pathogenic
bacteria growing under resource limitation and under the effect of two bacteriostatic antibi-
otics of concentrations A(t) and B(t), and we assume that the concentration of bacterium
per unit of volume is so high and uniformly distributed in space, then it is possible to de-
scribe the ecological interactions between different bacterial populations with deterministic
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models based on the mass action law [95], like the one described below
S˙ = u(S) · P, (7.8a)
P˙ = G(S,A,B) · P, (7.8b)
A˙ = −aA · P, (7.8c)
B˙ = −bB · P, (7.8d)
with initial conditions x(0) = (S (0),P(0),A(0),B(0)). Constants a and b are parameters
that denote the rate of binding of antibiotic molecules to their targets.
(a) (b)
Figure 7.3: Population-level inhibition of E. Coli growing in a glucose-limited environ-
ment and under the effect of different concentrations of doxycycline and erythromycin.
(a) Experimental data (b) Model predictions
To test our model, we measured experimentally the inhibitory effect on an isogenic popula-
tion of E. Coli growing under glucose limitation and under the effect of two bacteriostatic
antibiotics that target different sites in the ribosome, and thus inhibit protein synthesis:
doxycycline that binds to the 30s subunit and erythromycin that binds to the 50s sub-
unit. Using the simple model described by equations (7.8a-d) and the growth inhibition
surface for synergistic interactions derived in the previous section and illustrated by the
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isobolograms shown in Figure 7.2, we were able to predict with quantitative accuracy the
population-level inhibition of bacteria growing at different drug concentrations, as illus-
trated in Figure 7.3. Details of the experiment and the numerical fit are described in Ap-
pendix D. In the following chapter we will use this calibrated model to design optimal drug
combinations in a microbial model system that incorporates the evolution of resistance.
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Chapter 8
Ongoing work: Evolution of resistance
in multidrug environments
A common approach to dealing with the evolution of antibiotic resistance and to increase
the efficacy of antimicrobial treatments is to use multidrug combination therapies [75–77].
With this in mind, in this chapter we turn to a simple lab-based microbial system and
consider perhaps the simplest possible experimental model into which one can deploy an-
tibiotics: two antibiotics are used to target an isogenic bacterial inoculate in shaken flasks
with batch transfers. The term flask could also be interpreted as wells on a shaken mi-
crotiter plate, but as we work with units of bacterial cells per millilitre, the distinction is
not too important. This is a standard experimental system often used in microbial evolution
experiments [18] and has the advantage of removing a great deal of the chemical complex-
ity commonly found in the environmental niches occupied by microbes. This simplicity
can be exploited by the modeller to make predictive and testable statements regarding the
short-term microevolution of the bacteria.
The results presented in this chapter are based on a series of experiments performed in Kiel
in September of 2010 and designed to study the evolutionary consequences of different
multidrug combination protocols. Although the experiments are still in a preliminary stage,
we were able to calibrate our models with growth and inhibition parameters fitted from
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these experiments, and therefore instead of presenting general statements based on abstract
models, in this chapter we will attempt to make predictions that we aim to validate in future
experiments.
8.1 Optimal drug proportion
For decades the medical and pharmacological communities have sought antimicrobial drugs
that increase their effect when used in combination, an interaction known as synergism [44].
It is known, however, that synergistic drug combinations may select for multidrug resis-
tance [48] or have synergistic side effects [57]. For this reason, it has been proposed that
antagonistic interactions, usually dismissed in clinical settings, may in fact help to select
against the evolution of resistant phenotypes [21,117]. For the purpose of this thesis, how-
ever, instead of concentrating on how to design drug interactions that minimise selective
pressures in favour of resistant phenotypes, we are going to assume that the profile of
interaction between both antibiotics is given and focus on studying the ecological and evo-
lutionary implications of different drug usage strategies. Our aim is to understand whether
there are circumstances in which other types of therapy might be favoured over therapies
based on fixed-dose multidrug combinations.
Hence, for the remainder of this thesis we will consider the drug interaction preferred
in clinical contexts, where drugs increase their efficacy when used in combination. In
particular, we will consider two bacteriostatic antibiotics of different functional classes with
a strong synergistic interaction: erythromycin, a macrolide that binds to the 50s ribosomal
subunit with a concentration that we will denote with ERY and doxycycline, a tetracycline
that binds to the 30S ribosomal subunit at a concentration denoted by DOX .
Assuming that we can model their interaction as mutually non-exclusive competitive in-
hibitors, the derivation of the previous chapter allows us to describe their interaction through
the following growth rate inhibition coefficient:
γ(DOX,ERY ) = γdox(DOX) · γery(ERY ). (8.1)
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γdox(DOX) and γery(ERY ) are the drug inhibition coefficients that describe the single use
of each antibiotic, functions that can be written as
γdox(DOX) = 1−
(
κdox1 DOX
κdox2 +DOX
)
,
γery(ERY ) = 1−
(
κ˜ery1 ERY
κ˜ery2 + ERY
)
,
where κdox2 and κ
ery
2 are the corresponding antibiotic affinities to their targets, while κ
ery
1
and κdox1 represent the level of maximum growth inhibition achieved by each antibiotic.
Another assumption of this chapter is that the rate of input of antibiotics is fixed at a con-
centration ∆. This fixed-dose dosage assumption allows us to describe drug combinations
through a mixing parameter σ ∈ [0, 1].
Then if DOX0 and ERY0 are the basal concentrations of each drug, we can describe any
drug cocktail with the expression
σ ·DOX0 + (1− σ) · ERY0 = ∆. (8.2)
Note that this expression allows us to define the optimal drug ratio, denoted σ∗, as the
drug proportion that minimises the inhibition coefficient γ(σDOX0, (1 − σ)ERY0) for σ
in [0, 1], a property expressed by the following condition:
γ(σ∗DOX0, (1− σ∗)ERY0) = min
0≤σ≤1
{γ(σDOX0, (1− σ)ERY0)} .
Now, if we inoculate a flask with an isogenic population of susceptible bacteria, for exam-
ple wild-type E. Coli, and for the moment we assume that they cannot acquire antibiotic
resistance to any of the drugs used, then in order to reduce bacterial density maximally it
is clear that it would be optimal to deploy the drug cocktail that maximises the synergistic
effect.
Indeed, Figure 8.1 shows that the the drug ratio between erythromycin and doxycycline
at sub-inhibitory concentrations that maximises cellular-level inhibition, in this case σ∗ =
8.1 Optimal drug proportion 134
0.72, corresponds roughly with the drug proportion that minimises the density of bacteria
in a short-time experiment (T = 24 hours). Details of the experiment can be found in
Appendix D.
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Figure 8.1: (a) Growth rate inhibition at a single-cell level of a susceptible bacteria
under the effect of a fixed drug dose described by a proportion parameter σ ∈ [0, 1], where
σ = 0 corresponds to deploying erythromycin at maximum dose (5µg/ml) and σ = 1 the
maximum dose of doxycycline (0.15µg/ml). The optimal drug proportion is σ∗ = 0.72
and the parameter used are detailed in Table A.3. (b) Population-level growth inhibition
of E. coli growing at a fixed concentration of resource (S = 2000µg/ml) and exposed
to different drug proportions in a 24-hour experiment. Experimental data is represented
with standard error bars, while solid lines represent predictions of the model using the
growth inhibition curve defined in (a). Note how the drug proportion that maximises the
synergistic effect corresponds roughly with the drug ratio that maximises population-level
inhibition inhibition.
But what happens in a longer experiment where bacteria have enough time to evolve drug-
resistance? In this case the population structure would be changing over time and therefore
the inhibition curve predicted for susceptible bacteria would not be able to describe the in-
hibitory effect of the antibiotic on the resistant sub-population present in the system. Con-
sequently, for long-term experiments there is no reason to expect a direct correspondence
between the predicted optimal single-drug proportion σ∗ and the optimal population-level
inhibition. So we ask, in an evolutionary model what is the optimal drug combination?
In order to address this question, in the following section we model an evolvable bacteria
growing under resource limitation in a serial transfer experiment.
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8.2 Modelling serial transfers
To study the evolution of drug resistance in the presence of a given drug combination, we
will consider that a shaken flask with liquid growth medium is inoculated with an initial
density of isogenic bacteria. Cells are grown for a fixed amount of time, after which some
of the abiotic resources needed for cell growth are consumed, and therefore the population
density has reached an equilibrium. Then a small and fixed volume is taken from the flask
and transferred to a second flask which contains fresh liquid growth medium. Repeating
this process N times defines a serial transfer experiment.
Figure 8.2: Diagram illustrating a serial transfer experiment. The system is inoculated
with an isogenic type of bacteria and allowed to grow under resource limitation for T
units of time. Then a fraction of the population is transferred into a new flask with fresh
medium.
Now, in each transfer we introduce a combination of antibiotics with basal concentrations
DOX0 and ERY0, and thus we can describe any treatment protocol by a vector of drug
proportions
σ = (σ1, σ2, ..., σN+1)
where the relative concentration of drugs used in the j-th transfer is σj , a value between 0
and 1. The actual concentration of drug deployed in the j-th flask is then σj ·DOX0 µg/ml
of doxycycline and (1−σj)·ERY0 µg/ml of erythromycin; we cannot choose not to deploy
the drug in any of the flasks because we only have freedom to choose σj and not the overall
doses.
For the purpose of this chapter we will denote the vector containing the densities of each
phenotype of bacteria with the variable P (t) = (P s, P d, P e, P de), where P s represents
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an antibiotic-susceptible bacteria, P d and P e resistant phenotypes to doxycycline and ery-
thromycin respectively, and P de the multidrug-resistant bacterial phenotype.
Furthermore, if we denote with the variable S(t) the concentration of the limiting resource
and we run the system for N transfers and denote each one as j ∈ {1, N + 1}, then
the initial density of bacteria of transfer j is determined by the terminal condition of the
previous transfer. If we assume that every transfer has a duration of T hours, then our
temporal variable can be represented by t ∈ [0, T ], and the initial condition of each transfer
would be
Pj(0) = η · Pj−1(T )
where 0 < η  1 is a dilution parameter. Note that although shaken flasks remove spatial
structure, the transfer process introduces a temporal seasonality in the ecological dynamics
of the system that has been shown to be relevant in some circumstances [68].
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Figure 8.3: (a) The graph associated with the mutation process M illustrating that
with a probability  bacteria can evolve resistance to any of the antibiotics used or have
a compensatory mutation. The accumulation of two mutations can confer bacteria with
multidrug resistance. (b) Growth rate inhibition curves for each of the phenotypes present
in the system; the black line denotes susceptible bacteria, green and blue lines denote
resistant to erythromycin and doxycycline respectively, and red represents multidrug re-
sistance. Maximum drug doses are given by 3.5µg/ml for erythromycin and 0.07µg/ml
for doxycycline.
Chapter 8. Ongoing work: Evolution of resistance in multidrug environments 137
Now let us assume that bacteria can evolve resistance to each one of the antibiotics used
through a single point mutation occurring at a rate  > 0, and that the accumulation of two
mutations can confer multidrug resistance upon a susceptible bacteria. Of course, in reality
the path to drug resistance can follow different mutational trajectories, but as discussed
in [113] most of these trajectories are inaccessible through natural selection. Then for
simplicity we will consider the evolutionary dynamics illustrated in Figure 8.3 and we will
describe it mathematically by the mutation matrixM = (1 − )I + M , where I is the
identity matrix representing clonal reproduction,  the probability of mutation and M is
a n-by-n matrix where the mij entry represents the mutation rate of bacterial type i into
bacterial type j,
M =

1−  1
2
 1
2
 0
1
2
 1−  0 1
2

1
2
 0 1−  1
2

0 1
2
 1
2
 1− 
 = (1− )I + 
M︷ ︸︸ ︷
0 1
2
1
2
0
1
2
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2
1
2
0 0 1
2
0 1
2
1
2
0
 .
As discussed in Section 5.3, bacterial phenotypes can be defined using growth rates and
antibiotic susceptibility and resistance patterns, properties that are contained within the set
of parameters (Vmax, K, κ1, κ2). For example, the susceptible phenotype, P s, has a growth
rate described by the function
Gs(S,A) = c
(
V smaxS
Ks + S
)(
1− κ
s
1A
1 + κs2A
)
,
and the ERY-resistant phenotype would have, by definition, a higher growth rate than
antibiotic-susceptible bacteria at high concentrations of erythromycin. More formally, this
means that if the growth rate of a resistant phenotype is given by the function
Ge(S,A) = c
(
V emaxS
Ke + S
)(
1− κ
r
1A
1 + κr2A
)
then there exists of a critical concentration of erythromycinERY ∗ > 0 for whichGe(S, 0, ERY ) >
Gs(S, 0, ERY ) for all ERY ≥ ERY ∗.
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It is well-known [7, 43] that antibiotic-resistant phenotypes may encounter a reduction in
fitness in an antibiotic-free environment, a so-called fitness cost of resistance. In our mod-
elling framework, this property can be realised by imposing a lower resource uptake rate
ue(S) < us(S) and therefore a lower growth rate at low antibiotic concentrations that
results in Ge(S, 0, 0) < Gs(S, 0, 0).
An analogous statement can be made for the DOX-resistant pathogen P d and for the mul-
tidrug resistant pathogen P de. The growth inhibition surfaces for each phenotype are illus-
trated in Figure 8.4.
Figure 8.4: Growth inhibition surfaces for susceptible, single-drug resistant and mul-
tidrug resistant bacteria. Note how in multidrug environments the multidrug resistant
phenotype has the higher growth rate, but it pays a cost of being resistant having a
lower growth rate at low antibiotic concentrations. These inhibition surfaces were com-
puted using the parameters described in Table A.3 and at fixed resource concentration
S = 2000µg/ml.
Then if we denote the state of the system for transfer j with the variable
xj(t) := (Sj(t),Pj(t), DOXj(t), ERYj(t)),
the system of differential equations governing the evolution of the state in each transfer is
Chapter 8. Ongoing work: Evolution of resistance in multidrug environments 139
given by x˙j = F(xj, σj), and F can be written as
d
dt
S = −〈u(S),P 〉 , (8.3a)
d
dt
P = M(G(S) · P ), (8.3b)
d
dt
DOX = −aDOX · (P s + P e + P d + P de), (8.3c)
d
dt
ERY = −bERY · (P s + P e + P d + P de), (8.3d)
with each transfer having an initial condition xj(0) = (S(0),Pj(0), σj ·DOX0, (1− σj) ·
ERY0). Parameters a and b denote the binding of antibiotic molecules to their targets.
8.3 Designing optimal multidrug combinations
A fundamental problem when solving optimisation problems is defining an objective func-
tional. Is it more important to minimise conditions that select for resistant pathogens? Or
do we simply care about minimising the overall bacterial density? Of course, the nature
of the optimal solution would depend on the objective we choose to consider, and there-
fore it is a fundamental decision to make. For instance, we could consider the following
objectives
• Minimise drug-resistant bacteria. A possible optimality criterium would be to
minimise the average of resistance at the end of each transfer during an experiment
of N transfers, a payoff functional that can be written as
J1(x;σ) = −
N+1∑
j=1
Rj(T ). (8.4)
where Rj(t) = P dj (t) + P
c
j (t) + P
dc
j (t) represents the density of resistant bacteria at
the end of transfer j. Also, we could try to minimise the final density of bacteria at
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the end of the experiment. An objective functional defined as
J2(x;σ) = −RN+1(T ). (8.5)
• Minimise bacterial density. Similarly, we could try to minimise the overall average
of bacteria at the end of each transfer. An objective represented in the expression
J3(x;σ) = −
N+1∑
j=1
Pj(T ), (8.6)
or the density of bacteria at the end of the experiment,
J4(x;σ) = −PN+1(T ). (8.7)
• Minimise maximum bacterial density. A common approach in optimisation prob-
lems is to minimise the maximum value of a given set of costs. In this context, this
minimax optimisation criterium could be interpreted as minimising the bacterial den-
sity of the phenotype with the highest density at the end of each transfer, an objective
functional that could be written as
J5(x;σ) = − max
j∈{1,N+1}
(Pj) (8.8)
• Minimise the fitness of the population. For each transfer, let us define by ∆P =
P (T ) − P (0) the total increase in bacterial density. The time of adaptation, de-
noted tadapt, is defined as the interpolated time at which the population of bacteria
has reached half its maximum value. Then we say that the fitness of the bacterial
population to this particular environment is
φ =
∆P
2 ∗ tadapt . (8.9)
This measure is similar to the one proposed in [48], as the rate of adaptation is a
proxy of the overall fitness of the population as it adapts to a given environmental
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condition. This definition allows us to write down the following payoff functional
J6(x;σ) = −
N+1∑
j=1
φj. (8.10)
Maximising this objective could be interpreted as reducing optimally the ability of a
population of bacteria to adapt to a given environment.
From the different objectives discussed above, it is clear that there is not a single definitive
quantity that we can rely upon in order to define the optimal drug proportion, as each
objective would produce a different optimal solution. For instance, if our purpose was
simply to minimise drug resistant bacteria, it is clear that the optimal treatment is never
to use antibiotics. As we already discussed in Section 2.6.3, it has even been postulated
in [42] that we should put society before the individual, and to preserve the efficacy of
antibiotics for the community some patients should remain untreated. However, this is an
unreasonable strategy from the perspective of a single-host, because without treatment the
wild-type pathogen would colonise the host.
We also argue that goals defined in terms of “average of resistance" are more suitable for
our purposes than the ones based on end-point minimisation. The reason being that the
optimal strategy that minimises bacterial density at the end of the last transfer could be to
deploy a single drug, for example ERY, during the first N −1 transfers and then, when the
population consists mainly on ERY-resistant pathogens, switch to DOX in the last transfer.
This strategy may decrease the final density of bacteria, but would not guarantee that low
densities are maintained throughout the experiment. The minimax objective represented
by equation (8.8) would certainly take into account this possibility, but for simplicity we
would consider for our numerical simulations the objective defined in (8.6) and we will
denote it J (x;σ) hereafter.
Now, having defined our goal, computing the optimal fixed-proportion drug deployment
protocol, σ∗fixed, can be achieved by numerically solving the following one-dimensional
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optimisation problem:
J (x,σ∗fixed) = max
σ∈[0,1]
{J (x,σ) : 0 ≤ σi ≤ 1 andσi = σj for all i, j ∈ {1, N + 1}}
(8.11)
Figure 8.5 illustrates an example where the optimal drug ratio that maximises the payoff
functional defined in (8.6) corresponds to a drug combination described by the mixing
parameter σ∗fixed = 0.57. Note how this drug cocktail is very effective inhibiting bacterial
growth rate during the first few transfers, but at the end of the experiment its efficacy has
decreased considerably because the population is composed mainly of multidrug resistant
bacteria, growing without any problems until reaching stationary phase.
It is important to mention that the optimal fixed-dose proportion σ∗fixed = 0.57 was com-
puted for a 12-transfer simulated experiment. Of course, there is no reason to believe that
this optimal drug cocktail would continue to be optimal for a long-term experiment where
the population structure presents different patterns of resistance and susceptibility. In fact,
our simulations show that the optimal drug proportion is indeed a dynamic property of
the system that depends, among other factors, on the duration of the experiment. This
property is illustrated in Figure 8.6: for short-term experiments the optimal drug propor-
tion corresponds roughly with the drug ratio that maximises the synergistic effect, but this
correspondence does not hold for an experiment with more dilutions. In this particular ex-
ample the predicted optimal drug proportion seems to contain more doxycycline as time
increases.
Moreover, the optimisation problem defined in (8.11) assumes that the optimal drug com-
bination is fixed for the duration of the experiment, a property expressed by considering
that σi = σj for all i, j ∈ {1, N + 1}. Although this is a standard assumption in the lit-
erature (for example, see [48]), the experimental system under consideration allows us the
possibility of relaxing this suboptimal constraint, and hence define a different optimisation
problem:
J (x,σ∗opt) = max
σ∈[0,1]
{J (x,σ) : 0 ≤ σi ≤ 1 for all i ∈ {1, N + 1}} . (8.12)
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Figure 8.5: Simulations of a serial transfer experiment designed to test the optimal
combination protocol. (a) Optical densities of a population of bacteria treated with a
fixed combination of erythromycin and doxycycline. At the beginning of each transfer
fresh medium is deployed at concentration S = 2000µg/ml, as well as a fixed dose of
antibiotic with a drug ratio of σ∗fixed = 0.57. Cells are grown for 12 hours before propa-
gating a fraction of the end-population into the next transfer. The dotted line illustrates the
moment in time that the population enters the stationary phase and shaded areas represent
the densities of each bacterial phenotype. (b) Fitness of the overall bacterial population
as a function of the number of transfers. Note how the fitness increases monotonously as
the population adapts to the fixed-drug environment. (c) Frequencies of resistance to each
drug in the population as a function of the number of transfers performed. At the end of
the first transfer the population is composed mainly by susceptible bacteria but at the end
of the experiment more than eighty percent of the population is multidrug resistant.
Solving numerically (8.12) is not a difficult task either. We could use optimisation tech-
niques like the genetic algorithm described in Appendix C, but if the number of transfers is
not too large, it can even be solved by evaluating every 2N possibility and identifying the
control that maximises the payoff. In the example presented here, the optimal 12-transfer
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Figure 8.6: Optimal drug proportion as a function of the number of transfers performed.
Darker colours represent a lower payoff while lighter colours denote that in average there
is a low pathogen density at the end of each transfer. Circles denote the optimal drug
proportion for an experiment with the corresponding number of transfers. Note that for
short-term experiments the optimal drug proportion corresponds roughly with the drug
ratio that maximises the synergistic effect. But as the number of transfers in the exper-
iment increases and consequently bacteria start adapting to the fixed environment and
therefore the population structure changes, the optimal drug ratio also changes. This fig-
ure illustrates that the optimal drug combination is a dynamic property of the system that
depends on the population structure and the length of the experiment.
control is
σopt = (0.59, 0.54, 0.56, 0.55, 0.51, 0.99, 0.72, 0.61, 0.60, 0.53, 0.55, 0.48).
It is clear from the value of σ∗ that computing the optimal control gives us very little
insight into how these strategies could be implemented in practise. As discussed before,
the theoretical optimal control is not robust to parametric and modelling uncertainties and
hence there is no reason to believe that it would still be optimal in a real experimental setup.
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We argue, however, that the difference in payoffs obtained from solving problems (8.12)
and (8.11) is so considerable, that releasing the fixed-proportion constraint seems to be an
effective strategy. In the interest of simplicity, we could, for example, allow the drug ratio
to change over time, but imposing the constraint that we can only deploy a single antibiotic
in each transfer. This optimal rotation protocol, that we will denote σrot, can be computed
by solving the following optimisation problem:
J (x,σ∗rot) = max
σ∈[0,1]
{J (x,σ) : 0 ≤ σi ≤ 1 andσi = {0, 1} for all i ∈ {1, N + 1}}
(8.13)
Note that because the set of admissible rotation protocols is much smaller than the set of
admissible controls, then the optimal rotation protocol is suboptimal with respect to the
optimal dynamic multidrug combination.
It is important to emphasise that ERY and DOX have a synergistic interaction, and that
under a rotation protocol bacteria are exposed just to a single-drug. Then it is not a surprise
that at the beginning of the experiment the optimal rotation protocol seems to be very
ineffective at reducing bacterial growth rate, a feature illustrated in Figure 8.7. However,
because of the fitness costs of resistance and the fact that rotation protocols do not impose
strong selective pressures in favour of multidrug resistant pathogens, bacterial density at the
end of the experiment is lower than the optimal fixed-dose multidrug combination protocol,
as shown in Figure 8.8.
The conclusion we can draw from the exemplar situation presented in this chapter is that
there is a universal structure to all optimal multidrug treatments: they are dynamic. In
the following chapter we will expand on this idea and re-visit the colonisation resistance
problem discussed in Chapter 6 with the purpose of designing optimal multidrug deploy-
ment strategies that support the commensal microbiota while driving the pathogens towards
extinction in a continuous culture device.
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Figure 8.7: Example of a serial transfer experiment where only one drug is deployed
at the beginning of each transfer. (a) The antibiotic used in each transfer is denoted
by the colour code at the bottom of the figure; blue denotes that doxycycline was
used at a concentration 0.7µg/ml while green denotes erythromycin at 3.5µg/ml. The
optimal rotation protocol illustrated here can be represented with the vector σ∗rot =
(0, 1, 1, 0, 0, 1, 0, 1, 0, 1, 0, 0) and was determined after simulating all possible 12-transfer
rotations. (b) Fitness of the population as a function of the number of transfers. It is im-
portant to notice that switches between antibiotics are associated with a reduction in the
overall fitness of the population. (c) Frequencies of resistance as a function of the num-
ber of transfers. As opposed to the fixed-dose combination treatment that selected for
multidrug resistance, in this case even after several dilutions the population is still mainly
composed of susceptible bacteria.
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Figure 8.8: Optimal densities at the end of each transfer under two different drug de-
ployment regimes: the rotation protocol illustrated in Figure 8.7 and the fixed-proportion
combination protocol shown in Figure 8.5. At the beginning of the experiment the com-
bination protocols minimises the density of bacteria considerably more than the rotation
protocol. Interestingly, this trend is reversed at the end of the experiment, when the treat-
ment protocol that minimises bacterial density is the one that deploys both synergistic
antibiotics sequentially and not in combination.
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Chapter 9
Optimal deployment of synergistic
antibiotics into a chemostat
The purpose of this chapter is to pose an evolutionary model of commensal and pathogenic
bacteria competing for a single limiting resource in a continuous culture device that allows
us to control the input of two synergistic antibiotics in time. Exploiting well-known results
from optimal control theory, we use an evolutionary algorithm to design antibiotic deploy-
ment protocols that support commensal bacteria while minimising the density of pathogens.
The main result presented in this chapter can be stated thus: the optimal deployment of
synergistic antibiotics to remove a pathogen in the presence of commensal bacteria in our
model system occurs not in combination, but by deploying them sequentially.
9.1 Incorporating antibiotics into a continuous culture device
A basic chemostat like the one described in Chapter 6 could be readily adapted to have
two supply vessels with different antibiotics, as shown in Figure 9.1, whereby each sup-
ply vessel contains the same concentration of abiotic resources so that the deployment of
antibiotics does not unduly effect the underlying resource competition.
We can extend the model defined in equations (6.2) in order to consider the input of two
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two bacteriostatic antibiotics of concentrationA andB. Then the state of the system is now
represented by the variable x(t) := (S(t), C(t),P (t), A(t), B(t)) and the evolutionary
model for a population of commensal and an evolvable pathogenic bacteria competing in a
single resource-limited environment and subject to the inhibiting effect of two bacteriostatic
antibiotics of concentration A and B can be written as
S˙ =
d︷ ︸︸ ︷
(α + β) S0 − dS − uc(S) · C − 〈up(S),P 〉 , (9.1a)
C˙ = Gc(S,A,B) · C − dC, (9.1b)
P˙ = M(Gp(S,A,B) · P )− dP , (9.1c)
A˙ = αA0 − dA− aA(C + 〈1,P 〉), (9.1d)
B˙ = βB0 − dB − bB (C + 〈1,P 〉), (9.1e)
with initial conditions x(0) = (S(0), C(0),P (0), A(0), B(0)). Parameters a and b repre-
sent the binding rates of each bacterial phenotype to each of the corresponding antibiotic
molecules and 1 denotes a vector of ones (1, 1, . . . , 1) of the appropriate dimension. In the
remainder, the system (9.1a-e) will be written
x˙ = F(x;α, β)
for brevity, with initial datum given by a non-negative vector x(0) = x0. We want to
control the input of both antibiotics into the system throughout an experiment of duration
T , so our control variables will be α(t) and β(t), where 0 ≤ t ≤ T , and both control
variables are constrained to lie between 0 and d.
9.2 Complete competitive advantage
In order to mimic a potentially dire situation for the commensal bacteria we shall be in-
terested in the following situation. We shall suppose to begin with that the wild-type sus-
ceptible pathogen (denoted Ps) outcompetes the commensal bacteria (C) in the absence
of antibiotics. We then assume that in the presence of antibiotics and at sufficiently high
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Figure 9.1: Diagram of a chemostat adapted to supply antibiotics A at a rate α and an-
tibiotic B at a rate β, while maintaining the volume and supply rate of limiting resources
at a constant rate. In this diagram, the constraint α+ β = d must apply.
concentrations, the commensal bacteria are able to outcompete the wild-type pathogen.
However, Ps will then be able to evolve resistance to the drug A, say, and the A-resistant
pathogenic phenotype denoted (Pa) will outcompete the commensal and similarly, if drug
B is high in concentration the B-resistant pathogenic strain (Pb) will also outcompete the
commensal.
Moreover, in a multidrug environment we shall impose strong selective pressures in favour
of those pathogens who are resistant to both antibiotics and thus the multi-resistant strain
(Pab) will outcompete C and may eventually colonise the host when both A and B are
sufficiently high in concentration. Note that we are not assuming that commensals can
evolve drug resistance, the reason being that we consider the commensals to be a com-
munity composed of many different species, and while resistance might evolve in some of
these species, we are making the assumption that the commensal microbiota as a whole
will behave as if it is mostly composed of susceptible bacteria.
Then in the situation just described, there is no value for the concentration vector of the
two drugs (A,B) for which the commensals have the highest growth rate, as illustrated in
Figure 9.2. Therefore, for any fixed environment, there exist at least one pathogenic strain
that outcompetes the commensal type and we therefore say that pathogens have complete
competitive advantage. In this case, we pose the following questions: is there a drug de-
ployment policy that can make the commensals persist as time increases? And if one exists,
can we design the optimal treatment protocol that minimises the density of pathogens?
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Figure 9.2: Growth rate inhibition surfaces for each bacterial phenotype as a function
of the concentration of each antibiotic. Note that commensals are not the fittest bacteria
in any possible fixed environment (and here S is held at a fixed value).
9.3 Controlling the chemostat optimally
To minimise the evolution of antibiotic resistance, it is evident that the optimal strategy is
simply never use antibiotics, but this is suboptimal from the perspective of a single host,
because without treatment the wild-type pathogen will colonise the host. Conversely, drug
overdose selects for resistant phenotypes and as a consequence decreases the longer-term
efficacy of the antibiotic. Then, for a drug deployment policy to be considered optimal, it
has to be able to drive the pathogens to extinction whilst preserving its efficacy.
Taking into consideration the idea that we would like to support the commensal micro-
biota, we define the healthy state of the system whereby the commensal bacteria are in
equilibrium and there are no pathogens present. Ideally we would drive the system towards
the healthy state in such a way that we minimise antibiotic use but our present question
is simpler: do there exist treatment protocols that drive the pathogen density to zero and
the commensal to equilibrium even when the former has complete competitive advantage?
Motivated by results and techniques from optimal control, we shall use a genetic algorithm
to show numerically that this is possible by optimising the treatment protocol with respect
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to the following objective functional:
J (α, β) =
∫ T
0
(
C(t)−
n∑
j=1
Pi(t)
)
dt where x˙ = F(x;α, β),x(0) = x0. (9.2)
We shall assume throughout the remainder that the maximum input rate of antibiotic is the
same as the dilution rate of the chemostat, so that
0 ≤ α, 0 ≤ β, α + β ≤ d.
Now, it is a well-defined problem to seek functions α and β that satisfy
J (α∗, β∗) = max {J (α, β)|α ≥ 0, β ≥ 0, α + β ≤ d} , (9.3)
where the set of admissible controls for this problem is
Ω := {(α, β) ∈ L∞(0, T )× L∞(0, T ) |α ≥ 0, β ≥ 0, α + β ≤ d a.e.}.
However, in order to simplify computational aspects of the problem we also impose the
exogenous, suboptimal constraint that we must deploy antibiotics at a constant rate, d, and
so the control problem is to then determine only what proportion of both antibiotics we
should use at any given moment in time. We define another set of admissible controls
accordingly by
Ω′ := {(α, β) ∈ L∞(0, T )× L∞(0, T ) |α ≥ 0, β ≥ 0, α + β = d a.e.}
and our second constrained optimisation problem is to determine the admissible control α∗
and β∗ such that the payoff is maximised:
J (α∗, β∗) = max
(α,β)∈Ω′
J (α, β). (9.4)
The experimental protocol corresponding to the optimal control problem (9.4) is illustrated
in Figure 9.1.
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The dependence of equation (9.1a-e) on the control variables is affine in the sense that
there is an smooth mapping F0 : R1+n+3 → R1+n+3 such that the function F(x;α, β) =
F0(x) + αv+ βu and the objective functional J (α, β) in (9.2) is linear in the state x as it
can be written in terms of a weight w vector,
J (α, β) =
∫ T
0
〈w,x(t)〉 dt. (9.5)
As a result, J : L∞ × L∞ → R is continuous with respect to weak∗, L∞-convergence.
Moreover, both Ω and Ω′ are closed, convex subsets of L∞ × L∞ and so are compact with
respect to the weak* topology on L∞ × L∞.
The solutions of (9.1a-e) satisfy a control-independent, dissipative bound of the following
form: for each initial condition x(0) there is a t′ depending on x(0) such that
S(t) +
1
c
(C(t) + 〈1,P (t)〉) ≤ S0 + 1, (9.6a)
A(t) ≤ A0 + 1, B(t) ≤ B0 + 1, (9.6b)
for all t > t′. To see this, define Σ := S0 − S − 1c (C(t) + 〈1,P (t)〉) and note that
the differential inequality d
dt
Σ ≤ −dΣ follows from (9.1a-e), the bound in (9.6a) now
follows. The bounds in (9.6b) are obtained from the inequalities d
dt
A ≤ d(A0 − A) and
d
dt
B ≤ d(B0 − B) that satisfied by positive solutions of (9.1a-e) when max(α, β) ≤ d,
min(α, β) ≥ 0.
Theorem 9.3.1 There exists an optimal control (α∗, β∗) ∈ Ω′ such that J (α∗, β∗) ≥
J (α, β) for all (α, β) ∈ Ω′.
Proof Seeking an optimal control that maximises the payoff functional defined in (9.5)
subject to the system of differential equations given in (9.1a-e), suppose that
sup
(α,β)∈Ω
J (α, β) = lim
k→∞
J (αk, βk)
for a sequence {(αk, βk)} ⊂ Ω′ where βk = d − αk, a supremising sequence of ad-
missible controls. This sequence has an associated sequence of state responses {xk} ⊂
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W 1,∞((0, T ),R1+n+3) that satisfies d
dt
xk = F(xk, αk, βk) and xk(0) = x0 for each k.
Because 0 ≤ αk + βk ≤ d almost everywhere, we can assume without loss of generality
that
(αk, βk)
∗−⇀ (α∗, β∗) ∈ Ω
as k →∞ because Ω′ is compact with respect to the weak* topology in L∞.
Due to the dissipative bound (9.6), there is an M > 0 independent of k such that ‖xk‖∞ ≤
M and so, using d
dt
xk = F(xk;αk, βk),xk(0) = x0, we obtain a k-independent W 1,∞-
bound on xk. We may therefore assume without the loss of generality that xk
∗−⇀ x∗ in
W 1,∞ and so, basic compact embedding results allow us to take the latter convergence in
C0([0, T ],R1+n+3). As a result, the continuity of the nonlinear mapping F can be used to
deduce that d
dt
x∗ = F(x∗;α∗, β∗) and x∗(0) = x0. Furthermore,
lim
k→∞
J (αk, βk) = lim
k→∞
∫ T
0
〈w,xk〉dt =
∫ T
0
〈w, lim
k→∞
xk〉dt
=
∫ T
0
〈w,x∗〉dt = J (α∗, β∗)
and so J (α∗, β∗) = sup{J (α, β) | (α, β) ∈ Ω′}. 
We are interested in the idea of antibiotic rotation, defined as follows. Two admissible an-
tibiotic deployment protocols α and β are said to be in rotation if only one of the antibiotics
A and B is used at any one time:
α(t) · β(t) = 0 (9.7)
for almost all t between 0 and T . If we define the set of admissible rotational protocols
Ωrot := {(α, β) ∈ Ω′ | α(t) · β(t) = 0 a.e.}
then Ωrot is a weak∗ dense subset of Ω′. To see this, the following construction is useful.
Let IN = (tk)Nk=0 be a partition of the interval [0, T ] so that t0 = 0 < t1 < ... < tN−1 <
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tN = T and let PC(IN) be the space of real-valued, piecewise-constant functions on IN
taking only one of the values either 0 or 1 on each interval of the form (tk, tk+1). The set
of admissible bang-bang controls
Ωbb := {(α, β) ∈ Ω′ | ∃N, IN and a ∈ PC(IN) s.t. α(t) = d · a(t), β(t) = d · (1− a(t))}
is a subset of, and weak∗ dense in Ω′ (see [103]) but Ωbb ⊂ Ωrot and so Ωrot is also weak∗
dense in Ω′.
The outcome of applying these rather standard control theoretic ideas is the result that
rotational protocols can do as well as any within Ω′:
max
(α,β)∈Ω′
J (α, β) = sup
(α,β)∈Ωrot
J (α, β).
This means that antibiotic deployment protocols that rotate or alternate in turn between two
antibiotics can perform as well as any protocol in Ω′. In particular, since Ω′ contains the
entire spectrum of combination therapies, from drug A-only to drug-B only, we see that
rotational protocols are, in general, superior to ones that define a fixed proportion of each
drug throughout the term of the experiment.
The set of rotational protocols is not weak∗ closed as it contains the non-rotational 50%-
A, 50%-B combination therapy ψ(t) = d/2 in its weak∗ closure and the existence of an
optimal control within Ωrot cannot be established in general. Notice also that the optimal
deployment protocol in Ω is not a rotation in general because Ωrot is a much smaller set
than Ω itself.
It follows from the fact that Ωbb ⊂ Ω′ is weak∗ dense that
max
(α,β)∈Ω′
J (α, β) = sup
(α,β)∈Ωbb
J (α, β).
This property in turn informs us that to find an approximate optimal deployment protocol
(α, β) ∈ Ω′ we only need search within PC(IN) for large enough N , this property is
convenient for the numerical calculations performed using a genetic algorithm to locate
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near-optimal controls in the next section.
9.4 Supporting commensal bacteria with rotational protocols
Let us consider a dynamic whereby pathogenic bacteria and commensal bacteria are intro-
duced into the chemostat at t = 0. In order to colonise the chemostat, the pathogens have
to outcompete the commensal bacteria and to mimic a colonisation resistance experiment
we shall assume that the initial population of commensals and wild-type pathogens are at
equal densities when t = 0 with few or no drug-resistant mutants. Recalling our working
assumption that pathogens have a greater fitnesses than commensals in an antibiotic-free
environment, the pathogens will colonise the host in the absence of antibiotics. In effect,
we are forced into treating the chemostat host with antibiotics in order for the commensal
to survive.
Now suppose that pathogens can evolve resistance to the two different antibiotics of con-
centrations through point mutations that occur at mutation rate 0 <  1 and the accumu-
lation of two mutations will confer pathogens with multidrug resistance. To reflect this, the
mutation matrix for the population of pathogenic bacteria P = (Ps, Pa, Pb, Pab) is given
by the irreducible, stochastic matrix M = (1− )I + MP , where I is the identity matrix
representing clonal reproduction,  the probability of mutation and MP is a n-by-n matrix
where the mij entry represents the mutation rate of bacterial type i into bacterial type j.
To make the situation particularly stringent on the commensal bacteria we shall impose
the restriction that the commensal bacteria cannot evolve resistance to any of the antibi-
otics used. As mentioned before, this strong biological assumption is based on the idea of
considering the commensal as a community composed mainly of susceptible bacteria. But
also because we want to consider the worst possible scenario for the commensal popula-
tion and, for this reason, we will also assume that the pathogen population has complete
competitive advantage meaning there are no drug combinations for which the commensals
are not outcompeted by at least one pathogenic phenotype.
As already discussed, by controlling the input of antibiotics A and B at rates α(t) and
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β(t) respectively, we will attempt to drive the pathogens to extinction while promoting the
commensal microbiota. If we now denote the state of this system by
x = (S,C, Ps, Pa, Pb, Pab, A,B),
we aim to do this by taking advantage of the theoretical results of the previous section
and numerically maximising the objective functional (9.5) within the space of rotational
protocols where w = (0, 1,−1,−1,−1,−1, 0, 0) .
In the scenario of complete competitive advantage of the pathogen over the commensal
considered here, some numerical simulations are shown in Figure 9.3 to illustrate the dy-
namics of different drug deployment mechanisms. The single deployment of one antibiotic
will be ineffective and while the best combination strategy is very effective at suppressing
pathogens, it imposes a severe cost on the commensal population. Indeed, the constant de-
ployment of any two-drug cocktail at any fixed drug ratio will have as a consequence that
one of the pathogens will colonise the system (see Figure 9.3). It is clear, therefore, that in
order to find a drug deployment strategy that can allow the commensals to persist, we have
to allow the ratio between drugs to change over time.
Although optimal treatments can be obtained for the treatment objective J (α, β) either
with an optimisation algorithm or by solving the Euler-Lagrange equations associated with
this functional, in practice this can be a challenging computational task, particularly when
T is large. However, the optimal control for J under the constraint that we must deploy
antibiotic at all times is a rotational protocol that can be described as follows. Deploy one
antibiotic at the beginning of the experiment until some as yet unknown moment in time
when a switch to a different will be needed; a repetition of this process will then define
a rotation protocol. While computation of near-optimal controls could be achieved using
a variety of different optimisation methods, we chose the genetic algorithm described in
Appendix C.
Figure 9.4 shows the results of applying this genetic algorithm to the model (9.1) where
the parameter values are given in Table A.2, the result is a rotational protocol whereby the
commensals have the highest density at the end of the experiment obtained by numerically
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Figure 9.3: Numerical simulations with the parameter values given in Table A.4 show-
ing the densities of pathogens and commensals throughout an experiment of duration
T = 100 hours. (top-left) Bacterial densities when no antibiotics are used and drug-
susceptible pathogens colonise the system. (top-right) Because the two antibiotics are
synergistic, a 50-50 mixing strategy (equal concentrations of each drug) is very effec-
tive at suppressing the density of pathogens. However, commensals are also suppressed,
eventually allowing the multidrug-resistant pathogen to colonise the host. (bottom-left)
and (bottom-right) Single-drug protocols are particularly ineffective, allowing resistant
pathogens to colonise the system.
maximising the treatment objective J . The rotational protocol so-obtained is just one from
an infinite family of suboptimal controls that outperform all the fixed-ratio combination
protocols with respect to the treatment measure J , as shown in Figure 9.4b).
It is important to note that to determine the optimal control, or even a near-optimal control,
we essentially need to have access to complete information about the future dynamics of
the system which are not likely to be available in practise. Determining the temporal dy-
namics of drug resistance would be very difficult, necessitating vast amounts of genomic
data to be processed. An alternative to searching for the optimal protocol could be to im-
plement rotational treatment protocols based on on partial information of the present state
of the system as part of a feedback control. Depending on our precise goal, we could im-
plement such a feedback as part of a heuristic that allows us to decide upon the best drug
usage strategy at each moment in time, based on the information we currently have access
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Figure 9.4: (a) Bacterial densities under an antibiotic deployment regime determined
using a genetic algorithm (see Appendix C for details). The rotation protocol is repre-
sented by the barcode in the bottom of the figure, a blue (or green) box represents the time
that drug A (or B) is being deployed at maximal dose during that time interval. Note that
commensal bacteria have the highest density of all the types present, despite never being
the fittest cell type. (b) The solid line represents the treatment objective (J ) of every
possible combination with a fixed ratio between drugs (drug ratio, called σ in the text).
The dashed line shows the payoff of the rotational protocol illustrated in (left). Although
it is not the J -optimal treatment, it outperforms even the optimal combination strategy.
to. For example, consider the simple feedback controller contained in the rule described
immediately below:
1. deploy a single antibiotic into the chemostat;
2. after τ units of time, measure the levels of resistance to the current antibiotic used,
we call τ the sampling time;
3. if the density of pathogens resistant to that antibiotic is larger than the sum of the
densities of the other phenotypes, switch to the other drug. Otherwise, continue the
deployment of the same drug for another τ units of time. Repeat the process from
rule (2).
Surprisingly, this feedback heuristic can be sufficient to allow the commensals to persist and
so drive the pathogens to extinction (see Figure 9.5). This illustrates that even suboptimal
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rotational protocols can be effective at treating the presence of the pathogen in situations
where even the best combination treatment will not work, as shown in Figure 9.3(top right).
However, the practical implementation of this feedback rule is contingent upon knowing
the strain responsible for a bacterial infection and then knowing the relative densities of
strains carrying resistance alleles or plasmids. This is biologically detailed information,
although the increasing availability of tools to determine such information [11] would make
the implementation of such a feedback a practical possibility.
0 200 400 600 800 1000
0
1
2
x 106
Ba
ct
er
ia
l d
en
sit
ie
s 
(ce
lls
/m
l)
Time (t)
 
 
Pathogens
Commensals
Figure 9.5: Numerical simulations of a long-time experiment (T = 1000) of a complete
competitive advantage scenario where the numerical values of the parameters used are
given in Table A.4. In this example, commensals are able to persist with a drug rotation
protocol designed using a feedback control heuristic. The rotational protocol is illustrated
with the dark boxes denoting drug B and the light boxes denoting drug A at the bottom
of the figure, the dashed line represents the sum over all pathogenic phenotypes while the
solid line represents the density of commensals through the duration of the experiment.
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Selecting against antibiotic resistance in
clinical settings
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Chapter 10
An individual-based model of a hospital
ward
The purpose of the last part of this thesis is to pose an individual-based model of a hospital
ward that will allow us to test in silico different antibiotic deployment protocols used in
clinical trials that have taken place over the last decade. Unfortunately there is no standard
form of hospital interventions upon which we can focus to develop this model, but the
following brief survey highlights features of policies that have been trialled in practise, and
that we will be able to implement in our computational framework and thence consider
their relative merits.
10.1 Stewardship programs to control resistance in health care cen-
tres
The scheduled rotation of one antibiotic for another discussed in the first part of this thesis
is not the only type of policy trialled in hospitals. A striking example of this can be seen
in the number of different policies trialled in the treatment of ventillator-associated pneu-
monia as described in [91]. First a ten-month, patient-specific strategy was implemented
using multiple drug treatment, a twenty-four month period of scheduled rotation based on
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four-month prioritisation and restriction cycles then followed, ending with a ten-month pe-
riod of so-called antibiotic mixing whereby the first-line antibiotic was changed in each
consecutive patient.
The so-called PAMS methodology (periodic antibiotic monitoring and supervision) [105]
is not based on predetermined schedules of rotation but, as stated in [91], the basis of PAMS
is the adaptation of observed prescription patterns aimed at ‘... balancing the use of differ-
ent antimicrobials ... to reduce selection pressure’. The authors of [91, 105] achieve this
by seeking to maximise the heterogeneity of the drugs prescribed. This essentially means
that antibiotics used in the recent past must have a lower probability of being prescribed
in the near future and a numerical index (a so-called Peterson index) is used to measure
the heterogeneity of drug prescription and a committee was given the task of ensuring that
prescription patterns maximise this index as the trial proceeds. While this rationale is igno-
rant of the patterns of resistance that actually emerge during the trial, it is responsive to the
patterns of prescription that might be correlated with increased resistance and like the theo-
retical antibiotic mixing protocols proposed in [13,15], it does maximise the heterogeneity
of drug use.
While the PAMS methodology does seek to exploit information about previous drug use to
inform future policy, some studies have gone further in seeking collated, drug susceptibility
data as the basis for that policy. For example, patterns of drug prioritisation and withdrawal
have been set in response to previously observed levels of susceptibility and resistance in
an ICU unit [3]. Of their rotation-based microbiological surveillance methodology, the
authors of this article stated that ‘A non-premeditated change of antibiotics in empirical
therapy, on the basis of detected resistance patterns, provided promising results in reducing
some antimicrobial resistance rates.’
The individualisation of treatments can militate against the inappropriate use of antibiotics,
important because the wrong initial choice of antibiotics in empirical treatment has been
shown to increase the likelihood of patient death, for example in the case of intubation-
associated pneumonia [35]. As a result, this study recommended effecting a change in
antibiotics based on individual susceptibility measurements using patient-specific microbi-
ological data, data that became available between two and three days after admittance to
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the unit. However, even a delay of this length in providing a basic understanding of the
pathogens responsible for infection is known to be associated with an increase in patient
mortality across a range of multidrug resistant bacteria [87]. Furthermore, initially inap-
propriate therapy for non-nosocomial methicillin-resistant Staphylococcus aureus has been
observed in as many as 77% of patients admitted [93].
Dissatisfied with such delays, the authors of [11] proposed the exploitation of detailed mi-
crobiological information based on the rapid, within one hour, DNA-based identification of
microorganisms and the resistance genes they carry. It is known that the evolution of antibi-
otic resistance can occur in vivo in a matter of weeks, so rapidly that over thirty resistance
mutations were observed in isolates of MRSA from a single patient and identified using
whole-genome sequencing [78]. The sequenced mutations were correlated with changes in
the MICs for multiple drugs, including rifampin, vancomycin, oxacillin and daptomycin.
As the rapidity of sequencing technology increases and costs decrease, rather than wait
until treatment fails to assess the evolutionary path taken by the infection, why not use this
technology as a diagnostic tool to exert some control over that path?
This brief assessment of the clinical literature suggests at least five classes of antibiotic
deployment protocols that have been used in clinical trials and that we can implement in a
mathematical model. Collated according to the increasing degree of information required
for their implementation in an ICU unit or hospital, they are:
• antibiotic mixing∗ based on random drug prescription (see [13, 15]),
• scheduled, rotating cycles of antibiotic prioritisation and restriction (see [47,70,84]),
• antibiotic mixing based on prior patterns of prescription (see [91, 105]),
• surveillance-based rotation determined on previously observed, emergent patterns of
resistance (see [3]) and
• diagnosis-based treatments determined using patient-specific susceptibility, assess-
ing the appropriateness of treatment at least once (see [11, 93]).
∗The term mixing will refer to any protocol whereby two patients simultaneously diagnosed with infection
by the same pathogen may be purposefully prescribed different drugs.
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This list is not meant to be exhaustive but has been collated to test the hypothesis that
policies based on more information and which increase overall drug appropriateness as a
result are necessarily of greater efficacy. This list does not encompass all the protocols used
in practise, for example the de-escalation protocol used in the treatment of pneumonia [46]
uses an initially broad-spectrum empirical treatment in advance of receiving the results
of microbiological cultures. Nor, for example, does our list include the patient-by-patient
rotation of the first-line antibiotic implemented in [91].
Note that although our modelling framework allows us the possibility of considering that
single patients can be treated with a cocktail of multiple antibiotics like the ones discussed
in Part II of this thesis, we quite purposely have not included this treatment protocol in our
assessment of the clinical literature, but we will discuss this strategy later.
10.2 Modelling patients as single-hosts
As opposed to classic epidemiological models where the population is subdivided in com-
partments and the dynamics of the system is given by the transition rates between compart-
ments, here we will consider explicitly patients as individual hosts interacting through the
transmission of pathogens.
Individuals can be colonised both by commensal microbiota and by an evolvable pathogen.
In order to clear the pathogens from the host, patients can be treated with a combination of
two different antibiotics of concentrations that we will denote with the variables A(t) and
B(t); the details of the treatment protocol will be determined by the hospital-wide strategy
of drug usage.
Let C denote the density of commensal bacteria and P = (Ps, Pa, Pb, Pab) a vector con-
taining the densities of different phenotypes of pathogenic bacteria, where Ps represents
a susceptible pathogen, Pa and Pb pathogens resistant to antibiotics A and B respectively
and Pab a multidrug resistant pathogen. Phenotypic mutation rates during clonal reproduc-
tion for pathogenic bacteria are described by the irreducible and stochastic mutation matrix
M = (1 − )I + M , where I is the identity matrix representing clonal reproduction,
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0 <  1 the probability of point mutation and M is a 4-by-4 matrix where the mij entry
represents the mutation rate of pathogenic type i into phenotype j:
M =

1−  1
2
 1
2
 0
1
2
 1−  0 1
2

1
2
 0 1−  1
2

0 1
2
 1
2
 1− 

Growth rate of each bacterium type is not only determined by the concentration of available
resource, denoted by S, but also by the concentration of antibiotics present in the host.
Therefore growth rate of bacterial type i can be modelled as a resource uptake function
multiplied by an inhibition term that depends on the concentration of both drugs:
Gi(S,A,B) = ui(S) · γi(A,B), (10.1)
where γi(A,B) is the growth inhibition function derived from kinetic properties of the inter-
action between bacterium type i and both antibiotics, as discussed in Chapter 7, and ui(S)
is the standard Monod function with a maximal growth rate V imax and a half-saturation con-
stant Ki:
ui(S) =
V imax S
Ki + S
, (10.2)
We will assume that both drugs have a synergistic interaction and that we can model them
as non-exclusive competitive inhibitors. This implies that the pharmacodynamics of each
drug is acting on independent metabolic pathways or different parts of the cell division
process. Then the multidrug growth inhibition function can be written as
γi(A,B) =
(
1− κ
1
i A
κ2i + A
)
·
(
1− κ˜
1
i B
κ˜2i +B
)
, (10.3)
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where κ2i and κ˜
2
i represent the affinity of the cell to antibiotics A and B respectively, while
κ1i and κ˜
1
i control the level of maximal growth inhibition by each drug.
As discussed in Section 5.3, each bacterial phenotype has different profiles of drug resis-
tance, a property determined by the set of parameters (V imax, κ
1
i , κ˜
1
i , κ
2
i , κ˜
2
i ). For instance,
we say that Pa is resistant to drug A because 0 ≤ γs(A, ·) < γa(A, ·) ≤ 1 when A  0.
Fitness cost associated with drug resistance at low antibiotic concentrations is also consid-
ered, as we can choose parameters in such a way that Gs > Ga at low concentrations of A.
Analogous statements can be made about the B-resistant and the AB-resistant phenotypes.
It is important to notice that we are considering that antibiotics can be introduced into
the host continuously, as opposed to a discrete dosage schedule. The reason being that
critically ill patients in ICU units are usually treated with intravenous continuous infusion.
Then we will denote with A(t) and B(t) the concentration of each drug in a given patient
at time t and with x = (S,C,P , A,B) the state of the system, the evolutionary model for
a population of commensal and pathogenic bacteria competing for limited resources and
subject to the inhibitory effects of both antibiotics can be written as:
S˙ = m(S0 − S)− c (uc(S)C + 〈u(S), P 〉)
C˙ = Gc(S,A,B)C − dC
P˙ =M(G(S,A,B) · P )− dP
A˙ = αA0 −mA− aA(C +
∑
i
Pi)
B˙ = βB0 −mB − bB(C +
∑
i
Pi)
(10.4)
with initial conditions x(0) = (S0 ,C0 ,P0 ,A0 ,B0 ). Parameters a and b represent the
binding rates of each bacterial phenotype to each of the corresponding antibiotic molecules,
c denotes a resource conversion constant and m the constant influx and efflux of resources
from the system. Bacteria are also cleared from the system at a constant rate d.
The treatment protocol is represented by the control functions α(t) and β(t), that represent
the input rate of antibiotics A and B into the host. Both control functions are bounded,
0 ≤ α(t) ≤ 1 and 0 ≤ β(t) ≤ 1, and A0 and B0 denote the maximum dose allowed for
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each drug. Drugs are also washed out of the system at a constant rate m.
Now, if we define the health state of a given patient as:
h(t) =
C(t)
C(t) +
∑
i Pi(t)
(10.5)
then our goal will be to treat the patient until there are almost no pathogens present and the
commensal population has re-colonised the host. Let us define t = T to be the first time
when h(t) > δ for a given δ > 0, and we then say that the Length of Stay (LoS) of this
patient is T units of time.
10.3 A non-deterministic, spatially explicit model of a hospital ward
Let us consider that a hospital ward is composed of a linear array of B beds, each one
denoted by bj where j ∈ {1, B}. Now let Q = {p1, p2, . . . , pn} represent a randomised
queue of n patients, where each individual pi is colonised by initial densities of commensal
and pathogenic bacteria.
When admitted into the hospital each patient is assigned to an available bed, where it will
receive treatment until the health state defined in (10.5) is above a certain threshold and
then the patient is discharged from the hospital. Then the next patient from the queue is
assigned to the available bed where it will also receive treatment until healthy. When every
patient from the queue has been discharged from the hospital ward, we then calculate the
Mean Length of Stay (MLoS) of this ordered queue associated with this specific treatment
protocol.
Also, every τ units of time a proportion β of bacteria present in each patient are transmitted
between hosts of neighbouring beds. The reason we are assuming a discrete transmission
dynamics over a continuous within-host dynamics is because we are considering that most
of the transmission of bacteria between hosts is due to movement of patients and health
care workers from bed to bed.
Note that there are two main sources of stochasticity within our model: the initial frequency
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Figure 10.1: (a) Health state of a single patient treated with a cycling protocol. Coloured
areas show the density of each pathogenic phenotype as a function of time, while the black
line represents the density of commensal bacteria. (b) Diagram of a hospital ward with 5
beds where a queue of seven patients (here labelled {1, 2, 3, 4, 5, 6, 7} for convenience)
is to be treated (c) This Manhattan plot illustrates one realisation of the model using a
queue of 20 patients and 5 beds where a rapid 20-day cycling protocol between the two
drugs has been implemented. The left-hand illustration show the protocol used where
the green and blue boxes denote patients (beds) treated each day with one of the two
available drugs and a red outline denotes the discharge of a recovered patient followed by
the arrival of a new member from the treatment queue. The relative frequency of each of
the two single-drug resistant pathogens in each patient is shown in the right-most diagram
and illustrates that drug resistance is correlated with the current deployment policy; the
grey boxes in this plot show patients carrying equal fractions of two different single-drug
resistant pathogens.
of resistance of each patient of the queue and the order of the queue itself. The former is
very important as it represents the level of community-acquired resistance, but the latter is
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also relevant because the position of the patient in that queue can lead to a change in the
treatment administered to that patient. This implies that by re-ordering the queue of patients
and implementing the same drug usage strategy multiple times, we can obtain meaningful
statistics of the MLoS, allowing us to compare this antibiotic deployment strategy with
others implemented to the same queue of patients.
In summary, the key assumptions of our model are the following: (1) patients are colonised
both by commensal and pathogenic bacteria, if the pathogen density is very low (below a
measurable threshold) the patient is discharged from the ward; (2) pathogens can evolve re-
sistance to any drug used through a single-point mutation and the accumulation of multiple
mutations confers pathogens with multi-drug resistance. There is a fitness cost associ-
ated with drug resistance expressed by resistant pathogens having a lower growth rate than
susceptible bacteria in the absence of that antibiotic; (3) there is no infection-induced mor-
tality and, if left untreated, all patients will eventually recover, although more slowly than if
treated; (4) patients are always treated with one of two possible drugs, the drug prescribed
to each patient at any moment in time is decided based on the hospital-wide strategy under
consideration; (5) this model explicitly considers the transmission of pathogens between
patients of neighbouring beds.
The transmission dynamics of pathogens within the ward has a significant impact on the
efficacy of different drug usage strategies. For example Figure 10.1c) shows how epidemic
waves of drug-resistant pathogens pass through the ward as they are transmitted rapidly
from one bed to its neighbour under a cycling protocol. This dynamic forces the model
to exhibit the following property common to the theoretical models used in the previous
section: from the moment one drug is restricted and the other prioritised at the end of the
cycle, the rate of ascent of resistance to the new drug is greater than the rate of descent of
resistance to the previous drug.
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10.4 Evaluating the efficacy of different hospital-wide usage strategies
The strength of this modelling approach is that even though we may not be able to deter-
mine exactly the optimal drug deployment, we can simulate specific drug usage strategies
and obtain statistics about their performance, from hospital-wide protocols that restrict and
prioritise drugs based on predefined schedules, to individual-based strategies that decide
which drug to give to each patient based on local patterns of susceptibility and resistance.
We simulated N = 1000 replicates of different hospital interventions for a randomly gen-
erated queue of n = 100 patients receiving treatment in an 8-bed hospital. The protocols
simulated are the following:
• Random sequential treatment: each patient receives a random drug each day.
• Empirical treatment: a random drug is allocated to the patient and determined the
moment the patient arrives at the hospital.
• Periodic cycling: scheduled, rotating cycles of antibiotic prioritisation and restric-
tion are fixed before any patients have entered the hospital.
• Periodic antibiotic monitoring and supervision: the next patient to arrive at the
hospital will be treated with the drug that maximises the heterogeneity of drugs cur-
rently used within the hospital.
• Surveillance-based rotation: drug-resistance assays are regularly conducted on
samples from the patient population and the same drug, namely the one estimated
to have the lowest incidence of resistance, is prescribed to all patients.
• Dynamic, diagnosis-based treatments: an initial and rapid assessment of the bac-
terial responsible for each patient’s infection is made the moment a patient arrives at
the hospital, a reassessment may also be conducted later during the treatment.
Our computational results are summarised in the histograms of Figure 10.3a which shows
the per-patient mean length of stay (MLoS) distribution. One treatment is said to be more
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Figure 10.2: (a) The mean length-of-stay distribution for the null protocol applied to
multiple re-arrangements of the patient queue: a near-normal distribution with mean close
to 16 days. (b) The length of patient stay of the empirical treatment follows a log-normal
distribution.
effective than another for a given patient queue if the mean length of stay of patients in
that queue is smaller. As a matter of completeness, we note the following: if we do not
treat any patients from the queue when they enter the hospital (the null protocol), the mean
length of stay is normally distributed with respect to different arrangements of the queue
order, as shown in Figure 10.2a; moreover, the distribution of length of patient stay in the
simulations follows an approximately log-normal distribution for each queue, as illustrated
in Figure 10.2b.
There are three main features of note in our computational results illustrated in Figure
10.3a: (i) The empirical treatment distribution has a very long tail and so this protocol can
be very ineffective which is largely due to the number of patients receiving inappropriate
therapy in this protocol. The property that inappropriate treatment leads to longer MLoS
distributions is also illustrated in Figure 10.3b and Figure 10.3c. (ii) Diagnosis-based treat-
ments whereby the appropriate drug is prescribed to each patient each day perform better
than all the other treatments simulated. (iii) Surveillance-based rotation requires less in-
formation to implement than diagnosis-based treatments but it performs better than the
antibiotic mixing protocols.
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Figure 10.3: (a) The length of stay distributions of different scheduled treatment poli-
cies: diagnosis-based treatment, surveillance-based rotation, random sequential treat-
ment, PAMS and an empirical-only control treatment. (b-c) Mean length-of stay and
the inappropriate use of antibiotics: (b) the mean LoS per queue is normally distributed
for both classes, with higher mean and variance for the inappropriate drug class. (c) A
Kaplan-Meier plot illustrating the length of stay for each class.
And what of antibiotic cycling? Upon simulating strictly cyclical periods of drug rotation
across the hospital we found that appropriately chosen rapid cycles could prove as effective
as some of the patient-based diagnosis treatments. However, protocols based on cycles of
longer duration that might be implemented in practise, up to one month say, had the effect
of doubling the mean length of stay for the patient queue, as illustrated in Figure 10.4.
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This makes the scheduled rotation of different antibiotics an impractical and potentially
dangerous solution because it would be essential to know in advance of implementing such
a protocol which particular duration would be appropriate for each particular pathogen-
drug combinations [8].
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Figure 10.4: MLoS of antibiotic cycling as a function of the cycling period. Scheduled
rotation may work, but only when cycling at the correct cadence: very rapid cycling
performs as well as a random sequential treatment policy, longer cycles lead to a rapid
increase in the expected length of stay. Without the benefit of hindsight, these results do
not support the use of this protocol.
The fact that random drug deployment is easily outperformed by patient-specific, diagnosis-
based treatments is perhaps not a surprise, as any drug deployment policy that increases the
appropriateness of drug usage is sure to decrease the time to recovery from infection. How-
ever, more interesting is the question of how much information do we actually need in order
to maintain the effectiveness of the diagnosis-based protocol?
To probe this question we incorporated into our simulation the following delay in deter-
mining drug-susceptibility information: we assumed that from the moment each patient is
admitted to hospital, results are only available from the bacteriology lab some time later,
from one to fourteen days. Before this time, an empirical treatment is given, after this time
the most appropriate drug upon admission is then prescribed. Figure 10.5a shows that there
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Figure 10.5: a) Delaying the availability of drug susceptibility information decreases
drug appropriateness to no better than random b) delays for susceptibility determination
increase the expected length of stay.
is a correlation between the time for this susceptibility determination and the percentage of
patients receiving appropriate drugs, Figure 10.5b then shows that an increase in this delay
is responsible for an almost linear increase in the observed MLoS.
Interestingly, Figure 10.9e shows that multiple diagnoses have little effect on the perfor-
mance of the diagnosis-based protocol: although drug-resistance pathogens could be trans-
mitted through the hospital and go on to infect and colonise a patient already receiving
treatment for a different bacterial strain, in our simulation this was not an important factor.
Much more important was that the correct diagnosis of the strain responsible for infec-
tion was determined quickly after the time each patient was admitted to hospital. Just one
genetic test performed at that moment in time was sufficient to yield a treatment more
effective in average than any other mixing or rotational protocol.
Our computational framework allows us to treat every host with a combination of both
available antibiotics, so we evaluated the effect that a drug combination has on the disease
dynamics of our theoretical hospital ward. As expected, because the drugs considered have
a strong synergistic interaction, patients recovered considerably faster than with a 50-50
drug combination than with any monotherapy. It is important to notice, however, that this
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Figure 10.6: Under a dynamic diagnosis-based treatment protocol, if the initial rapid
diagnosis is performed immediately, subsequent diagnoses as long as one week later may
have little effect on the mean length of stay.
treatment protocol imposes strong selective pressures in favour of multidrug resistance and
in consequence decreases the long-term drug efficacy. We also found that the efficacy
of combination treatments depends on the levels of drug resistance in the community, a
property discussed in the following section.
10.5 Community structure and the efficacy of treatment protocols
The variation between nosocomial and community-acquired resistance is very high and
with a significant impact on the epidemiology of drug resistance. For instance, countries
that implement infection control programs report that methicillin-resistant Staphilococus
aureus (MRSA) represent only 1% of the over-all Staphilococus aureus bacteramia, while
the incidence of MRSA is above 50% in countries where there are no infection control poli-
cies [112]. Consequently, the efficacy of different strategies would depend not only in the
hospital dynamics but also in the community structure. In our computational framework
we can study the effect that the levels of drug resistance in the community have on the effi-
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Figure 10.7: As the frequency of resistance in the community increases, so does the
relative merits of diagnosis-based treatment. Single-host multidrug combination is very
effective when resistance levels are low, but performs even worse than empirical treat-
ments when community-acquired resistance is high.
cacy of different hospital interventions by varying a parameter, ρ ∈ [0, 1], that denotes the
probability that a patient admitted into the ward is infected by a given resistant pathogen.
If ρ = 0 then every drug resistant pathogen in the system is nosocomial-acquired, while
ρ = 1 denotes the case when every patient in the queue is colonised with drug-resistant
pathogens when admitted into the hospital ward.
When levels of drug resistance in the community are low and thus patients are admitted into
the hospital ward infected mainly with susceptible pathogens, then A and B are similarly
effective in clearing the infection. In this case, the empirical treatment performs as well as
the diagnosis-based protocol. Conversely, when levels of resistance in the community are
high there is a considerable benefit obtained from the correct diagnosis and the consequent
prescription of the appropriate drug. In this case a diagnosis-based treatment performs
significantly better than the empirical therapy, as shown in Figure 10.7. Moreover, as dis-
cussed in the previous section, when antibiotics have a synergistic interaction multidrug
combination treatments are very effective, in particular when patients are colonised mainly
with susceptible pathogens. Interestingly when patients are admitted into the ward with
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Figure 10.8: Replacement scenario. Patients are colonised with random densities
of commensal and pathogenic bacteria. The probability of pathogens being single-drug
resistant is given by parameter 0 < ρr < 1.
(left) Initial bacterial densities of patients in the queue. (right) Frequencies of single-drug
and multidrug resistant pathogens. (a-b) No drug resistance in the community, ρr = 0.
(c-d) Intermediate levels of resistance in the community, ρr = 0.5. (e-f) High levels of
resistance in the community, ρr = 1.
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Figure 10.9: Addition scenario. Patients are colonised with random densities of com-
mensal bacteria, as well as infected by susceptible, single-drug and multi-drug resistant
pathogens. Frequency of resistance is given by parameter 0 < ρa < 1.
(left) Initial bacterial densities of patients in the queue. (right) Frequencies of single-drug
and multidrug resistant pathogens. (a-b) No drug resistance in the community, ρa = 0.
(c-d) Intermediate levels of resistance in the community, ρa = 0.5. (e-f) High levels of
resistance in the community, ρa = 1.
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high levels of drug resistance, then multidrug resistance spreads very quickly throughout
the hospital ward and this treatment protocol turns out to be very ineffective, performing
even worse than the empirical treatment.
In addition to the community structure, the distribution of susceptible and resistant pathogens
within hosts is also relevant [112]. The addition scenario illustrated in Figure 10.9 refers
to the case where resistant and susceptible pathogens coexist within a single-host. In con-
trast, Figure 10.8 represents a queue of patients generated under a replacement scenario,
so-called because patients are infected by a single pathogenic phenotype, either resistant or
susceptible. For brevity we have only included in this chapter simulations that consider the
addition scenario, and although the results presented would differ quantitatively, the main
conclusions presented here seem to be independent of the single-host patterns of resistance.
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Conclusion
The many different physical scales relevant to modelling antibiotic resistance evolution,
from the physical chemistry of drug molecules and their targets to the clinical and epi-
demiological effects of drug usage in patients and communities, may mean that a strongly
data-driven predictive model across those scales may simply be too much to ask for. While
we would like to re-iterate the limitations of our study and suggest the necessity of develop-
ing calibrated models designed for specific pathogens and specific antimicrobials, we argue
that the models presented in this thesis may still be able to explain some features observed
in practise.
In particular, the numerical simulations of the last chapter present one feature in common
with clinical trials: over-lapping distributions. We believe this is an important issue when
comparing the performance of different interventions, because if we were to test just two
simulated trials and compare them, it is possible that our single samples would not reflect
the true nature of the distributions from which they were drawn. In our computational
study, we can overcome this problem by forming an empirical distribution from repeated
simulations, but this exercise cannot be carried out in clinical trials. The same conclusion
can be drawn from standard SI models of drug deployment, where it can be shown that the
statistical distribution of the performances of different sets of protocols, for example mix-
ing and periodic cycling, must have overlapping supports. In other words, it is a general,
mathematical result that there must be mixing policies that outperform cycling policies and
vice versa.
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Another conclusion that seems to hold across the different modelling frameworks discussed
in this thesis is that strategies that increase drug appropriateness are the most effective in
the long-term. This leads us to postulate that the one feature common to all successful
treatments in our theoretical models is information: the more information we have, the
better the performance of the best treatments, although a caveat commensurate with the
law of diminishing returns is appropriate.
In summary, it is our contention that the search for effective antibiotic usage strategies
should not be reduced to a straightforward comparison between mixing and rotation pro-
tocols. More recent treatment paradigms place the individual patient at the core of the
treatment and, for example, seek to maximise the appropriateness of the drugs prescribed
while minimising the duration of empirical therapy [72]. With these goals in mind, the de-
velopment of DNA-based rapid sequencing tools that aim to reduce the delay in obtaining
microbiology results, as discussed in [12], may prove to be a successful strategy.
We conclude by agreeing with [16] that the last word on the nature of the optimal antibi-
otic deployment protocol has not been spoken. This is a difficult theoretical and practical
problem and we hope that no avenue of investigation will be set aside when searching for
measures to combat the scourge of antibiotic resistance.
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Appendix A
Model parameters
Table A.1: Model parameters for the scenario in which a single-drug is deployed into a
population of pathogens with complete competitive advantage over commensals.
Parameter Description Value
d Chemostat dilution rate 0.6h−1
 Rate of phenotypic mutations 0.1
ap & ac antibiotic-cell binding rates 4 · 10−6µg/cell/hr
c Resource-cell conversion rate 1× 106cell/µg
in antibiotic-free environment
K Half-saturation constant for all 0.06µg/ml
bacterial types (com,wt and mut)
V ∗max Maximal resource uptake rate µ
com
max = 1.2/h, µ
wt
max = 1.6/h
of bacterial type ∗, V ∗max = µ∗max/c µmutmax = 1.0/h
S0 Resource supply concentration 1µg/ml
A0 Antibiotic supply concentration 2µg/ml
κ∗1 Affinity for antibiotic of κ
com
1 = κ
wt
1 = κ
mut
1 = 0.05ml/µg
bacterial type ∗
κ∗2 Maximal growth inhibition κ
com
2 = 0.71ml/µg, κ
wt
2 = 0.5ml/µg,
of bacterial type i κmut2 = 0.9ml/µg
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Table A.2: Model parameters for the example where two synergistic antibiotics are de-
ployed to preserve the commensal population while driving a fitter pathogen to extinction.
Parameter Description Value
d Chemostat dilution rate 0.6h−1
 Rate of point mutations 0.01
c Resource conversion rate 108cell/µg
K Bacterial half-saturation constant 0.06µg/ml
µi Maximal growth rate µc = 1.16, µs = 1.3,
of bacterial type i per hour µa = 1, µb = 1,
(note c · V imax = µi) µab = 0.87
S0 Resource supply concentration 6µg/ml
A0 Antibiotic A supply concentration 1µg/ml
B0 Antibiotic B supply concentration 1µg/ml
a Antibiotic A binding rate 1× 10−8µg/cell
b Antibiotic B binding rate 1× 10−8µg/cell
κi1 Maximal growth inhibition κ
c
1 = 0.59, κ
s
1 = 0.45
of bacterial type i by antibiotic A κa1 = 0.81, κ
b
1 = 0.41
κab1 = 0.69
κ˜i1 Maximal growth inhibition κ˜
c
1 = 0.56, κ˜
s
1 = 0.47
of bacterial type i by antibiotic B κ˜a1 = 0.38, κ˜
b
1 = 0.79,
κ˜ab1 = 0.71
κi2 Affinity for antibiotic A κ
c
2 = 0.15, κ
s
2 = 0.2,
of bacterial type i κa2 = 0.3, κ
b
2 = 0.2,
κab2 = 0.4
κ˜i2 Affinity for antibiotic B κ˜
c
2 = 0.18, κ˜
s
2 = 0.25,
of bacterial type i κ˜a2 = 0.2, κ˜
b
2 = 0.4,
κ˜ab2 = 0.39
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Table A.3: Parameters estimated from the experiments described in Appendix D
Parameter Description Value
c Resource conversion rate 1.8 x 104cells/µg
K Bacterial half-saturation constant 0.62µg/ml
Vmax Maximal growth rate 0.000251µg/cell/h
κd Maximal growth inhibition by doxycyclin 0.068
κe Maximal growth inhibition by erythromycin 3.46
κ˜d Affinity for doxycyclin 0.198
κ˜e Affinity for erythomycin 0.079
S0 Resource supply concentration 2000µg/ml
DOX0 Maximum doxycyclin concentration 0.7µg/ml
ERY0 Maximum erythomycin concentration 3.5µg/ml
η Fraction of the population transferred 0.1
 Rate of point mutations 0.001
κi1 Maximal growth inhibition κ
d
d = 0.285, κ
e
d = 0.0767,
of bacterial type i by doxycyclin κded = 0.274
κ˜i1 Maximal growth inhibition κ
d
e = 1.12, κ
e
e = 0.8,
of bacterial type i by erythromycin κdee = 2.156
κi2 Affinity for doxycyclin κ˜
d
d = 0.000000214,
of bacterial type i κ˜ed = 0.000000219,
κ˜ded = 0.0000016
κ˜i2 Affinity for erythomycin κ˜
d
e = 0.4147, κ˜
e
e = 0.753,
of bacterial type i κ˜dee = 0.685
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Table A.4: Model parameters considered for the stochastic and spatially explicit model
of a hospital ward.
Parameter Description Value
N Number of hospitals simulated 1000
(unless specified otherwise)
n Number of patients in the queue 100
B Number of beds in hospital 8
β Rate of transmission between neighbouring beds 0.1
δ Ratio of commensals and pathogens required 0.9
in order to patients to be discharged
m Rate of input and output of resources 0.4h−1
d Rate of clearance of bacteria 0.4h−1
 Rate of point mutations 0.01
c Resource conversion rate 108cell/µg
K Bacterial half-saturation constant 0.06µg/ml
µi Maximal growth rate µc = 1.5, µs = 1.3,
of bacterial type i per hour µa = 1, µb = 1,
(note c · V imax = µi) µab = 0.87
S0 Resource supply concentration 6µg/ml
A0 Antibiotic A supply concentration 1µg/ml
B0 Antibiotic B supply concentration 1µg/ml
a Antibiotic A binding rate 1× 10−8µg/cell
b Antibiotic B binding rate 1× 10−8µg/cell
κi1 Maximal growth inhibition κ
c
1 = 0.59, κ
s
1 = 0.45
of bacterial type i by antibiotic A κa1 = 0.81, κ
b
1 = 0.41
κab1 = 0.69
κ˜i1 Maximal growth inhibition κ˜
c
1 = 0.56, κ˜
s
1 = 0.47
of bacterial type i by antibiotic B κ˜a1 = 0.38, κ˜
b
1 = 0.79,
κ˜ab1 = 0.71
κi2 Affinity for antibiotic A κ
c
2 = 0.15, κ
s
2 = 0.2,
of bacterial type i κa2 = 0.3, κ
b
2 = 0.2,
κab2 = 0.4
κ˜i2 Affinity for antibiotic B κ˜
c
2 = 0.18, κ˜
s
2 = 0.25,
of bacterial type i κ˜a2 = 0.2, κ˜
b
2 = 0.4,
κ˜ab2 = 0.39
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Appendix B
Entropic Regularisation
It will be convenient for the purpose of numerically calculating near-optimal controls with
respect to the functional J (δ) defined in (6.1) to regularise it by introducing an entropic
term of the form
e(δ) := δ ln δ + (d− δ) ln(d− δ)
and then defining
Jη(δ) := −η
∫ T
0
e(δ)dt+ J (δ),
where η is a temperature-like parameter. We then seek a solution of the unconstrained
optimal problem
find δ∗(η) ∈ L∞(0, T ) such that Jη(δ∗(η)) = sup{Jη(δ) : δ ∈ L∞(0, T )}. (B.1)
It is easy to prove from the convexity properties of the function e(·), on defining an optimal
control δ∗ by
δ∗ ∈ L∞(0, T ) satisfies J (δ∗) = sup{J (δ) : δ ∈ L∞(0, T ), 0 ≤ δ ≤ d} (B.2)
that δ∗(η) ∗⇀ δ∗ in L∞ as η → 0 where η > 0.
The effect of this regularisation is to ensure that minimisers of Jη, members of L∞(0, T )
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denoted δ∗(η)(t), are in fact analytic functions of t and it also ensures that convergence
to the maximal entropy state δ∗(η)(t) → d
2
as occurs in an appropriate strong topology as
η →∞.
The value of the regularisation is that it allows us to readily determine δ∗(η) numerically,
largely by smoothing singularities in the optimal solution, but it also allows us to use a
numerical continuation procedure akin to annealing to compute small-η optimal controls.
This continuation procedure starts with η at a high value and with an initial guess of δ∗guess =
d/2 and then successively reduces η. By coupling this continuation algorithm to an adaptive
meshing strategy ensures that we are able to resolve the switches that we anticipate to be
present in the optimal control δ∗ between the deployment and non-deployment of antibiotic.
We used the Matlab code bvp4c [52] to implement this numerical continuation strategy.
To understand the effect of the regularisation in more detail, a necessary condition for the
optimality of δ∗(η) with respect to J states, using the Pontryagin Maximum Principle, that
the associated Hamiltonian
H(x, λ, δ) := 〈w,x〉+ 〈λ,G(x; d, S0) + δA0e〉
is maximised along the optimal trajectory. Here λ = (λS, λC , λP , λA) ∈ R1+n+m+1 is an
adjoint variable that satisfies the adjoint equation (B.3a) below
− λ˙ = w + (∇xG(x; d, S0))Tλ, λ(T ) = 0, (B.3a)
x˙ = G(x; d, S0) + δA0e, x(0) is given. (B.3b)
The regularised payoff functional Jη requires a suitably modified Hamiltonian, namely
H˜(x, λ, δ; η) = H(x, λ, δ)− ηe(δ). (B.4)
Observe that the only terms in (B.4) that depend on the control variable δ are
〈λ,A0δe〉 − ηe(δ) = A0δ(λ, e)− ηe(δ) = A0δλA − ηe(δ) (B.5)
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and so we define
h(δ) := λAA0δ − ηe(δ).
As η > 0, the modified Hamiltonian H˜ is maximised with respect to δ when 0 = h′(δ) =
λAA0 − ηe′(δ), a condition that holds if and only if log
(
δ
d−δ
)− A0λA
η
= 0 from where we
find an expression for δ in terms of the regularisation parameter η and the adjoint variable
λA:
δ = δ 〈η, λA〉 := d(1 + e−A0λAη−1)−1.
If we now define Λ := (ΛS,ΛC ,ΛP ,ΛA) = λ/η then Λ satisfies the final-value equation
− Λ˙ = wη−1 + (∇xG(x; d, S0))TΛ, Λ(T ) = 0, (B.6)
and the control associated with it can be written δ(t) = d(1 + e−A0ΛA(t))−1, illustrating
that (B.3) is singularly perturbed with respect to η near η = 0. The nature of this singular
perturbation will result in the appearance of internal layers where the optimal control δ∗(η)
switches between the two extreme states, δ = 0 and δ = d. As the behaviour of λA(t)
decides when the control switches from one regime to the other, this function is called the
switching function. However, (B.3) is regularly perturbed about η = ∞ in the sense that
we can formally substitute η = ∞ in (B.6) and find a solution of the resulting differential
equation. The resulting solution is analytic, unique and satisfies Λ(t) ≡ (0, 0, 0, 0) from
where the corresponding optimal control is given by the maximum entropy state. This
occurs at max0≤δ≤d(−e(δ)) namely when δ = d/2 and we therefore conclude that
lim
η→∞
δ∗(η) =
d
2
in a C1 sense. This argument can be made rigorous using the implicit function theorem
and it provides an initial guess (the function δ∗guess = d/2) for the numerical annealing
procedure used to numerically determine optimal controls.
As ΛA(T ) = 0 it follows that δ∗(η)(T ) = d(1 + e0)−1 = d/2 and so the regularisation
introduces an artefact into the Jη-optimal control which forces this control to equal d/2 at
the end-point of the time domain.
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Appendix C
Genetic algorithm
In order to compute near-optimal antibiotic deployment protocols we used a genetic al-
gorithm to exploit the fact that bang-bang controls are optimal in a certain sense. The
algorithm searches for near-optimal rotational protocols through the space of bang-bang
controls using the following simple-minded strategy. Consider a partition of the time in-
terval [0, T ] into n regular sub-intervals, a single drug must flow into the chemostat at
maximum dose on each sub-interval but we allow the possibility of switching antibiotics at
the end of each sub-interval.
The set of all potential switches σ := {σ1, σ2, . . . , σn} can be expressed as a binary string
of length n and this represents the chromosome, C, of a given treatment. Each gene, σi,
can be expressed by allele 0 meaning that the same drug is going to be deployed at the
next sub-interval, or by allele 1 meaning that a switch to the other drug is necessary. We
can therefore associate each chromosome C ∈ {0, 1}n with a bang-bang control strategy
α(t; C) and from this we can compute its fitness that we define to be J(α(t; C), β(t; C))
where β(t; C) = d − α(t; C), J is computed using an accurate time-stepping algorithm to
solve the differential equation (9.1).
The number of different rotation protocols to search through is 2n and the following algo-
rithm located a near-optimal control with a reasonable amount of computer time:
1. Fix a population size N and choose a random initial population of N chromosomes,
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PC0 = {C1, C2, . . . . , CN}
Given PCk define PCk+1 as follows.
2. Compute the numerical fitness J(α(t; Ci), β(t; Ci)) where β(t; Ci) = d− α(t; Ci) for
every chromosome Ci of the current population.
3. Select the fittest chromosomes and reproduce them pair-wise. The chromosome of
the offspring is constructed by recombination, inheriting each allele from only one
of the parents, where these are chosen randomly for each gene.
4. Mutate a fixed proportion of genes of the population by randomly bit-flipping the
alleles of some proportion of chromosome, also randomly chosen.
The population PCk+1 then contains only the fittest N members of the previous gen-
eration, their offspring and the mutated chromosomes.
20 40 60 80 100
480
500
520
540
560
Generations
∫ 0T  R
1 
+
 R
2 
dt
 
 
optimal mixing
rotation protocols
Figure C.1: Illustration of the genetic algorithm applied to Problem 2. Black circles
represent the rotation protocols that have a lower fitness than the optimal mixing proto-
col (yellow line), while red circles represent protocols that outperform the best mixing
strategy.
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Appendix D
Experimental methods
Bacterial Strain. E. coli Strain MC4100 (ordered from the Coli Genetic Stock Center:
http://cgsc2.biology.yale.edu/Strain.php?ID=9973) was used. Stocks
were made from a single colony picked for an overnight LB-culture and frozen for further
use.
M9 Growth Medium. The experiment was then performed in M9 Growth Medium pre-
pared as follows: Part A: 350 g
L
K2HPO4, 100 gL KH2HPO4; Part B: 29.4
g
L
Trisodium
citrate, 50 g
L
(NH4)2SO4, 5 gL MgSO4. Parts A and B were 50x stock solutions in water,
that were sterilised by autoclaving. For M9 Minimal Medium they were diluted in water
accordingly. 0.2 % Glucose and 0.1 % Casamino Acid were added as nutrients for the M9
Growth Medium.
Antibiotics used. Antibiotics used were Erythromycin (from Aldrich, Product # 856193)
and Doxycycline (Sigma, Product # D9891), two antibiotics known to synergise [48]. Liq-
uid stocks were prepared from powder stocks at 50 mg
ml
. For this purpose, Erythromycin
hydrate was dissolved in Ethanol and Doxycycline hyclate in sterile water (afterwards filter
sterilised).
Maximal antibiotic concentrations were determined for each antibiotic in preliminary tri-
als as concentrations leading to full inhibition of bacterial growth for 24 hours using just
one of the antibiotics at a time. For Erythromycin 10 µg
ml
was the maximal concentration,
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for Doxycycline 0.3 µg
ml
. For each, 11 dilutions in M9 Growth Medium ranging from no
antibiotic to maximal concentration.
Setup. A grid of all combinations of these concentrations was replicated 6 times and spread
in a systematically randomised way over three 384-well plates at 50 µl per well. Extra
wells were filled with growth medium but not inoculated with bacteria for background OD
measurements. For inoculation, the wells of a 96-well plate were filled with 100 µl of
MC4100 overnight culture and then a very small subsample was taken by dipping a full 96-
rack of 10 µl tips first into the 96-well plate and then into one of the four 96-well subsets
of the 384-well plate.
The three plates were sealed with a transparent plastic foil, the liquid was centrifuged down
with a short spin and the OD was measured in a Tecan genios plate reader. They were then
grown in a 37◦C incubator and shaken at 130 rpm for 24 hours. For OD measurements,
they were taken out of the incubator every 30 minutes.
Figure D.1: Dose-response grid of E. Coli growing under glucose limitation and under
the effect of different concentrations of docycyclin and erythromycin.
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